
<html lang="en"     class="pb-page"  data-request-id="2205c6b1-cfc1-4b86-a001-f55d2edf8f88"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-8;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00181;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications" /></meta><meta name="dc.Creator" content="Marta  Serafini" /></meta><meta name="dc.Creator" content="Sarah  Cargnin" /></meta><meta name="dc.Creator" content="Alberto  Massarotti" /></meta><meta name="dc.Creator" content="Gian Cesare  Tron" /></meta><meta name="dc.Creator" content="Tracey  Pirali" /></meta><meta name="dc.Creator" content="Armando A.  Genazzani" /></meta><meta name="dc.Description" content="The World Health Organization assigns international nonproprietary names (INN), also known as common names, to compounds upon request from drug developers. Structures of INNs are publicly available..." /></meta><meta name="Description" content="The World Health Organization assigns international nonproprietary names (INN), also known as common names, to compounds upon request from drug developers. Structures of INNs are publicly available..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 13, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00181" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00181" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00181" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00181" /></link>
        
    
    

<title>What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00181" /></meta><meta property="og:title" content="What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0018.jpeg" /></meta><meta property="og:description" content="The World Health Organization assigns international nonproprietary names (INN), also known as common names, to compounds upon request from drug developers. Structures of INNs are publicly available and represent a source, albeit underused, to understand trends in drug research and development. Here, we explain how a common drug name is composed and analyze chemical entities from 2000 to 2021. In the analysis, we describe some changes that intertwine chemical structure, newer therapeutic targets (e.g., kinases), including a significant increase in the use of fluorine and of heterocycles, and some other evolutionary modifications, such as the progressive increase in molecular weight. Alongside these, small signs of change can be spotted, such as the rise in spirocyclic scaffolds and small rings and the emergence of unconventional structural moieties that might forecast the future to come." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The World Health Organization assigns international nonproprietary names (INN), also known as common names, to compounds upon request from drug developers. Structures of INNs are publicly available and represent a source, albeit underused, to understand trends in drug research and development. Here, we explain how a common drug name is composed and analyze chemical entities from 2000 to 2021. In the analysis, we describe some changes that intertwine chemical structure, newer therapeutic targets (e.g., kinases), including a significant increase in the use of fluorine and of heterocycles, and some other evolutionary modifications, such as the progressive increase in molecular weight. Alongside these, small signs of change can be spotted, such as the rise in spirocyclic scaffolds and small rings and the emergence of unconventional structural moieties that might forecast the future to come." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0018.jpeg" /></meta><meta name="twitter:title" content="What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00181"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00181">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00181&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00181&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00181&amp;href=/doi/10.1021/acs.jmedchem.1c00181" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4410-4429</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00051" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01895" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Marta Serafini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marta Serafini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marta++Serafini">Marta Serafini</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5305-8359" title="Orcid link">http://orcid.org/0000-0002-5305-8359</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah Cargnin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah Cargnin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Cargnin">Sarah Cargnin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alberto Massarotti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alberto Massarotti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alberto++Massarotti">Alberto Massarotti</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9306-8845" title="Orcid link">http://orcid.org/0000-0001-9306-8845</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gian Cesare Tron</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gian Cesare Tron</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gian+Cesare++Tron">Gian Cesare Tron</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tracey Pirali</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tracey Pirali</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tracey++Pirali">Tracey Pirali</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3936-4787" title="Orcid link">http://orcid.org/0000-0003-3936-4787</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Armando A. Genazzani</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Armando A. Genazzani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 0039-0321-375827. Email: <a href="/cdn-cgi/l/email-protection#84e5f6e9e5eae0ebaae3e1eae5fefee5eaedc4f1eaedf1f4ebaaedf0"><span class="__cf_email__" data-cfemail="0362716e626d676c2d64666d627979626d6a43766d6a76736c2d6a77">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Armando+A.++Genazzani">Armando A. Genazzani</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1923-7430" title="Orcid link">http://orcid.org/0000-0003-1923-7430</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00181&amp;href=/doi/10.1021%2Facs.jmedchem.1c00181" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4410–4429</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 13, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 February 2021</li><li><span class="item_label"><b>Published</b> online</span>13 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00181"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4835</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00181" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Marta&quot;,&quot;last_name&quot;:&quot;Serafini&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Cargnin&quot;},{&quot;first_name&quot;:&quot;Alberto&quot;,&quot;last_name&quot;:&quot;Massarotti&quot;},{&quot;first_name&quot;:&quot;Gian&quot;,&quot;last_name&quot;:&quot;Cesare Tron&quot;},{&quot;first_name&quot;:&quot;Tracey&quot;,&quot;last_name&quot;:&quot;Pirali&quot;},{&quot;first_name&quot;:&quot;Armando&quot;,&quot;last_name&quot;:&quot;A. Genazzani&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4410-4429&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00181&quot;},&quot;abstract&quot;:&quot;The World Health Organization assigns international nonproprietary names (INN), also known as common names, to compounds upon request from drug developers. Structures of INNs are publicly available and represent a source, albeit underused, to understand trends in drug research and development. Here, we explain how a common drug name is composed and analyze chemical entities from 2000 to 2021. In the analysis, we describe some changes that intertwine chemical structure, newer therapeutic targets (e.g., kinases), including a significant increase in the use of fluorine and of heterocycles, and some other evolutionary modifications, such as the progressive increase in molecular weight. Alongside these, small signs of change can be spotted, such as the rise in spirocyclic scaffolds and small rings and the emergence of unconventional structural moieties that might forecast the future to come.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00181&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00181" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00181&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00181" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00181&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00181" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00181&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00181&amp;href=/doi/10.1021/acs.jmedchem.1c00181" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00181" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00181" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26pmid%3D33847110%26genre%3Darticle%26aulast%3DSerafini%26date%3D2021%26atitle%3DWhat%25E2%2580%2599s%2Bin%2Ba%2BName%253F%2BDrug%2BNomenclature%2Band%2BMedicinal%2BChemistry%2BTrends%2Busing%2BINN%2BPublications%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290692" title="Elements">Elements</a>,</li><li><a href="/action/doSearch?ConceptID=291494" title="Medicinal chemistry">Medicinal chemistry</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/8" title="Go to Volume 64, Issue 8"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/jmcmar.2021.64.issue-8/20210422/jmcmar.2021.64.issue-8.largecover.jpg" alt="Go to Volume 64, Issue 8"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The World Health Organization assigns international nonproprietary names (INN), also known as common names, to compounds upon request from drug developers. Structures of INNs are publicly available and represent a source, albeit underused, to understand trends in drug research and development. Here, we explain how a common drug name is composed and analyze chemical entities from 2000 to 2021. In the analysis, we describe some changes that intertwine chemical structure, newer therapeutic targets (e.g., kinases), including a significant increase in the use of fluorine and of heterocycles, and some other evolutionary modifications, such as the progressive increase in molecular weight. Alongside these, small signs of change can be spotted, such as the rise in spirocyclic scaffolds and small rings and the emergence of unconventional structural moieties that might forecast the future to come.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Remember the biblical story of the Tower of Babel, in which the attempt to build a tower that would reach the heavens by the Babylonians was disrupted by the inability of the builders, that spoke different languages, to understand each other? Well, apparently there are today over 7000 spoken languages, and 34 of them are spoken by at least 45 million people.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> If each pharmacological active principle were to be called differently in each country and language, it would be disastrous for health as well as for scientific progress. Think, for example, of pharmacovigilance, of scientific publications, and of those traveling around the world.</div><div class="NLM_p">Brand names that exist in most parts of the world well-exemplify this situation. In many countries the same drug is sold with multiple brand names, and, to make matters worse, these brand names change from country to country. While chemists might think that International Union of Pure and Applied Chemistry (IUPAC) names represent unique identifiers, it must be acknowledged that these are complicated, almost impossible to memorize for the lay public, and error prone. A common name, short and easy to pronounce, that identifies the same medicine everywhere in the world, is therefore required.</div><div class="NLM_p">This was realized soon after World War II, and in 1953 the World Health Assembly, the governing body of the World Health Organization (WHO), passed resolution WHA3.11, which stated that an expert Committee of the WHO “<i>should undertake the selection and approval of non-proprietary names for drugs</i>” together with the recommendation that national pharmacopoeias should adopt such names.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Such a resolution was the birth of the international nonproprietary names (INN) system for drug identification that we still use today for the effective and safe identification of medicines, for safe prescribing, and for teaching. It has also been a pivotal pillar for the development of the generic market of off-patent drugs, whereby in most countries the INN substitutes the brand name and allows therefore to unlink the manufacturer from the therapeutic effect. The INN has not substituted naming agencies altogether (e.g., in the United States (U.S.), England, Japan, and China, to cite some, national naming agencies are still active), but intense cooperation between these agencies has led, with very few exceptions, to identical names around the world. To imagine a world in which drugs are identified with different names, think if all drugs used were in the situation of paracetamol, salbutamol, and adrenaline, which in the U.S. are known, respectively, as acetaminophen, albuterol, and epinephrine.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Fortunately, these are some of the very few exceptions.</div><div class="NLM_p">While the present review will concentrate on the INN, it is interesting that contiguous fields have also adopted common names for their products, as a question of safety or consumer protection. Cosmetic ingredients, for example, have common International Nomenclature Cosmetic Ingredient (INCI) names issued by the Personal Care Product Council.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Pesticides and agricultural chemicals also have their standardization for naming, which is the result of several different naming committees. In the U.S., the American National Standards Institute (ANSI) issues common names for chemicals, although other agencies, such as the International Standards Organization (ISO), or national standard organizations (e.g., British) also do so. It may occur that a few molecules receive common names by multiple bodies for different uses, and, while in most instances these names coincide (e.g., ascorbic acid is both an INCI and an INN), this is not always the case (e.g., nicoboxil is an INN, while the corresponding INCI is butoxyethyl nicotinate; the INN cetomacrogol 1000 corresponds to the INCI ceteth-20, both identifying the same tensioactive molecule; the ISO insecticide trichlorfon is equivalent to the INN drug metrifonate, once used for schistosomiasis,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and the INN oxindanac, an anti-inflammatory drug that has never reached the market, is equivalent to the ISO herbicide quinclorac).</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> How are INNs Defined?</h3><div class="NLM_p">INNs are issued upon request to the WHO and, in particular, to the Secretariat of the Expert Advisory Panel of the International Pharmacopoeia and Pharmaceutical Preparations, designated for this purpose, also known as the “INN Expert Group”. The INN Expert Group is composed of experts from all over the world that are led and coordinated by a Secretariat. Experts may include, among others, medicinal chemists, pharmacologists, biochemists, molecular biologists, and clinicians. Given that experts change over time and the scientific community modifies viewpoints on what is important in a drug, the composition of the group may also have an impact on the names chosen for a particular substance, with more or less emphasis given to the chemistry/structure, to the nature of the active principle, or to the mechanism of action. The current composition may be found on the WHO Web site.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> To provide consistency across fields, the meetings of the Committee are also attended by a number of other learned scientists, for example, representatives of national naming agencies and pharmacopeias, IUPAC experts, and Anatomical Therapeutic Chemical Classification System (ATC) code experts.</div><div class="NLM_p">The person or company requesting the INN may propose a name that should abide by the rules and conventions of the INN system, and this may be accepted or modified by the Committee.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Briefly, the core element of the INN is the stem, which is composed of one or two syllables, and is usually located at the end of the drug name. Such a stem identifies drugs that have a shared feature, usually the mechanism of action, although it can also be a therapeutic use or a chemical/structural characteristic. As an example, think of proton pump inhibitors: ome<i>prazole</i>, esome<i>prazole</i>, panto<i>prazole</i>, rabe<i>prazole</i> all share the common stem <i>prazole</i> that identifies “antiulcer, benzimidazole derivatives” (these brief definitions are given by the Committee once a stem is officially identified).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> If drugs are not recognized by the INN Expert Group as being part of a broader category, they will be assigned a unique ending. If other molecules that share the new feature will have an INN requested for them in the future, then these will receive the same ending, and the committee will promote it as an official stem. The WHO publishes a “stem book” and regular updates that can be freely consulted.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Yet, it is not only the stem that qualifies a name, as there are prefixes (a syllable at the beginning of the INN), infixes (a syllable in the middle of the word), or suffixes (a syllable at the end of the INN) that characterize the name and may give information to the learned reader. For example, the syllable -<i>gli</i>- characterizes many drugs used in diabetes (e.g., <i>gli</i>benclamide, cana<i>gli</i>flozin, sita<i>gli</i>ptin, saro<i>gli</i>tazar, rosi<i>gli</i>tazone; note that <i>-glifozin</i>, <i>-gliptin</i>, <i>-glitazar</i>, and -<i>glitazone</i> are all stems identifying different drug classes and that the prefix <i>gli-</i> identifies anti-hyperglycemics, which are sulfonamide derivatives; for examples of the most frequent stems used by the INN Expert Group since 2000, see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> below. Another example of how INNs work is represented by the manner by which chiral switches are represented in INNs, in which an infix illustrates the change, for example, in <i>es</i>omeprazole (S isomer of omeprazole), <i>es</i>citalopram (S isomer of citalopram), <i>es</i>ketamine (S isomer of ketamine), <i>levo</i>floxacin (levo-rotatory stereoisomer of ofloxacin) or <i>dex</i>ketoprofen (the dextro-rotatory stereoisomer of ketoprofen).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Stems of SCEs Used at Least 10 Times in the Last 20 Years</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ranking of stems in SCEs</th><th class="colsep0 rowsep0" align="center">stem</th><th class="colsep0 rowsep0" align="center">definition</th><th class="colsep0 rowsep0" align="center">example</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#1<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">-<i>ine</i></td><td class="colsep0 rowsep0" align="left">alkaloids and organic bases</td><td class="colsep0 rowsep0" align="left">atrop<i>ine</i> (according to WHO, ∼17.5% of INNs have used this stem in lists p1-p119)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#2<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">-<i>tinib</i></td><td class="colsep0 rowsep0" align="left">tyrosine kinase inhibitors</td><td class="colsep0 rowsep0" align="left">ima<i>tinib</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#3<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">-<i>stat</i>–/–<i>stat</i></td><td class="colsep0 rowsep0" align="left">enzyme inhibitors</td><td class="colsep0 rowsep0" align="left">atorva<i>stat</i>in, cobici<i>stat</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#3<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>vir</i>–/–<i>vir</i>–/–<i>vir</i></td><td class="colsep0 rowsep0" align="left">antivirals (undefined group)</td><td class="colsep0 rowsep0" align="left">mara<i>vir</i>oc, remdesi<i>vir</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#5<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>gli</i>–/–<i>gli</i>-</td><td class="colsep0 rowsep0" align="left">antihyperglycaemics</td><td class="colsep0 rowsep0" align="left"><i>gli</i>benclamide, dapa<i>gli</i>flozin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#5<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">-<i>one</i></td><td class="colsep0 rowsep0" align="left">ketones</td><td class="colsep0 rowsep0" align="left">nalox<i>one</i> (according to WHO, ∼7.5% of INNs have used this stem in lists p1-p105)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#7<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">-<i>imod</i></td><td class="colsep0 rowsep0" align="left">immunomodulators, both stimulant/suppressive and stimulant</td><td class="colsep0 rowsep0" align="left">fingol<i>imod</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#8</td><td class="colsep0 rowsep0" align="left">-<i>sertib</i></td><td class="colsep0 rowsep0" align="left">serine/threonine kinase inhibitors</td><td class="colsep0 rowsep0" align="left">no drug is yet on the market</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#9<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><i>fos</i>–/–<i>fos</i>-</td><td class="colsep0 rowsep0" align="left">phosphorus derivatives; various pharmacological categories belonging to “<i>fos</i>”, other than insecticides, anthelminthics, pesticides, etc.</td><td class="colsep0 rowsep0" align="left"><i>fos</i>carnet, so<i>fos</i>buvir</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#10</td><td class="colsep0 rowsep0" align="left">-<i>lisib</i></td><td class="colsep0 rowsep0" align="left">phosphatidylinositol 3-kinase inhibitors, antineoplastics</td><td class="colsep0 rowsep0" align="left">idela<i>lisib</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#11<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">-<i>ast</i></td><td class="colsep0 rowsep0" align="left">antiallergic or anti-inflammatory, not acting as antihistaminics</td><td class="colsep0 rowsep0" align="left">zafirluk<i>ast</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#11<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">-<i>tant</i></td><td class="colsep0 rowsep0" align="left">neurokinin (tachykinin) receptor antagonists</td><td class="colsep0 rowsep0" align="left">aprepi<i>tant</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#13</td><td class="colsep0 rowsep0" align="left">-<i>anib</i></td><td class="colsep0 rowsep0" align="left">angiogenesis inhibitors</td><td class="colsep0 rowsep0" align="left">ninted<i>anib</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#13</td><td class="colsep0 rowsep0" align="left">-<i>bulin</i></td><td class="colsep0 rowsep0" align="left">antineoplastics; mitotic inhibitors, tubulin binders</td><td class="colsep0 rowsep0" align="left">eri<i>bulin</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#13</td><td class="colsep0 rowsep0" align="left">-<i>ciclib</i></td><td class="colsep0 rowsep0" align="left">cyclin dependent kinase inhibitors</td><td class="colsep0 rowsep0" align="left">palbo<i>ciclib</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#16<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">-<i>abine</i></td><td class="colsep0 rowsep0" align="left">arabinofuranosyl derivatives; nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives</td><td class="colsep0 rowsep0" align="left">capecit<i>abine</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#17</td><td class="colsep0 rowsep0" align="left">-<i>entan</i></td><td class="colsep0 rowsep0" align="left">endothelin receptor antagonists</td><td class="colsep0 rowsep0" align="left">bos<i>entan</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#17</td><td class="colsep0 rowsep0" align="left">-<i>oxacin</i></td><td class="colsep0 rowsep0" align="left">antibacterials, nalidixic acid derivatives</td><td class="colsep0 rowsep0" align="left">levofl<i>oxacin</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#19</td><td class="colsep0 rowsep0" align="left">-<i>conazole</i></td><td class="colsep0 rowsep0" align="left">systemic antifungal agents, miconazole derivatives</td><td class="colsep0 rowsep0" align="left">keto<i>conazole</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#19<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>prost</i>–/–<i>prost</i>–/–<i>prost</i></td><td class="colsep0 rowsep0" align="left">prostaglandins</td><td class="colsep0 rowsep0" align="left"><i>prost</i>alene (veterinary use), miso<i>prost</i>ol, latano<i>prost</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#21</td><td class="colsep0 rowsep0" align="left"><i>-caftor</i></td><td class="colsep0 rowsep0" align="left">cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers</td><td class="colsep0 rowsep0" align="left">iva<i>caftor</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#21</td><td class="colsep0 rowsep0" align="left">-<i>nicline</i></td><td class="colsep0 rowsep0" align="left">nicotinic acetylcholine receptor partial agonists/agonists</td><td class="colsep0 rowsep0" align="left">vare<i>nicline</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#23</td><td class="colsep0 rowsep0" align="left">-<i>tecan</i></td><td class="colsep0 rowsep0" align="left">antineoplastics, topoisomerase I inhibitors</td><td class="colsep0 rowsep0" align="left">irino<i>tecan</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#23</td><td class="colsep0 rowsep0" align="left">-<i>adol</i>–/–<i>adol</i></td><td class="colsep0 rowsep0" align="left">analgesics</td><td class="colsep0 rowsep0" align="left">tram<i>adol</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#23</td><td class="colsep0 rowsep0" align="left">-<i>ciguat</i></td><td class="colsep0 rowsep0" align="left">guanylate cyclase activators and stimulators</td><td class="colsep0 rowsep0" align="left">rio<i>ciguat</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#23</td><td class="colsep0 rowsep0" align="left">-<i>denoson</i></td><td class="colsep0 rowsep0" align="left">adenosine A receptor agonists</td><td class="colsep0 rowsep0" align="left">rega<i>denoson</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#27</td><td class="colsep0 rowsep0" align="left">-<i>parib</i></td><td class="colsep0 rowsep0" align="left">poly-ADP-Ribose polymerase inhibitors</td><td class="colsep0 rowsep0" align="left">ola<i>parib</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#27</td><td class="colsep0 rowsep0" align="left">-<i>terol</i></td><td class="colsep0 rowsep0" align="left">bronchodilators, phenethylamine derivatives</td><td class="colsep0 rowsep0" align="left">formo<i>terol</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">#27</td><td class="colsep0 rowsep0" align="left">-<i>vaptan</i></td><td class="colsep0 rowsep0" align="left">vasopressin receptor antagonists</td><td class="colsep0 rowsep0" align="left">tol<i>vaptan</i></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">A number of other stems include this one (e.g., -<i>terone</i> for androgens).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">These stems possess substems that categorize in more detail. For example,  -<i>brutinib</i>, -<i>citinib</i>, -<i>ertinib</i>, and -<i>metinib</i> group together tyrosine kinase inhibitors (-<i>tinib</i>) with the same target (Bruton kinase, Janus Kinase, EGFR, MAPK, respectively).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">The stem -<i>fos</i> is, instead, used for insecticides, anthelmintics, pesticides, etc., phosphorus derivatives.</p></div></div></div><div class="NLM_p">In general, INNs are selected for the active moiety of drugs. Pharmaceutical reasons may drive slight modifications to be made during the drug development process or during the lifetime of the product. This is the case of salified forms, ester prodrugs, hydrates or solvate forms, combination products, or complexes. To reduce the number of published INNs, all these cases do not result in the publication of a different INN from that assigned to the active moiety but to the creation of a modified INN (INNM), which does not necessarily need to be devised by the INN Expert Group and may be created by the manufacturer. Nonetheless, INNMs follow strict rules and lead to two- or three-word names, the first of which refers to the active principle, and the subsequent ones are attributable to the inactive moiety. Yet, in some specific cases, the radicals or groups composing the inactive parts are highly complex, and therefore the INN Expert Group selects a common name for them, and WHO publishes periodically a list of “names for radicals and groups” to be used in combination with an already assigned INN.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">For those drugs that allow it, and that have emerged more recently on the horizon, more rigid schemes have been devised to name substances. This is particularly true for monoclonal antibodies and for advanced gene and cell therapies. The naming of these substances has recently been reviewed elsewhere.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">It has been advocated that INNs, stems, and radicals could be an excellent learning tool for students.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> illustrates part of the value of this approach. Starting from a name, links can be made to other drugs of the same class, to drugs that share the same mechanism of action, to drugs that have similar structural features, to drugs that have the same therapeutic use, and to drugs that have been salified or esterified in similar manners, thus creating mnemonic aids. The INN Expert Committee recently also set up a School of INN to educate on how to construct, design, and interpret INNs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Use of stems, prefixes, infixes, and suffixes in INNs. The definitions of the stems in the figure are the official definitions that can be found in the stem book.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The name chosen by the Committee, which meets in Geneva twice a year, is known as the proposed INN (pINN) and is circulated among all stakeholders (Ministries of Health, industries, learned societies, etc.) that may object to the name for a number of reasons, including trademark infringements, similarity to other substances, or inappropriate meaning in a particular language. If an objection is raised, then the Committee is asked to re-evaluate the name, while if no objections are received by WHO, the name is, approximately a year later, declared a recommended INN (rINN). Each year two lists of the pINNs are published on the WHO Web site<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> reflecting the choices made by the Committee. At present, list p123 has been published, and the first list dates to 1953. The latest rINN list published in 2020 is r84, and the difference of numeration between the proposed and the recommended list dates back to the initial years, in which several pINN lists were usually incorporated in the same rINN list. Since 2000, the two lists differ minimally, although some substances may see a deferral of their publication because of objections.</div><div class="NLM_p">Regulatory agencies (e.g., European Medicines Agency (EMA), Food and Drug Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA)) require that drugs submitted for their assessment are identified with an INN (or with a name given by the national naming agency), and therefore an INN is in most instances issued before the completion of clinical trials. While the WHO INN Expert Committee has a preference for drugs to be submitted after the beginning of Phase II trials, this is not always the norm, and an INN can be issued before or after, although it is very unlikely that applicants submit an application in the absence of encouraging data from Phase I trials. While receiving an INN for a drug increases the value of the portfolio, as it gives the feeling that it is closer to the market, companies are well-aware that the INN publication will allow competitors to know their intentions on the lead molecule being developed.</div><div class="NLM_p last">In our opinion, the pINN and rINN publications<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> are a unique opportunity to scrutinize drug development as well as the recent trends in drug research and development (R&D) (as they precede marketing by a few years, see below), and, to our knowledge, this has been overlooked by scholars. Moreover, the INN publications have never been scrutinized from a medicinal chemistry viewpoint, unlike other chemical catalogues, such as FDA-approved drugs,<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21">(14−21)</a> including veterinary drugs,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> the Essential Medicines List (EML),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> or molecules published in medicinal chemistry journals.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> In the present contribution, we concentrated on the chemical entities published in the INN lists in this millennium. Indeed, the publication of the INN represents at times the first public disclosure of the molecule and, while obviously not all substances that have been assigned an INN turn into approved drugs, these are all compounds that the industry has invested in. It is therefore an intermediate approach between analyzing only successful molecules (approved by the FDA or present on the EML) and analyzing discovery compounds (e.g., molecules published in the <i>Journal of Medicinal Chemistry</i>), as it includes promising molecules, which might turn out to be successes or clinical failures. Our approach of concentrating on molecules in the last 20 years gives us the ability to investigate long-term trends in drug development and in medicinal chemistry, although we acknowledge that historical trends could be also investigated by taking all molecules published since 1953, or, on the contrary, features of newer molecules could be investigated by taking only the past few years.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Bird’s-Eye View Analysis of the INNs of the Millennium</h3><div class="NLM_p">From 2000 to September of 2020, 3159 substances have received an INN published as a rINN. Note that r43 (2000) presents 43 substances whose publication had been delayed because of long-lasting objections and most likely date to the 1990s.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> For our analysis, we used drugs listed in the recommended lists from 2000 to 2020 (r43 to r83), and we added the drugs present in the latest two proposed lists (p122 and p123), to include the most recent applications, leading to a total of 3456 molecules.</div><div class="NLM_p">Not surprisingly, 2021 brought a surge of molecules, for which INNs were sought urgently, to be developed for the coronovirus disease of 2019 (COVID-19), and an extraordinary list (p124-COVID) was created for these drugs. These 25 drugs were not considered in our analysis. p124 is composed of monoclonal antibodies (<i>N</i> = 10), followed by RNA-based approaches (<i>N</i> = 5), organic compounds (<i>N</i> = 6), biologicals (<i>N</i> = 3), and advanced therapies (<i>N</i> = 1). <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> depicts the five novel small chemical entities (SCEs) against severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) found in this list. It is important to highlight, in this context, that the potential activity is self-declared by the applicant, and it is not up to the Committee to evaluate data that back efficacy or safety claims.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of the five SCEs present in list p124 devoted to drugs potentially of use in the COVID pandemic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As mentioned above, lists are published on the WHO Web site.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compounds are described to uniquely identify them (e.g., IUPAC, amino acid sequence), and the lists also include other information. In the proposed lists, organic compounds are also described by their brute formula, the Chemical Abstracts Service (CAS) number and the chemical structure as well as by the broad class they belong to, while recommended lists lack some information, such as the CAS number and drug class. The description of the class is usually broad and heterogeneous: for example, it may refer to its chemistry (e.g., vitamin D analogue), to its pharmacological action (e.g., antiviral), or to its mechanism of action (e.g., toll-like receptor antagonist), following a common law on how the first compounds of the class were first described.</div><div class="NLM_p">At first, we visually inspected all 3456 molecules and classified them in broad categories (see definitions in ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>), which include “inorganic small chemical entities” (<i>N</i> = 2), “organic small chemical entities (SCEs)” (<i>N</i> = 2018), “biologicals” (<i>N</i> = 411), “monoclonal antibodies” (mAbs) (<i>N</i> = 578), “conjugates” (<i>N</i> = 83), “DNA/RNA-based therapies” (<i>N</i> = 91), “advanced therapies” (ATMPs) (<i>N</i> = 129), “polymers” (<i>N</i> = 25), “veterinary” (<i>N</i> = 45), and “mixtures” (<i>N</i> = 3). This classification required a number of compromises, and we do acknowledge that the great variety of compounds included means that some compounds could also have been classified differently. To represent this difficulty, 71 compounds were classified as “other”, as they did not meet our criteria of active principle (diagnostics, excipients, radiodiagnostics, sunscreens) or could not be reconducted to any other category (i.e., belzupacap sarotalocan).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows how these categories have changed over time, both from a quantitative and qualitative point of view. Notice that the number of applications over time has dramatically increased, starting from 40 to 60 INNs for each volume in the 2000s and rising to a maximum of 163 in the last published list (p123). The number of SCEs that have received yearly an INN has roughly remained the same (between 70 and 120 depending on the year), although their weight percentage-wise has decreased significantly (from ∼80% in volume r43 to ∼40% in the last volume), in favor of mAbs, biologicals, ATMPs, conjugates, and DNA/RNA therapies. It is often stated that SCEs are being replaced by biotechnological products, but the analysis made, instead, suggests that biotech compounds are added, and are not a substitute, of traditional medicinal chemistry molecules.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. INNs issued between 2000 and 2021. Categories composed of less than 10 substances were excluded from the figure (two inorganics and three mixtures), while the same were included in the calculation of the percentage of approved INNs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then decided to evaluate how many of the molecules that are published in the rINN lists eventually become approved drugs in the main global markets, U.S., Europe, or Japan, and how anticipated is the disclosure in the INN publications. The dotted line in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows the percentage of drugs published by the WHO in that particular year eventually approved by the FDA,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> EMA,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> or PMDA.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> As it can be observed, between 20% and 30% of drugs from each list are approved. Data from 2017 onward are significantly lower, as most drugs from those years have not been approved yet, and this shows that the INN anticipates by a few years drug approval.</div><div class="NLM_p">As a whole 639 of 3456 drugs (19%) were approved by at least one agency by Nov 1, 2020. Briefly, 493 (14%) were approved by the FDA, 441 (13%) by the EMA, and 345 (10%) by the PMDA. Notice that the database we used for PMDA includes approval data from 2004, and therefore the number of approved drugs in Japan is underestimated. INNs, by definition, are used globally, and it is possible that some drugs that have been classified as “not approved” in our analysis have been approved elsewhere in the world. To support this statement, we searched different Web sites and databases<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to investigate whether the molecules depicted in the figures of this review and not listed in the FDA, EMA, or PMDA sites had been authorized elsewhere in the world, and we found that a number of these are indeed marketed (mainly in South America or the Far East). This therefore suggests that approved drugs are underestimated, as our analysis does not take into account a number of other markets. When classified in broad categories, the percentage of approval for each class, considering U.S., Europe, and Japan, was found to be 24% for biologicals, 20% for SCEs, 15% for conjugates, 13% for mAbs, 12% for polymers, 10% for DNA/RNA based therapies, and 5% for ATMP, while no inorganic drug or molecule classified as a mixture was approved.</div><div class="NLM_p">We then analyzed the time to approval in the three regulatory districts. This is displayed in the Kaplan–Meier plot in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. This manner of expressing data allows an estimation of events over time and, in this particular instance, the probability that an INN is approved after a given time. As it can be observed in panel A, it is estimated that ∼22.5% of the total INNs will be approved by the FDA, and a slightly lower number will be approved by the EMA and PMDA. It is estimated that half of these drugs will be approved within four years in the U.S. and Europe, while it will take slightly longer for Japanese approval (this latter analysis might be nonetheless skewed by the loss of data between 2000 and 2004). Very few drugs are approved after 10 or more years from the INN publication. Notice that our analysis is performed on the rINN list, but a disclosure by the WHO in the pINN lists occurs approximately a year earlier. In brief, therefore, it is expected that, for each new list published, a fifth to a quarter of the drugs will be authorized and that half of these authorizations will occur within the first five years. We also investigated whether the different categories of drugs took different amounts of time to get approved (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C). Briefly, the median approval time for ATMPs was two years; for polymers and biologics it was three years, for small chemical entities it was four years, for mAbs it was five years, and for conjugates it was six years.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Probability of INN approval from the year of publication on the recommended INN list.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Analysis of the Medicinal Chemistry of the INNs in the Last 20 Years</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67741" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67741" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Having characterized the data set, we then decided to proceed evaluating the medicinal chemistry solely of SCEs listed in the INN publications. While we took inspiration from other reviews on chemical catalogues for a systematic analysis,<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22">(14−22)</a> we also arbitrarily concentrated on particular aspects or molecules that caught our attention or on details that have recently emerged in the literature. The main goal of the review is to sprout interest in the INN catalogue, and we believe that this data set will be used in the future by others, which might concentrate on other aspects.</div><div class="NLM_p">The decision to concentrate solely on SCEs meant that we excluded mixtures (i.e., plauracin, guaifylline, and latidectin A3+A4) and polymers (<i>N</i> = 25, e.g., paclitaxel poliglumex) from our analyses due to the impossibility of assigning them precise physicochemical characteristics, albeit recognizing that these might be of interest to the medicinal chemist. Last, conjugates were also excluded, as this group contained a number of medicines that do not pertain to the medicinal chemistry arena (e.g., mAbs+toxins/peptides, mAbs+radiolabeled isotopes). Yet, the same group also contained 59 antibody-SCE conjugates (antibody-drug conjugates (ADCs)), and we felt that this deserved to be flagged, given that the synthesis and characterization of chemical payloads are becoming an important field in medicinal chemistry and in anticancer therapy.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> As it can be observed in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, there are five different families of payloads that are more often used in conjugates: auristatin analogues (e.g., vedotin), maytansinoids (e.g., emtansine), pyrrolobenzodiazepine derivatives (e.g., talirine), irinotecan analogues (e.g., govitecan), and chelating agents (e.g., tiuxetan; to which a radioactive isotope is usually added). Some of the 21 payloads are conjugated with more than one mAb (e.g., labetuzumab govitecan and sacituzumab govitecan). In a similar manner, the same mAb can be conjugated with distinct payloads (e.g., trastuzumab emtansine and trastuzumab deruxtecan, both of which are currently approved).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative structures of SCEs that are conjugated with mAbs. Payloads that are part of approved ADCs are highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The different payloads that compose a family (indicated by different INNs with the same stem, such as -<i>dotin</i>, -<i>xetan</i>, -<i>tansine</i>, and -<i>tecan</i>) may differ by their linker function or by chemical modifications in the core molecule (although these are not indicated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, and a single representative member is depicted). Last, we also found three payloads, namely, ozogamicin, duocarmazine, and clezutoclax, that are unique representatives, not being part of a family of molecules. Eight distinct payloads have been approved so far in 11 ADCs, with vedotin being approved in three different drugs and ozogamicin in two.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Trends in SCEs Drug Classes Developed</h3><div class="NLM_p">It is probably overambitious to prime the INN catalogue to investigate for diseases that have received the most attention from industry, as the description of drug use present in the database is given early on in development and may not accurately represent the later stages of development (i.e., industries may decide to repurpose a drug for a different disease while in clinical development; see apremilast in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> as an example). Furthermore, the descriptions are rather vague, and drugs undergo an extension of indications that would not be represented in the initial description.</div><div class="NLM_p">For this reason, we decided instead to take a “nomenclature” approach and investigated which are the stems (e.g., drug classes) used in at least 10 INNs in the last 20 years. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> lists the most frequent stems found in the 2018 SCEs, their definition as described in the stem book,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and examples of approved drugs for each of them. As it can be observed, a few of these (-<i>ine</i>, -<i>one</i>, -<i>fos</i>-, -<i>abine</i>) are traditional and refer to chemical moieties, but most stems nowadays refer to pharmacological targets or to drug use.<named-content content-type="anchor" rid="tbl1" type="simple"></named-content></div><div class="NLM_p">We then analyzed the frequency of these stems in two different periods, subdividing the SCEs in two subsets of a similar size: period A from 2000 to 2011 composed of 1038 SCEs and period B from 2012 to 2021 composed of 980 SCEs (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). A qualitative analysis reveals some striking changes. First, tyrosine kinase, cyclin-dependent kinase, serine/threonine kinase, and phosphatidylinositol 3-kinase inhibitors have seen a surge of interest among developers in the last 10 years. Almost 20% of all SCEs issued an INN since 2011 belong to one of these four classes, with tyrosine kinase inhibitors accounting for most of them. It is also of interest that, of the 37 serine/threonine kinase inhibitors, none has so far been approved, possibly owing to the recent investment. Possibly an unexpected finding, remaining in the oncology field, is that some chemotherapeutic classes have not gone out of fashion altogether (e.g., -<i>bulin</i>, -<i>abine</i>), while some others (-<i>tecan</i>) have completely lost popularity. Alongside cancer chemotherapeutic agents, a significant drop in INN assignments is also observed for the diabetes field and for some other drug targets (e.g., neurokinin receptors, vasopressin receptors, and endothelin receptors) that were popular in the first decade of the millennium. Of great interest is that a drug class exclusively developed for a single rare disorder (cystic fibrosis) has sprouted sufficient interest to issue 12 names in the last 10 years (-<i>caftor</i>). Overall, this analysis points, as expected, to a great dynamism of the pharmaceutical industry, with significant shifts in interest and development, which are bound to shape the drugs eventually approved for the market and the patients cared for.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Frequency of the most common stems in period A (blue; 2000–2011: <i>N</i> = 1038) and period B (orange; 2012–2021: <i>N</i> = 980).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Elemental Composition</h3><div class="NLM_p">We then analyzed the elemental composition of the 2018 SCEs in the INN lists. To speed up and automate the analysis process, a python protocol was prepared using a module designed for a chemoinformatic analysis (RDKit).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This protocol made it possible to extract the SMILES structures of INN lists from Pubmed and use them both to calculate chemical descriptors (see below) and to count the number of elements present in each molecule.</div><div class="NLM_p">The elemental composition of the 2018 SCEs was compared to the one described in an analysis made on FDA-approved pharmaceuticals in 2014,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the frequency of elements was compared between periods A and B (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Frequency of elements beyond CHON in SCEs in period A (blue; 2000–2011: <i>N</i> = 1038) and period B (orange; 2012–2021: <i>N</i> = 980). In the INN lists, four molecules are listed as containing sodium, but a visual inspection revealed that this indicates the salified molecule. These molecules were thereby excluded from the figure. Numbers in parentheses refer to the relative ranking of elements in FDA-approved drugs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> *<i>The occurrence of each element group refers to the number of SCEs containing at least one</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Obviously, carbon, hydrogen, oxygen, and nitrogen (CHON) are present in the vast majority of compounds, as was the case for FDA-approved drugs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Just after CHON, the INN list presents fluorine in just over 30% of compounds. This shows a change in medicinal chemistry strategies compared to the past, with fluorine taking over from chlorine and sulfur as the most frequent element after CHON.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> While this could be somehow expected,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> the extent of the use of fluorine might possibly surprise some. Indeed, a recent analysis made on FDA-approved drugs from 2015 to 2020 showed that 26% of drugs displayed fluorine,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> already a very high number, but in our analysis we find 40% of drugs in the same time frame (compared to 17% in the first four years of the century) and 55% of fluorinated drugs issued a name in 2020.</div><div class="NLM_p">No substantial differences were found on the percentage of approved drugs containing chlorine or fluorine, which have remained approximately similar between 2000 and 2020.</div><div class="NLM_p">Iodine is present in only 19 compounds, a frequency very close to that of boron, which occurs in 14 molecules. The rate of approval of the iodine-containing molecules is lower (11%), while the one of boron-containing molecules is significantly higher (43%) compared to the INN SCE benchmark (20%). Of the 14 boron-containing molecules, nine have been published in period B, demonstrating that the use of this element is increasing over time,<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> although numbers remain small. While most of these molecules present boronic acid (<i>N</i> = 8), four contain five-membered boron heterocycles, and two contain six-membered boron heterocycles.</div><div class="NLM_p">The remaining elements are platinum (<i>N</i> = 5), silicon (<i>N</i> = 3), iron (<i>N</i> = 3), palladium (<i>N</i> = 2), manganese (<i>N</i> = 2), bismuth (<i>N</i> = 1), tin (<i>N</i> = 1), and arsenic (<i>N</i> = 1), and molecules that contain these uncommon elements are represented in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. INN molecules containing unconventional elements. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue, and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Silicon is a proposed carbon isostere that improves the drug-likeness of bioactive compounds,<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> and, similarly, deuterium has gained academic popularity as an isostere of hydrogen.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42−45)</a> The INN database lists three silicon-containing (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) and five deuterium-containing molecules (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Some of these SCEs are initially developed with silicon or deuterium (e.g., cositecan or deucravacitinib), although it is interesting to note that most deuterium-containing molecules resulted from deuterium switches and that the cystic fibrosis drug ivacaftor has been the object of both a silicon and a deuterium switch (dirocaftor, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and deutivacaftor, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). While for silicon no prefix has been established yet (but the syllable -<i>si</i>- is present in two of the three retrieved drugs), deuterated molecules can be easily recognized by the prefix <i>deu-</i>/<i>deut-</i>, although this is not officially recognized.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The five compounds in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> represent the only deuterated INNs published so far. However, deuterated molecules are flourishing in the literature. An example of this is provided by the recently published dosimertinib,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> a deuterated analogue of osimertinib (r75; 2016). It is likely that this name represents the preferred choice of the drug developer of what the compound should be called, but to our knowledge this is not an official INN and should not be used in the scientific literature, to avoid confusion (indeed, INN rules would suggest that the putative name should be deutosimertinib). Similar confusion is generated by the use of the name donafenib,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> which is the deuterated analogue of sorafenib, as this molecule has never been issued an INN (which would putatively be deusorafenib according to the rules). It is important to note that the absence of these two drugs from our analysis is not a drawback of our data set, because these molecules cannot be marketed in Europe or the U.S. unless they reach the WHO for an official INN, which would probably not be the one they have so far used in the scientific literature.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. INN deuterated molecules. EMA, FDA, or PMDA approved SCEs are highlighted in blue. The numbers in brackets indicate the rINN list and the year in which the molecule was published. <i>*To avoid a proliferation of stems and definitions, the WHO uses broad categories. Deucravacitinib well exemplifies that this choice is not flawless and might result in grouping molecules with distinct features. Indeed, both the stem (-citinib) and the definition place this drug as a Janus kinase (JAK) inhibitor, although the drug has been designed and developed as a specific inhibitor of TYK2, one of the four protein members of the JAK family (the others being JAK1, JAK2, and JAK3)</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Functional Groups</h3><div class="NLM_p">We next evaluated the occurrence of functional groups, taking inspiration from Ertl et al.,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> who scanned medicinal chemistry journals, both for the most popular groups to search for and for the in silico approach to employ (we used the SMARTS listed in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00181/suppl_file/jm1c00181_si_001.xlsx" class="ext-link">Supporting Information</a> using RDKit).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The analysis was then performed subdividing our data set in period A and period B, in order to make a comparison between the two decades (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Frequency of selected functional groups in SCEs in period A (blue; 2000–2011: <i>N</i> = 1038) and period B (orange; 2012–2021: <i>N</i> = 980). <i>*The occurrence of each functional group refers to the number of SCEs containing at least one</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, the most abundant group is ether (<i>N</i> = 962), with approximately half of the INN molecules displaying this group, followed by amide, either linear or lactam (<i>N</i> = 840, 42%), aliphatic amine (primary, secondary, and tertiary; <i>N</i> = 797, 39%), and aromatic amine (<i>N</i> = 633, 31%). The 45% increase in aromatic amines in period B is not surprising considering that kinase inhibitors are particularly rich in this moiety and have significantly increased over time (e.g., <i>-tinib</i>, <i>-sertib</i>, <i>-lisib</i>, and -<i>ciclib</i>, see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><div class="NLM_p">When looking at the functional groups present in at least 60 molecules, no seismic change between the two periods occurs, although a few trends can be observed. Esters, for example, are usually thought to be groups not privileged in drug design, due to their hydrolytic instability. Despite this, ∼10% of the INN molecules display this group, including prodrugs, even if a trend toward a reduction in period B is observed. Another little change is represented by sulfur-containing functional groups. While the number of SCEs displaying sulfur is the same in the two periods (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), the use of this element has changed, with a decrease in the use of thioether, a little increase of sulfonamide, and a dramatic rise in sulfone,<a onclick="showRef(event, 'ref17 ref49'); return false;" href="javascript:void(0);" class="ref ref17 ref49">(17,49)</a> which is spread over different classes of INNs (e.g., in -<i>pirdine</i>, a proposed stem for serotonin receptor antagonists, and in <i>-sertib</i> and -<i>tinib</i>). While α,β-unsaturated carbonyl groups decrease in period B, α,β-unsaturated amides slightly increase in the same period, despite being well-known structural alerts. Interestingly, their marginal rise is consistent with the surge of covalent kinase inhibitors and follows the approval of afatinib,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> ibrutinib,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and osimertinib,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> three tyrosine-kinase inhibitors approved as antineoplastic drugs.</div><div class="NLM_p">Both carboxylic acids and aliphatic amines have experienced a small decrease in their use over time, and we therefore decided to investigate the fraction of acidic, basic, neutral, and zwitterionic compounds (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) using an approach similar<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> to the one described by Charifson et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The distribution of the SCEs in the four categories was similar (neutral 47%; basic: 27%; acidic: 19%; zwitterionic: 7%) compared to that described in Charifson et al. with a slight increase of neutral SCEs over time, rising from an average 43% of neutral drugs in period A to 51% in period B.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Distribution of neutral, acid, basic, and zwitterionic SCEs in period A (2000–2011: <i>N</i> = 1038) and period B (2012–2021: <i>N</i> = 980). <i>* To define the acid/base properties of the SCEs, their ionization state at pH 7.4 was considered</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, uncommon functional groups are starting to appear: indeed, we found four aldehydes and three sulfoximines (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Despite the fact that aldehydes are considered structural alerts in medicinal chemistry<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> due to their high reactivity toward a vast array of nucleophiles, in our data set two aldehyde-containing SCEs (i.e., alcaftadine in period A, voxelotor in period B) out of four have been approved, confirming that the safety and utility of this functional group should be assessed on a case by case basis in R&D.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Sulfoximine, a neglected functional group in medicinal chemistry, has made its appearance in the lists since 2014. While none of the three SCEs has been approved so far, a recent article pointed at sulfoximine as an emerging group to further expand the toolbox of medicinal chemists.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of selected SCEs-containing α,β-unsaturated amide, aldehyde, or sulfoximine. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> The Ring Systems</h3><div class="NLM_p">After having analyzed the functional groups represented in our SCE data set, we investigated the nature of the ring systems by a visual inspection. To do so, we used a slightly modified approach to the original work by Taylor et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> that considered a ring system as a complete ring or rings formed by removing all terminal and acyclic linking groups.</div><div class="NLM_p">From a methodological point of view, all rings and fused rings were retained, together with endocyclic bonds and exocyclic carbonyls, sulfonyls, imines, sulfinyls, and thiocarbonyls. Differently from the previous work,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> SCEs displaying steroid core substructures<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> were grouped, while spiro groups were broken into their corresponding rings, as we dedicated a separate analysis to these substructures (see below). We removed macrocycles (number of atoms greater than 11; <i>N</i> = 69) as a potentially special case. Similarly to the approach described above, the resulting data set (<i>N</i> = 1949) was divided into two subsets: the first (<i>N</i> = 994) from 2000 to 2011 (named period A) and the second (<i>N</i> = 955) from 2012 to 2021 (named period B). This allowed us to capture the general occurrence of ring systems in the INN list as well as to compare two decades.</div><div class="NLM_p">Overall, we found 362 distinct ring systems in period A and 419 in period B, with 224 and 257 ring systems used only in a single SCE. This is a small but significant sign that the chemical novelty is increasing and that the accessible chemical space is expanding and also shows the great chemical diversity of INNs. This is further supported by the fact that Taylor et al., when analyzing the 1175 drugs found in the FDA Orange book (which included drugs approved between 1983 and 2012), found 351 distinct ring systems, of which 204 were present only once.</div><div class="NLM_p">We then compiled the list of the top 30 most frequently used ring systems (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) and compared it with the one reported by Taylor et al.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The similarity between the two lists confirmed that medicinal chemists still rely on a subset of ring systems that have not changed in the last decades and are in part related to intrinsic properties and synthetic accessibility (e.g., benzene, pyridine, piperidine, cyclohexane). Yet, some substantial changes have occurred: azetidine, oxazole, and indazole are newcomers that were not present in the top 100 ring systems detected by Taylor et al., while pyrazole, pyrazine, and pyrrole have gained prominence. Interestingly, cephalosporins (<i>N</i> = 4 in period A; <i>N</i> = 2 in period B) and penicillins (<i>N</i> = 2 in period A; <i>N</i> = 0 in period B) are almost absent in our list, while they are well-represented in the FDA Orange Book, highlighting a progressive decrease of interest in β-lactam antibiotics. Similarly, the phenothiazine core, which is featured in 11 molecules in the FDA-approved drugs, is almost absent in our data set (<i>N</i> = 1 in period A; <i>N</i> = 1 in period B).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Frequency of selected ring systems in SCEs in period A (blue; 2000–2011: <i>N</i> = 994) and period B (orange; 2012–2021: <i>N</i> = 955). Numbers in parentheses refer to the relative ranking of ring systems in FDA-approved drugs.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a><i>The occurrence of each ring system was determined by counting the number of SCEs containing at least one</i>. *Steroids were grouped<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a>, while in Taylor et al. they were subdivided, considering the different ring systems. With our methodology, steroids would have risen to second place in Taylor et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then compared the ring systems in the two periods. At first glance, it is impressive that most nitrogen-containing aromatic ring systems are more represented in period B. Pyridine, benzimidazole, and pyrazine have doubled or nearly doubled, pyrimidine has almost tripled, and indazole, despite the small numbers, is experiencing a significant increase over time. While we did not investigate this systematically, our impression is that this revolution is largely attributable to the advent of tyrosine kinase inhibitors (-<i>tinib</i>, see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and, to a lesser extent, to cyclin-dependent kinase inhibitors (-<i>ciclib</i>, see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and to the fact that they usually contain adenine mimetic scaffolds in their pharmacophore. An increase also occurs in nitrogen-containing aliphatic rings, including azetidine, pyrrolidine, and morphine, as well as in piperidine and piperazine, albeit to a less extent. This is not surprising, as all these substructures are more and more frequently introduced as solubility enhancers. Cyclopropane has significantly increased in period B, and this is mainly related to the recent trend to escape from flatland, as described below. It is interesting to note that, while 1,2,4-triazole shows a steady trend, 1,2,3-triazole, despite being outside the top 30 list, is experiencing a significant increase, thanks to the advent of the click chemistry approach and its exploitation in drug development (<i>N</i> = 3 in period A; <i>N</i> = 12 in period B).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p last">Overall, when adding up the top 30 rings, we found an ∼25% increase in ring systems (1385 in period A and 1710 in period B). The difference is remarkable, considering that periods A and B display a similar number of molecules (<i>N</i> = 994 in period A; <i>N</i> = 955 in period B), and we therefore believed that this imbalance deserved in-depth consideration. We wondered what counterbalanced this shortage of ring systems in period A, also in consideration that we observed a small increase in molecular weight (MW) in period B (see below), which per se cannot account for this alone. Once we discarded the possibility that there was a decrease in total phenyl rings in period B (total number of phenyl rings, period A = 897; period B = 880), we then hypothesized that the difference could be related to polycyclic fused ring systems. This was indeed consistent with the fact that, in period A, more steroids (<i>N</i> = 23 period A; <i>N</i> = 14 period B), irinotecan analogues (-<i>tecan</i>; see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), and taxanes (<i>-taxel</i>; see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) were present, and these, according to the methodology used, were not disconnected. While the polycyclic decrease might partially explain our observation, the numbers are too small to believe that this is the sole explanation. Indeed, it is likely that it is a plethora of small changes that add up to explain a large effect that we observe in ring systems. For example, we also found a difference in the number of exocyclic carbons between period A (<i>N</i> = 7149) and period B (<i>N</i> = 6125) that, while not being decisive, might partially contribute to fill the observed void.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Symmetric Compounds</h3><div class="NLM_p">While we were visually inspecting the data set, we were impressed by the abundance of symmetric compounds that were present (<i>N</i> = 29, referring to <i>C</i><sub>2</sub> symmetry). It is interesting that there has been a doubling in the last two decades of these molecules, from 10 between 2000 and 2011 to 19 in the last 10 years. Two compounds are actually prodrugs bearing one inactivating portion and two identical molecules of the active principle (lodenafil carbonate, dinalbuphine sebacate). As expected, most of the remaining symmetric compounds are traditional twin drugs designed to target proteins displaying dimeric structures.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Among them, we found the NS5A inhibitors used as a hepatitis C virus (HCV) treatment (i.e., daclatasvir,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> ombitasvir,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> pibrentasvir<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a>), diquafasol (a P2Y2 antagonist),<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> firibastat (an aminopeptidase A inhibitor),<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> and tegavivint (a TBL1 inhibitor).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Similar are those twin drugs intended to bind two identical target proteins (albitiazolium bromide,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> miridesap<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a>). In this regard, it is interesting to see that the Chemically-Inducible Dimerization (CID) technology<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> has led to the development of rimiducid,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> a tacrolimus analogue that behaves as a protein dimerizer, triggering the homodimerization of Fv-containing drug-binding domains of genetically engineered proteins such as the Caspase 9, Fas intracellular domain, and iCD40 receptor. Molecules where symmetry can be found as a means to complex metals are plerixafor<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> (zinc) and elesclomol<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> (copper). Finally, two porfirinic compounds are included (i.e., exeporfinium chloride, redaporfin). <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a> shows some selected examples of symmetric molecules.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of selected symmetric compounds. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue, and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Molecular Complexity</h3><div class="NLM_p">It is often believed that medicinal chemistry is becoming more complex to deal with the increasingly challenging drug targets and in line with increased synthetic accessibility. However, chemical complexity remains an elusive concept.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The ranking of compounds mainly depends on what parameters are used to describe complexity, but an unambiguous definition is yet to be defined. While several complexity descriptors have been reported,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> what universal parameters should be used as proxies is still a controversial issue. In the literature, a broad range of possibilities is described, from simple topological or physicochemical descriptors to more complex indexes that combine several features into a single score.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> Since a universally accepted index does not exist and a systematic evaluation of the proposed alternatives is beyond the scope of this review, we decided to consider only some descriptors that are undoubtably linked to complexity, well-aware that further work will be required in this field. It is our hope that this catalogue might be used to prime molecular complexity by others, possibly using a historical approach from 1953.</div><div class="NLM_p">The first element we investigated was whether molecules are getting larger: bigger and more complex molecules can access greater chemical space, can better complement the three-dimensional target binding site, and can possibly escape from existing Markush formulas. The MW<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> of INNs is slowly but steadily increasing over time both in the entire data set and in the restricted data set of approved drugs. This can be seen when evaluating the mean, which may be skewed by particularly large drugs, but also when evaluating the median (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B), which should exclude artifacts given by outliers. Briefly, there is an upward trend seen for all INN compounds (mean 435 in 2000–2004; mean 467 in 2016–2020). Furthermore, the MW of drugs in period B is ∼10% higher compared to those in period A (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A). Approved INN drugs have a slightly higher MW (mean 478) compared to the overall INN compounds (mean 462) when the mean is compared, which we determined to compare our data with that of the literature. Our data (which necessarily include molecules that will fail along the way) are in contrast with the report that MW significantly decreases at each stage of development, from discovery to market,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> but are in line with the hypothesis that a correlation exists between high MW and increased selectivity and reduced attrition rate.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">The increment in MW in drugs is not a new trend, as noticed by Ivanenkov et al.,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> that saw a strong difference between drugs approved in the past decade compared to drugs approved in the first 50 years of the previous century. This finding is also supported by other reports that show that discovery compounds<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> as well as marketed drugs and oral drugs<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> have experienced a consistent time-dependent increase, with a dramatic increment over the past decade.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><div class="NLM_p">As recently reported by Raymer et al.,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> in spite of the fact that MW is increasing, lead-like drugs (drugs below MW 300) still represent a fruitful area of research and a therapeutic opportunity (2011–2016: 17% of drug approvals), and we find 14% of these molecules in our INN data set. To our great surprise, a substantial number of compounds has an MW below 150, of which five are approved worldwide (three in the main regulated areas we focused on), and one is contained in dietary supplements (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Similarly, while 500 is considered the threshold for drug-like compounds, 29% of INN compounds are above this limit, and 11.5% of these are represented by macrocycles (<i>N</i> = 69).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of the 12 SCEs with MW below 150 Da. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue, and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published. It is interesting to note that, at times, the INN does not reflect the common name by which a compound is known (which in the case of tramiprosate would be homotaurine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2009, in their seminal paper Lovering et al. suggested that the medicinal chemistry community should “escape from the flatland” by increasing the fraction sp<sup>3</sup> (Fsp<sup>3</sup> = number of sp<sup>3</sup>-hybridized carbons/total carbon count).<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> The authors proposed Fsp<sup>3</sup> as an important descriptor of molecular complexity: saturation makes molecules less planar and more structurally complicated, allowing them to access a greater chemical space, without significantly increasing MW. Disruption of molecular planarity is reflected in an increase of aqueous solubility,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> target selectivity, and metabolic stability,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> and this should in principle improve the clinical success. This prediction is consistent with the finding that Fsp<sup>3</sup> increases through the five stages of development, going from 0.36 for discovery compounds to 0.47 for drugs on the market.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> It has been suggested that a value of Fsp<sup>3</sup> that is higher than or equal to 0.42 is a suitable benchmark, and 84% of marketed drugs meet this requirement.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> In the entire INN data set the mean Fsp<sup>3</sup> is 0.41,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> in accordance with this criterion and with the fact that the INN is usually requested prior to Phase II. Unlike the trend observed by Lovering, Fsp<sup>3</sup> is identical between approved and not approved drugs.</div><div class="NLM_p">We then evaluated whether medicinal chemistry has escaped from flatland in the last 20 years but found that Fsp<sup>3</sup> is roughly similar between period A and B (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A),<named-content content-type="anchor" rid="fig16" type="simple"></named-content> in line with what was reported by Ivanenkov et al. for launched drugs.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> This somehow is a surprising finding, and when attempting to find a trend in the last 20 years, we found a small downward trend (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B), in analogy to what reported when analyzing discovery compounds published in the <i>Journal of</i><i>Medicinal Chemistry</i> in the period of 1995–2009.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Despite this, small signs of change toward an enhanced spatial complexity can be observed at the granular level, and we concentrated on chirality, spirocyclic compounds, and small rings.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Median MW and mean Fsp<sup>3</sup> in period A (2000–2011: <i>N</i> = 1038) and period B (2012–2021: <i>N</i> = 980) and (B) per year; number of spirocycles (C) in periods A and B and (D) per year and number of SCE-containing small cycles (E) in periods A and B and (F) per year. <i>*The occurrence of spiro and small cycles refers to the number of SCEs containing at least one. Benzofused systems were excluded from the count of spiro compounds. Lactones and lactams were excluded from the count of small cycles</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The chiral nature of drugs has an impact on molecular complexity and correlates with the chance of approval in the process of R&D.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> The number of chiral centers<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> increases through the different steps of clinical stages, reaching the maximum in the approved drugs, where 64% of them have at least one stereocenter. We therefore analyzed the counts of stereocenters in our data set, and we found that 60% of our SCEs have at least one stereocenter, a percentage comparable to that of Phase II compounds,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> with a constant trend in the calculated period, 2000–2020. On the contrary, in the same period, the average number of stereocenters per SCE is slightly decreased. We did not undertake a classification of the origin of compounds in our data set (e.g., synthetic, natural, etc.), and therefore we are unable to determine whether a change in the origin has an impact on our findings. Eight SCEs have a number of stereocenters equal to or higher than 20, with a maximum of 35 stereocenters in evernimicin (r44; 2000), followed by pixatimod (r79; 2018) with 29 stereocenters. Chirality is also a regulatory issue, and the FDA-guidelines for the development of chiral active substances published in 1992 prompted the development of pure stereoisomers.<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83−85)</a> It is therefore not surprising that only 10% of all the SCEs containing at least one chiral center are named as a mixture of stereoisomers. Finally, the approval percentage of chiral SCEs is 27%, slightly above the mean of 20%, with no differences among the subset of pure stereoisomers (28%) and mixtures of stereoisomers (26%).</div><div class="NLM_p">We next focused our attention on spirocyclic motifs that, similarly to quaternary carbon stereocenters, provide an opportunity to project substituents in all three dimensions. Their exploitation in medicinal chemistry has been aided by the recent advances in synthetic strategies that allow access to these substructures.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> A significant increase in their use is evident when considering the publications with the keyword “spiro” in the medicinal chemistry field, as done by Hiesinger et al.:<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> a progressive increase can be found starting from 2000. It is therefore not surprising that, when we analyzed the occurrence over time of spirocyclic motifs<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> in the INN, more than double spirocycle-containing SCEs have been assigned an INN in period B (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>C) with 62% of them being assigned a name after 2014 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>D). The impact of these scaffolds is exemplified by two drugs approved in 2020, oliceridine and risdiplam (r76; 2016 and r80; 2018, respectively).</div><div class="NLM_p">Besides spirocyclic substructures, aliphatic three- and four-membered rings<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> contribute to the overall Fsp<sup>3</sup>. While cyclopropanes have been exploited for many years in drug discovery, cyclobutanes, azetidines, and oxetanes have become popular only recently, an uptrend that goes hand-in-hand with the advent of synthetic methods that allow their incorporation. Bauer et al. have recently described the occurrence of these cycles in the patent literature (2009–2019) and have found that cyclopropane is the most-used small ring, followed by cyclobutane, azetidine, and oxetane.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Albeit numbers are small, it is evident that, with the exception of oxetane, all rings have increased over time also in the INN lists, with cyclopropane experiencing the most significant increase (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>F). Interestingly, cyclobutane is not represented in the period of 2000–2007 and makes its entrance in 2008, occurring 15 times since then. Overall, the occurrence of these small cycles in period B compared to period A has almost doubled (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>E). <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a> shows some representative examples of molecules bearing spirocyclic scaffolds and small rings.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Selected SCEs containing spirocyclic scaffolds and small rings. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Overall, therefore, the data from the INN lists show a clear trend in increased MW. Synthetic feasibility has counterbalanced the putative advantages of escaping from flatland, and this is evident when considering the chemical reactions used in current medicinal chemistry, which is overpopulated by amide bond formation, Suzuki-Miyaura coupling, and S<sub>N</sub>Ar reactions.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A main objective of this review was to disseminate the INN nomenclature schemes and allow readers to recognize the features of a name (stems, infixes, radicals, prefixes, and suffixes) that are important to detect some of the characteristics of the medicine, which may be important for teaching medicinal chemistry and pharmacology, as well as for clinical practice.</div><div class="NLM_p">A second objective was to evaluate the ∼2000 small molecules that received an INN in the last 20 years, (i) paralleling some of the previous analyses done on different chemical catalogues by others and (ii) comparing the two decades of this century.</div><div class="NLM_p">Many before us, possibly more skilled, have scrutinized chemical catalogues to describe the essence of pharmaceutical R&D. This has been done on FDA-approved drugs,<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21">(14−21)</a> patents by the pharmaceutical industry,<a onclick="showRef(event, 'ref88 ref90'); return false;" href="javascript:void(0);" class="ref ref88 ref90">(88,90)</a> publications by academics,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and drugs under clinical investigation.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><div class="NLM_p">Now we propose to use the publications related to the INN, freely accessible on the WHO Web site,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> as a new chemical catalogue, that presents different features, possibly advantageous, over other databases. First, compared to patents and publications, these molecules should represent lead compounds that industry has decided to invest in at the clinical level. Second, these publications anticipate the market by approximately four to five years and therefore can foresee trends and changes before the databases on approved medicines. These advantages are obviously counterbalanced by the fact that ∼75% of the molecules in this catalogue will never be approved.</div><div class="NLM_p">A peculiar finding of our analysis is that medicinal chemistry is largely unchanged, despite the significant modification in drug targets that we describe. Therefore, at first glance, one might be led to believe that medicinal chemistry is largely conservative. Yet, a closer look under the lens shows subtle evolutionary changes that make the baseline constantly drift. Molecular weight is a good example of this, and, while the constant drift might be related to the change in drug targets, it should be noted that this trend follows similar transformations observed since 1910.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Small signs that might pave the path to more significant changes in the future, or might just represent a historical coincidence, also creep up in our analyses. In particular, we identified a cluster of approved boron-containing drugs, a few molecules that incorporate deuterium, and an increased exploitation of small rings (e.g., cyclopropane, cyclobutane, azetidine) and of spirocyclic scaffolds. These small changes are going hand-in-hand with the advent of new synthetic strategies<a onclick="showRef(event, 'ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89">(87−89)</a> that ease access to such structural features.</div><div class="NLM_p">Two other results caught our attention: first, among the elements beyond CHON, fluorine is being used above expectations and, in the latest INN publications, is represented in ∼40% of the molecules (with a peak of 55% in the publications from 2020); second, in the last 10 years there has been an increase in the use of N-containing ring systems, with some heterocycles significantly contributing to this (e.g., pyridine, pyrimidine, and pyrazole). Fluorine use had been predicted,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and it is highly likely that the increase in N-containing ring systems is partly linked to the fact that the kinome has become a popular target. We also observed a strong decrease in beta-lactam containing drugs, in steroids, and in phenothiazines, most likely representing a change in therapeutic areas.</div><div class="NLM_p last">While this database will be of great use to scrutinize drugs under development and to inform on trends in medicinal chemistry, it is unlikely to ever allow a determination of the features that confer success to a molecule, as too many variables, alongside chemistry, influence this aspect. In this respect, an acknowledgment of a referenced paper<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> quotes an anonymous referee that provides an enlightening truth: “<i>Drugs have to survive multiple hurdles followed by attritional factors including toxicity, clinical safety, efficacy in humans, differentiation, market viability, organizational strategy, regulatory approval and acceptance by payers. It is not a surprise that drug-likeness resists accurate description</i>.”</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00181" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05738" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05738" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00181?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00181</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Data set of the INN molecules and list of SMARTS used for searching functional groups (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00181/suppl_file/jm1c00181_si_001.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00181/suppl_file/jm1c00181_si_001.xlsx">jm1c00181_si_001.xlsx (1.92 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00181" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60548" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60548" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Armando A. Genazzani</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Sciences, Università del Piemonte
Orientale, Largo Donegani 2, 28100 Novara, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1923-7430" title="Orcid link">http://orcid.org/0000-0003-1923-7430</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d9b8abb4b8b7bdb6f7bebcb7b8a3a3b8b7b099acb7b0aca9b6f7b0ad"><span class="__cf_email__" data-cfemail="d4b5a6b9b5bab0bbfab3b1bab5aeaeb5babd94a1babda1a4bbfabda0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marta Serafini</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Sciences, Università del Piemonte
Orientale, Largo Donegani 2, 28100 Novara, Italy</span>; 
    <span>Present Address:
                        Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5305-8359" title="Orcid link">http://orcid.org/0000-0002-5305-8359</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Cargnin</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Sciences, Università del Piemonte
Orientale, Largo Donegani 2, 28100 Novara, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alberto Massarotti</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Sciences, Università del Piemonte
Orientale, Largo Donegani 2, 28100 Novara, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9306-8845" title="Orcid link">http://orcid.org/0000-0001-9306-8845</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gian Cesare Tron</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Sciences, Università del Piemonte
Orientale, Largo Donegani 2, 28100 Novara, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracey Pirali</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Sciences, Università del Piemonte
Orientale, Largo Donegani 2, 28100 Novara, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3936-4787" title="Orcid link">http://orcid.org/0000-0003-3936-4787</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>(M.S., S.C., A.M.) These authors contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Marta Serafini</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=BIO-d7e1808-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marta Serafini</b> received her degree in Pharmaceutical Chemistry and Technology in 2015 and her Ph.D. in 2021 from the Università del Piemonte Orientale (Novara, Italy). At present, she is a post-Doc in Medicinal Chemistry funded by Fondazione AIRC (Associazione Italiana per la Ricerca sul Cancro). Her fields of interest focus on the discovery of bioactive compounds towards unconventional targets.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Sarah Cargnin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=BIO-d7e1813-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sarah Cargnin</b> received her degree in Pharmacy in 2011 and her Ph.D. in Pharmaceutical and Food Biotechnologies in 2016 at the Università del Piemonte Orientale (Novara, Italy). At present, she is a post-Doc in Pharmacology at the Dept. of Pharmaceutical Sciences in Novara. Her main research interest focuses on personalized medicine.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Alberto Massarotti</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=BIO-d7e1818-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Alberto Massarotti</b> received his M.Sc. in medical and pharmaceutical biotechnology in 2006 and his Ph.D. in 2009 from the Università del Piemonte Orientale. He is currently an Associate Professor of medicinal chemistry at the same university. In 2014 he cofounded the Start Up IXTAL. His field of interest covers the development and application of novel computational methodologies to discover new lead compounds.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Gian Cesare Tron</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=BIO-d7e1823-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Gian Cesare Tron</b> is Full Professor of medicinal chemistry at the Universita′ del Piemonte Orientale (Novara, Italy). He received his degree in Pharmaceutical Chemistry and Technology in 1994 and his Ph.D. in Organic Chemistry in 2001 from the Universita′ di Torino (Italy) under the supervision of Prof. G. Appendino. He has spent sabbatical leaves in the laboratories of Prof. J. Zhu (Institut de Chimie des Substances Naturelles, Gif-sur-Yvette, France), Prof. V. Aggarwal (School of Chemistry, Bristol, UK), and Prof. V. Fokin (The Scripps Research Institute, La Jolla, United States). His research interests concern the discovery of new multicomponent reactions and their application in the field of medicinal chemistry.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Tracey Pirali</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=BIO-d7e1828-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tracey Pirali</b> received her Ph.D. in Science of Bioactive Compounds from the Università del Piemonte Orientale (Novara, Italy) in 2007. In 2016 she cofounded the Start Up ChemICare. Currently, she is Associate Professor of Medicinal Chemistry at the Università del Piemonte Orientale, and her research interests include the discovery of small molecules targeting IDO and SOCE.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Armando A. Genazzani</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=BIO-d7e1833-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Armando A. Genazzani</b> received his medical degree from the Università di Catania (Italy) and obtained his D.Phil. in Pharmacology from the University of Oxford (UK). At present, he is Head of Department and Full Professor of Pharmacology at the Università del Piemonte Orientale (Novara, Italy). He has participated in the 22nd Expert Committee for Essential Medicines in 2019, has been previously a member of the WHO INN Expert Committee, is part of the Technical and Scientific Committee of the Italian Medicines Agency (AIFA), and is a member of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).</p></figure></div><div class="ack" id="ACK-d7e2041-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">M.S. is supported by Fondazione AIRC (Associazione Italiana per la Ricerca sul Cancro) fellowship for abroad (Rif. 25278). S.C. holds a grant from Ministero della Salute (Bando Finalizzata 2016-GR-2016-02363848). T.P. and A.A.G. hold grants from Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) (PRIN 2017 Nos. 2017WJZ9W9 and 2017CBNCYT), from Telethon Foundation (GGP19110), and from Fondazione AIRC (IG201821842). The authors thank O. Mapelli for initial contributions in data mining. A.G. thanks Dr. R. Balocco, the entire INN Secretariat, and all his colleagues at the WHO for the rewarding experience serving the INN Expert Group between 2014 and 2019.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody-drug conjugate</p></td></tr><tr><td class="NLM_term">ANSI</td><td class="NLM_def"><p class="first last">American National Standards Institute</p></td></tr><tr><td class="NLM_term">ATC</td><td class="NLM_def"><p class="first last">Anatomical Therapeutic Chemical Classification System</p></td></tr><tr><td class="NLM_term">ATMP</td><td class="NLM_def"><p class="first last">advanced therapies</p></td></tr><tr><td class="NLM_term">CAS</td><td class="NLM_def"><p class="first last">Chemical Abstract Service</p></td></tr><tr><td class="NLM_term">CHON</td><td class="NLM_def"><p class="first last">carbon, hydrogen, oxygen and nitrogen</p></td></tr><tr><td class="NLM_term">CID</td><td class="NLM_def"><p class="first last">Chemically-Inducible Dimerization</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EML</td><td class="NLM_def"><p class="first last">Essential Medicines List</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">Fsp<sup>3</sup></td><td class="NLM_def"><p class="first last">fraction sp<sup>3</sup></p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">INCI</td><td class="NLM_def"><p class="first last">International Nomenclature Cosmetic Ingredient</p></td></tr><tr><td class="NLM_term">INN</td><td class="NLM_def"><p class="first last">international nonproprietary name</p></td></tr><tr><td class="NLM_term">INNM</td><td class="NLM_def"><p class="first last">international nonproprietary name modified</p></td></tr><tr><td class="NLM_term">ISO</td><td class="NLM_def"><p class="first last">International Standards Organization</p></td></tr><tr><td class="NLM_term">IUPAC</td><td class="NLM_def"><p class="first last">International Union of Pure and Applied Chemistry</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NS5B</td><td class="NLM_def"><p class="first last">nonstructural protein 5B</p></td></tr><tr><td class="NLM_term">pINN</td><td class="NLM_def"><p class="first last">proposed INN</p></td></tr><tr><td class="NLM_term">PMDA</td><td class="NLM_def"><p class="first last">Pharmaceuticals and Medical Devices Agency</p></td></tr><tr><td class="NLM_term">rINN</td><td class="NLM_def"><p class="first last">recommended INN</p></td></tr><tr><td class="NLM_term">SCE</td><td class="NLM_def"><p class="first last">small chemical entities</p></td></tr><tr><td class="NLM_term">U.S.</td><td class="NLM_def"><p class="first last">United States</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82424" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82424" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 91 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> Wikipedia. <a href="https://en.wikipedia.org/wiki/List_of_languages_by_total_number_of_speakers" class="extLink">https://en.wikipedia.org/wiki/List_of_languages_by_total_number_of_speakers</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Wikipedia.+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FList_of_languages_by_total_number_of_speakers+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <i>Ethnologue: Languages of the World</i><i>,</i> <span class="NLM_edition">23</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D. M.</span>, <span class="NLM_string-name">Simons, G. F.</span>, <span class="NLM_string-name">Fennig, C. D.</span></span>, Eds; <span class="NLM_publisher-name">SIL International</span>: <span class="NLM_publisher-loc">Dallas, TX</span>, <span class="NLM_year">2020</span>. Online version: <a href="http://www.ethnologue.com" class="extLink">http://www.ethnologue.com</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=D.+M.+Eberhard&author=G.+F.+Simons&author=C.+D.+Fennig&title=Ethnologue%3A+Languages+of+the+World"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DEthnologue%253A%2520Languages%2520of%2520the%2520World%26aulast%3DEberhard%26aufirst%3DD.%2BM.%26pub%3DSIL%2520International%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">World Health
Organization</span>. <a href="https://apps.who.int/iris/bitstream/handle/10665/86211/WHA3.11_eng.pdf" class="extLink">https://apps.who.int/iris/bitstream/handle/10665/86211/WHA3.11_eng.pdf</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization.+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F86211%2FWHA3.11_eng.pdf+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. K.</span></span> <span> </span><span class="NLM_article-title">“Where name and image meet”–the argument for “adrenaline”</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1136/bmj.320.7233.506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1136%2Fbmj.320.7233.506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10678871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BD3c7ktlKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2000&pages=506-509&author=J.+K.+Aronson&title=%E2%80%9CWhere+name+and+image+meet%E2%80%9D%E2%80%93the+argument+for+%E2%80%9Cadrenaline%E2%80%9D&doi=10.1136%2Fbmj.320.7233.506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">"Where name and image meet"--the argument for "adrenaline"</span></div><div class="casAuthors">Aronson J K</div><div class="citationInfo"><span class="NLM_cas:title">BMJ (Clinical research ed.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">7233</span>),
    <span class="NLM_cas:pages">506-9</span>
        ISSN:<span class="NLM_cas:issn">0959-8138</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsSZkL2tiuY_h3YQQtAhNufW6udTcc2eZII8xFI8Ym7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7ktlKhtQ%253D%253D&md5=0a8fb7303156e6dff7b72b571672f61d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1136%2Fbmj.320.7233.506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.320.7233.506%26sid%3Dliteratum%253Aachs%26aulast%3DAronson%26aufirst%3DJ.%2BK.%26atitle%3D%25E2%2580%259CWhere%2520name%2520and%2520image%2520meet%25E2%2580%259D%25E2%2580%2593the%2520argument%2520for%2520%25E2%2580%259Cadrenaline%25E2%2580%259D%26jtitle%3DBMJ.%26date%3D2000%26volume%3D320%26spage%3D506%26epage%3D509%26doi%3D10.1136%2Fbmj.320.7233.506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. K.</span></span> <span> </span><span class="NLM_article-title">Medication errors resulting from the confusion of drug names</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1517/14740338.3.3.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1517%2F14740338.3.3.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=15155145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ovVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=167-172&author=J.+K.+Aronson&title=Medication+errors+resulting+from+the+confusion+of+drug+names&doi=10.1517%2F14740338.3.3.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Medication errors resulting from the confusion of drug names</span></div><div class="casAuthors">Aronson Jeffrey K</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug safety</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-72</span>
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    </div><div class="casAbstract">If drug names are similar, errors can occur.  Problems arise when different drugs have similar names (whether proprietary or non-proprietary), when formulations with the same brand name contain different drugs, when the same drug is marketed in formulations with different names, and when drug names are abbreviated.  The risk of errors could be reduced by some simple precautions at different stages of drug development, prescribing, supply, and administration.  Regulatory authorities and manufacturers should maintain their vigilance when naming new drugs and formulations, and should be prepared to change names if errors occur.  Before they write an unfamiliar name on a prescription, prescribers should check what they are prescribing and what other medications the patient is taking (patients should be familiar with their medicines), and pharmacists should check patients' medicines.  At all times there should be good communication among those who prescribe, supply, and administer medicines, and those who take them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUm9ReelARjwqdek-gHSrIfW6udTcc2eYA8wDpZ2iuN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ovVSnsg%253D%253D&md5=1221787ce9905ec262e78cfd8effe146</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14740338.3.3.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.3.3.167%26sid%3Dliteratum%253Aachs%26aulast%3DAronson%26aufirst%3DJ.%2BK.%26atitle%3DMedication%2520errors%2520resulting%2520from%2520the%2520confusion%2520of%2520drug%2520names%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2004%26volume%3D3%26spage%3D167%26epage%3D172%26doi%3D10.1517%2F14740338.3.3.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Personal Care Products Council</span>. <a href="https://www.personalcarecouncil.org/resources/inci/" class="extLink">https://www.personalcarecouncil.org/resources/inci/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Personal+Care+Products+Council.+https%3A%2F%2Fwww.personalcarecouncil.org%2Fresources%2Finci%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olliaro, P. L.</span></span> <span> </span><span class="NLM_article-title">Drugs for treating urinary schistosomiasis</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">CD000053</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD000053.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1002%2F14651858.CD000053.pub3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=CD000053&author=C.+V.+Kramerauthor=F.+Zhangauthor=D.+Sinclairauthor=P.+L.+Olliaro&title=Drugs+for+treating+urinary+schistosomiasis&doi=10.1002%2F14651858.CD000053.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD000053.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD000053.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DC.%2BV.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DSinclair%26aufirst%3DD.%26aulast%3DOlliaro%26aufirst%3DP.%2BL.%26atitle%3DDrugs%2520for%2520treating%2520urinary%2520schistosomiasis%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2014%26volume%3D8%26spage%3DCD000053%26doi%3D10.1002%2F14651858.CD000053.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/medicines/services/inn/inn_expert_group/en/" class="extLink">https://www.who.int/medicines/services/inn/inn_expert_group/en/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fservices%2Finn%2Finn_expert_group%2Fen%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">World Health
Organization</span>. <a href="https://www.who.int/medicines/services/inn/publication/en/" class="extLink">https://www.who.int/medicines/services/inn/publication/en/</a> (accessed
2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fservices%2Finn%2Fpublication%2Fen%2F+%28accessed%0A2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span>Stem Book
2018. <a href="https://www.who.int/publications/i/item/who-emp-rht-tsn-2018-1" class="extLink">https://www.who.int/publications/i/item/who-emp-rht-tsn-2018-1</a> (accessed 2021-01-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Stem+Book%0A2018.+https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fwho-emp-rht-tsn-2018-1+%28accessed+2021-01-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span>Radical
Book 2015. <a href="https://www.who.int/medicines/services/inn/RadicalBook2015.pdf?ua=1" class="extLink">https://www.who.int/medicines/services/inn/RadicalBook2015.pdf?ua=1</a> (accessed 2021-01-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Radical%0ABook+2015.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fservices%2Finn%2FRadicalBook2015.pdf%3Fua%3D1+%28accessed+2021-01-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López
de la Rica Manjavacas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balocco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span> <span> </span><span class="NLM_article-title">The INN global nomenclature of biological medicines: A continuous challenge</span>. <i>Biologicals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.biologicals.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.biologicals.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31130314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB3M7pvFSksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=15-23&author=J.+S.+Robertsonauthor=W.+K.+Chuiauthor=A.+A.+Genazzaniauthor=S.+F.+Malanauthor=A.+L%C3%B3pez%0Ade+la+Rica+Manjavacasauthor=G.+Mignotauthor=R.+Thorpeauthor=R.+Baloccoauthor=M.+Rizzi&title=The+INN+global+nomenclature+of+biological+medicines%3A+A+continuous+challenge&doi=10.1016%2Fj.biologicals.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The INN global nomenclature of biological medicines: A continuous challenge</span></div><div class="casAuthors">Robertson James S; Thorpe Robin; Chui Wai-Keung; Genazzani Armando A; Malan Sarel F; Lopez de la Rica Manjavacas Ana; Mignot Gilles; Balocco Raffaella; Rizzi Menico</div><div class="citationInfo"><span class="NLM_cas:title">Biologicals : journal of the International Association of Biological Standardization</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Medicines are assigned International Nonproprietary Names (INN) by the World Health Organization (WHO), pursuing the aim to increase patient safety.  Following scientific developments in drug discovery and biotechnology, the number of biological medicines is constantly growing and a surge in INN applications for them has been observed.  Pharmacologically active biological substances have a complex structure and mechanism of action posing new challenges in selecting names that appropriately reflect such properties.  As a consequence, existing nomenclature naming schemes may need to be revised and new ones developed.  This review reports on the recently implemented policies for naming fusion proteins, monoclonal antibodies, advanced therapy substances that cover gene and cell therapy, virus-based therapies as well as vaccines and vaccine-like substances.  Different approaches, based on the use of a one-word versus a two-word naming scheme, have been developed for different categories of biological substances highlighting a major and still not completely resolved issue, i.e. how to assign a name that is both informative, short and euphonic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSFdG8dheR5wWRJ3OJdH_qfW6udTcc2eYA8wDpZ2iuN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7pvFSksQ%253D%253D&md5=4ce97e0a760415c62c858a8bab02bf20</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.biologicals.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biologicals.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BS.%26aulast%3DChui%26aufirst%3DW.%2BK.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26aulast%3DMalan%26aufirst%3DS.%2BF.%26aulast%3DL%25C3%25B3pez%2Bde%2Bla%2BRica%2BManjavacas%26aufirst%3DA.%26aulast%3DMignot%26aufirst%3DG.%26aulast%3DThorpe%26aufirst%3DR.%26aulast%3DBalocco%26aufirst%3DR.%26aulast%3DRizzi%26aufirst%3DM.%26atitle%3DThe%2520INN%2520global%2520nomenclature%2520of%2520biological%2520medicines%253A%2520A%2520continuous%2520challenge%26jtitle%3DBiologicals%26date%3D2019%26volume%3D60%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.biologicals.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span> </span><span class="NLM_article-title">School of International Non-proprietary
Names</span>. <a href="https://extranet.who.int/soinn/" class="extLink">https://extranet.who.int/soinn/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=School+of+International+Non-proprietary%0ANames.+https%3A%2F%2Fextranet.who.int%2Fsoinn%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSchool%2520of%2520International%2520Non-proprietary%250ANames" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/medicines/publications/druginformation/innlists/en/" class="extLink">https://www.who.int/medicines/publications/druginformation/innlists/en/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fpublications%2Fdruginformation%2Finnlists%2Fen%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A survey of the structures of US FDA approved combination drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4311</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4265-4311&author=P.+Dasauthor=M.+D.+Delostauthor=M.+H.+Qureshiauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=A+survey+of+the+structures+of+US+FDA+approved+combination+drugs&doi=10.1021%2Facs.jmedchem.8b01610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Structures of US FDA Approved Combination Drugs</span></div><div class="casAuthors">Das, Pradipta; Delost, Michael D.; Qureshi, Munaum H.; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4265-4311</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combination drugs are an important class of US FDA approved pharmaceuticals.  These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s.  In this Perspective, we report the first comprehensive compilation and anal. of US FDA approved combination drugs, from the first approval in 1943 through 2018.  Our database contains 419 combination drugs, which are represented by 328 unique small mol. structures.  Breakdown of these drugs according to disease category, structure, combination compn., and year of approval is presented as well as the top 24 most commonly used small mol. combination drug components.  For frequently used small mol. components, we present "relationship diagrams" to aid in the visualization of the many drug combinations these structures are part of.  The main body contains 10 disease-focused sections wherein every small mol. component utilized as part of a combination for each disease category is displayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8XxgcuwxFEbVg90H21EOLACvtfcHk0lgnyXAflAje7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J&md5=caeeef6298591e300a93782176e87ab8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01610%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DP.%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DQureshi%26aufirst%3DM.%2BH.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520survey%2520of%2520the%2520structures%2520of%2520US%2520FDA%2520approved%2520combination%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4265%26epage%3D4311%26doi%3D10.1021%2Facs.jmedchem.8b01610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two decades under the influence of the rule of five and the changing properties of approved oral drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+decades+under+the+influence+of+the+rule+of+five+and+the+changing+properties+of+approved+oral+drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lgnyXAflAje7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520decades%2520under%2520the%2520influence%2520of%2520the%2520rule%2520of%2520five%2520and%2520the%2520changing%2520properties%2520of%2520approved%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">From oxiranes to oligomers: Architectures of U.S. FDA approved pharmaceuticals containing oxygen heterocycles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10996</span>– <span class="NLM_lpage">11020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00876</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10996-11020&author=M.+D.+Delostauthor=D.+T.+Smithauthor=B.+J.+Andersonauthor=J.+T.+Njardarson&title=From+oxiranes+to+oligomers%3A+Architectures+of+U.S.+FDA+approved+pharmaceuticals+containing+oxygen+heterocycles&doi=10.1021%2Facs.jmedchem.8b00876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles</span></div><div class="casAuthors">Delost, Michael D.; Smith, David T.; Anderson, Benton J.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10996-11020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals.  Anal. of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals contg. at least one oxygen heterocycle.  Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five.  The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-contg. heterocycles.  For each section, all oxygen heterocycle-contg. drugs are presented along with a brief discussion about structural and drug application patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor-PzQmLXoGbVg90H21EOLACvtfcHk0lgEx7N47UnFoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE&md5=18f3979c80513bfbbc263dd5945c63f0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00876%26sid%3Dliteratum%253Aachs%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DAnderson%26aufirst%3DB.%2BJ.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DFrom%2520oxiranes%2520to%2520oligomers%253A%2520Architectures%2520of%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%2520containing%2520oxygen%2520heterocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10996%26epage%3D11020%26doi%3D10.1021%2Facs.jmedchem.8b00876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of US FDA-approved drugs containing sulfur atoms</span>. <i>Top Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1007/s41061-018-0184-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2Fs41061-018-0184-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=29356979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjtVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2018&pages=5&author=K.+A.+Scottauthor=J.+T.+Njardarson&title=Analysis+of+US+FDA-approved+drugs+containing+sulfur+atoms&doi=10.1007%2Fs41061-018-0184-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of US FDA-Approved Drugs Containing Sulfur Atoms</span></div><div class="casAuthors">Scott Kevin A; Njardarson Jon T; Scott Kevin A</div><div class="citationInfo"><span class="NLM_cas:title">Topics in current chemistry (Cham)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn">2365-0869</span>.
    </div><div class="casAbstract">In this review, we discuss all sulfur-containing FDA-approved drugs and their structures.  The second section of the review is dedicated to structural analysis and is divided into 14 subsections, each focusing on one type of sulfur-containing moiety.  A concise graphical representation of each class features drugs that are organized on the basis of structural similarity, evolutionary relevance, and medical indication.  This review offers a unique and comprehensive overview of the structural features of all sulfur-containing FDA-approved drugs to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX4OluBMto4cULxIEhxUjPfW6udTcc2eaRN9PdAUQv0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjtVWksA%253D%253D&md5=2dcb48e2346e2d3df04fa1c24e3d6dfe</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs41061-018-0184-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41061-018-0184-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520US%2520FDA-approved%2520drugs%2520containing%2520sulfur%2520atoms%26jtitle%3DTop%2520Curr.%2520Chem.%26date%3D2018%26volume%3D376%26spage%3D5%26doi%3D10.1007%2Fs41061-018-0184-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the rule of 5: Lessons learned from AbbVie’s drugs and compound collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&author=D.+A.+DeGoeyauthor=H.+J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+rule+of+5%3A+Lessons+learned+from+AbbVie%E2%80%99s+drugs+and+compound+collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0lgEx7N47UnFoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520rule%2520of%25205%253A%2520Lessons%2520learned%2520from%2520AbbVie%25E2%2580%2599s%2520drugs%2520and%2520compound%2520collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+U.S.+FDA+approved+pharmaceuticals&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0lgEx7N47UnFoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Beyond C, H, O, and N! Analysis of the elemental composition of U.S. FDA approved drug architectures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9764</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/jm501105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9764-9773&author=B.+R.+Smithauthor=C.+M.+Eastmanauthor=J.+T.+Njardarson&title=Beyond+C%2C+H%2C+O%2C+and+N%21+Analysis+of+the+elemental+composition+of+U.S.+FDA+approved+drug+architectures&doi=10.1021%2Fjm501105n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond C, H, O, and N! Analysis of the Elemental Composition of U.S. FDA Approved Drug Architectures</span></div><div class="casAuthors">Smith, Brandon R.; Eastman, Candice M.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9764-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The diversity of elements among U.S.  Food and Drug Administration (FDA) approved pharmaceuticals is analyzed and reported, with a focus on atoms other than carbon, hydrogen, oxygen, and nitrogen.  Our anal. reveals that sulfur, chlorine, fluorine, and phosphorous represent about 90% of elemental substitutions, with sulfur being the fifth most used element followed closely by chlorine, then fluorine and finally phosphorous in the eighth place.  The remaining 10% of substitutions are represented by 16 other elements of which bromine, iodine, and iron occur most frequently.  The most detailed parts of our anal. are focused on chlorinated drugs as a function of approval date, disease condition, chlorine attachment, and structure.  To better aid our chlorine drug analyses, a new poster showcasing the structures of chlorinated pharmaceuticals was created specifically for this study.  Phosphorus, bromine, and iodine contg. drugs are analyzed closely as well, followed by a discussion about other elements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLwTieDN1HbVg90H21EOLACvtfcHk0ljYkuVYXLLUWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL&md5=95e1ab686ba41c63070059ad0987ff6c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm501105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501105n%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DEastman%26aufirst%3DC.%2BM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DBeyond%2520C%252C%2520H%252C%2520O%252C%2520and%2520N%2521%2520Analysis%2520of%2520the%2520elemental%2520composition%2520of%2520U.S.%2520FDA%2520approved%2520drug%2520architectures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9764%26epage%3D9773%26doi%3D10.1021%2Fjm501105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2842</span>, <span class="refDoi"> DOI: 10.1021/jm401375q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+design+and+discovery&doi=10.1021%2Fjm401375q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0ljYkuVYXLLUWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842%26doi%3D10.1021%2Fjm401375q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellaire, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, B. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A Structural analysis of the FDA Green Book-approved veterinary drugs and roles in human medicine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">15449</span>– <span class="NLM_lpage">15482</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2iu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=15449-15482&author=K.+A.+Scottauthor=M.+H.+Qureshiauthor=P.+B.+Coxauthor=C.+M.+Marshallauthor=B.+C.+Bellaireauthor=M.+Wilcoxauthor=B.+A.+R.+Stuartauthor=J.+T.+Njardarson&title=A+Structural+analysis+of+the+FDA+Green+Book-approved+veterinary+drugs+and+roles+in+human+medicine&doi=10.1021%2Facs.jmedchem.0c01502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine</span></div><div class="casAuthors">Scott, Kevin A.; Qureshi, M. Haziq; Cox, Philip B.; Marshall, Christopher M.; Bellaire, Bailey C.; Wilcox, Michael; Stuart, Bradey A. R.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15449-15482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The FDA Green Book is a list of all drug products that have been approved by the FDA for use in veterinary medicine.  The Green Book, as published, lacks structural information corresponding to approved drugs.  To address this gap, we have compiled the structural data for all FDA Green Book drugs approved through the end of 2019.  Herein we discuss the relevance of this data set to human drugs in the context of structural classes and physicochem. properties.  Anal. reveals that physicochem. properties are highly optimized and consistent with a high probability of favorable drug metab. and pharmacokinetic properties, including good oral bioavailability for most compds.  We provide a detailed anal. of this data set organized on the basis of structure and function.  Slightly over half (51%) of vet drugs are also approved in human medicine.  Combination drugs are biologics are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGJ3v34Bzi-7Vg90H21EOLACvtfcHk0ljYkuVYXLLUWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2iu7zL&md5=bfccb59426934314de5e774431af78ea</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01502%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26aulast%3DQureshi%26aufirst%3DM.%2BH.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DMarshall%26aufirst%3DC.%2BM.%26aulast%3DBellaire%26aufirst%3DB.%2BC.%26aulast%3DWilcox%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DB.%2BA.%2BR.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520Structural%2520analysis%2520of%2520the%2520FDA%2520Green%2520Book-approved%2520veterinary%2520drugs%2520and%2520roles%2520in%2520human%2520medicine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D15449%26epage%3D15482%26doi%3D10.1021%2Facs.jmedchem.0c01502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Essential medicinal chemistry of essential medicines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10170</span>– <span class="NLM_lpage">10187</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00415</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotl2qt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10170-10187&author=M.+Serafiniauthor=S.+Cargninauthor=A.+Massarottiauthor=T.+Piraliauthor=A.+A.+Genazzani&title=Essential+medicinal+chemistry+of+essential+medicines&doi=10.1021%2Facs.jmedchem.0c00415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Essential Medicinal Chemistry of Essential Medicines</span></div><div class="casAuthors">Serafini, Marta; Cargnin, Sarah; Massarotti, Alberto; Pirali, Tracey; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10170-10187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Since 1977, the World Health Organization publishes a list of essential medicines, i.e., those that satisfy the priority health care needs of the population and are selected with regard to disease prevalence and public health relevance, evidence of clin. efficacy, and safety, as well as comparative costs and cost-effectiveness.  The Essential Medicines List (EML) is an invaluable tool for all countries to select those medicines that have an excellent risk/benefit ratio and that are reputed to be of pivotal importance to health.  In the present perspective, we describe the chem. compn. and the main features of the small mols. that are included in the EML, spanning from their origin, to their stereochem. and measure of drug-likeness.  Most and foremost, we wish to disseminate the importance of the EML, which can be both a helpful teaching tool in an ever-expanding world of medicines and an inspiration for those involved in pharmaceutical R&D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9SxMf0szdPrVg90H21EOLACvtfcHk0lh8fdn-LnHRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotl2qt74%253D&md5=db1e89fcc1eac121a5c23af2b063bb3a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00415%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DEssential%2520medicinal%2520chemistry%2520of%2520essential%2520medicines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10170%26epage%3D10187%26doi%3D10.1021%2Facs.jmedchem.0c00415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, J.</span></span> <span> </span><span class="NLM_article-title">The most common functional groups in bioactive molecules and how their popularity has evolved over time</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8408</span>– <span class="NLM_lpage">8418</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00754</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00754" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8408-8418&author=P.+Ertlauthor=E.+Altmannauthor=J.+McKenna&title=The+most+common+functional+groups+in+bioactive+molecules+and+how+their+popularity+has+evolved+over+time&doi=10.1021%2Facs.jmedchem.0c00754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time</span></div><div class="casAuthors">Ertl, Peter; Altmann, Eva; McKenna, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8408-8418</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of functional groups (FGs), sets of connected atoms that can det. the intrinsic reactivity of the parent mol. and in part are responsible for the overall properties of the mol., form a foundation within modern medicinal chem.  In this Article, we analyze the occurrence of various FGs in mols. described in the medicinal chem. literature over the last 40 years and show how their development and utilization over time has varied.  The popularity of various FGs has not evolved randomly, but instead, clear patterns of use are evident.  Various factors influencing these patterns, including the introduction of new synthetic methods, novel techniques, and strategies applied in drug discovery and the better knowledge of mol. properties affecting the success of candidate development, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6iMIvgb6l7Vg90H21EOLACvtfcHk0lh8fdn-LnHRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurjO&md5=17fc5a390c5642ab234c0fa7202f7a74</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00754%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DAltmann%26aufirst%3DE.%26aulast%3DMcKenna%26aufirst%3DJ.%26atitle%3DThe%2520most%2520common%2520functional%2520groups%2520in%2520bioactive%2520molecules%2520and%2520how%2520their%2520popularity%2520has%2520evolved%2520over%2520time%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8408%26epage%3D8418%26doi%3D10.1021%2Facs.jmedchem.0c00754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Where do recent small molecule clinical development candidates come from?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Where+do+recent+small+molecule+clinical+development+candidates+come+from%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0lh8fdn-LnHRvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DWhere%2520do%2520recent%2520small%2520molecule%2520clinical%2520development%2520candidates%2520come%2520from%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">These substances have been labeled with an asterisk in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00181/suppl_file/jm1c00181_si_001.xlsx" class="ext-link">Supporting Information</a> database, since their proposed INNs were submitted by WHO several years before their publication in the rINN list.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">On the one hand, the category of biologicals includes proteins, including those in which some amino acid residues have been modified, low molecular weight heparins, purified hormones, and small peptides. On the other hand, when a short peptide (up to four-five amino acids) was present in an otherwise SCE (e.g., vintafolide, r69;2013), this substance was inserted in the SCE category. Note that the number of mAbs is slightly overestimated, as often, in the same rINN list, the applicant applied for the mAb itself together with a second application for the relative conjugate (30 examples in the analyzed lists). Pegylation, indicated as either the prefix “peg” or the suffix “pegol”, has not been considered in the classification of the substances. RNA/DNA-based therapies broadly comprise antisense, siRNA, and mRNA-based therapies. Advanced therapies comprise gene and cell therapies, oncolytic viruses, or bacteria. The category of veterinary drugs has been compiled following the indication reported in the proposed INN volumes, and not on chemical or biological structures, but it must be recognized that also drugs not specifically categorized as veterinary during the INN application process may be then developed for veterinary use. Surprisingly, the lists also include a few sunscreens, possibly because these are not considered cosmetic ingredients for the U.S. legislation.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="note"><p class="first last">Belzupacap sarotalocan is described in list p122 as “A modified human papillomavirus (HPV) type 16-derived empty nanoparticle, 55 nm in diameter conjugated to approximately 200 molecules of a phthalocyanine-based photosensitizer (sarotalocan group). Each nanoparticle is comprised of 72 capsomeres, made of 5 molecules of modified viral capsid protein L1 [P78 > R, T176 > N, D273 > T, N285 > T, S288 > N, T353 > P, T389 > S] and one molecule of viral capsid protein L2”.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span> </span><span class="NLM_article-title">FDA-approved
drugs</span>. <a href="https://www.accessdata.fda.gov/scripts/cder/daf/" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/</a> (accessed 2020-09-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA-approved%0Adrugs.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2F+%28accessed+2020-09-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA-approved%250Adrugs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span> </span><span class="NLM_article-title">EMA EPARs for human
and veterinary medicines</span>. <a href="https://www.ema.europa.eu/en/medicines/download-medicine-data" class="extLink">https://www.ema.europa.eu/en/medicines/download-medicine-data</a> (accessed 2020-09-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EMA+EPARs+for+human%0Aand+veterinary+medicines.+https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fmedicines%2Fdownload-medicine-data+%28accessed+2020-09-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEMA%2520EPARs%2520for%2520human%250Aand%2520veterinary%2520medicines" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span> </span><span class="NLM_article-title">PMDA-approved drugs</span>. <a href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html" class="extLink">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html</a> (accessed 2020-09-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PMDA-approved+drugs.+https%3A%2F%2Fwww.pmda.go.jp%2Fenglish%2Freview-services%2Freviews%2Fapproved-information%2Fdrugs%2F0002.html+%28accessed+2020-09-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPMDA-approved%2520drugs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">To this aim, we used the following Web sites and databases:</p></div><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <a href="http://adisinsight.springer.com" class="extLink">adisinsight.springer.com</a> (accessed 2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+adisinsight.springer.com+%28accessed+2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <a href="http://www.wikipedia.org" class="extLink">www.wikipedia.org</a> (accessed
2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+www.wikipedia.org+%28accessed%0A2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span> <a href="http://newdrugapprovals.org" class="extLink">newdrugapprovals.org</a> (accessed
2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+newdrugapprovals.org+%28accessed%0A2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bargh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidro-Llobet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cleavable linkers in antibody-drug conjugates</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4361</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/C8CS00676H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2FC8CS00676H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31294429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=4361-4374&author=J.+D.+Barghauthor=A.+Isidro-Llobetauthor=J.+S.+Parkerauthor=D.+R.+Spring&title=Cleavable+linkers+in+antibody-drug+conjugates&doi=10.1039%2FC8CS00676H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cleavable linkers in antibody-drug conjugates</span></div><div class="casAuthors">Bargh, Jonathan D.; Isidro-Llobet, Albert; Parker, Jeremy S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4361-4374</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clin. treatment of cancer.  The properties of the linker between the antibody and the payload are proven to be crit. to the success of an ADC.  Although ADC linkers can be 'non-cleavable', the vast majority of ADCs in clin. development have specific release mechanisms to allow controlled linker cleavage at the target site and are thus termed 'cleavable'.  In recent years, the development of new methods of drug release from ADCs has continued in parallel to the deepening understanding of the biol. processes underlying the mechanisms of action of pre-existing technologies.  This review summarises the advances in the field of cleavable linker technologies for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG2Xk9IvLpLVg90H21EOLACvtfcHk0ljvwzxSHyMk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M&md5=bc73619319b21c2b85e3d613ca72f778</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1039%2FC8CS00676H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00676H%26sid%3Dliteratum%253Aachs%26aulast%3DBargh%26aufirst%3DJ.%2BD.%26aulast%3DIsidro-Llobet%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCleavable%2520linkers%2520in%2520antibody-drug%2520conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26spage%3D4361%26epage%3D4374%26doi%3D10.1039%2FC8CS00676H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8751</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVagurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8751-61&author=G.+Casiauthor=D.+Neri&title=Antibody-Drug+Conjugates+and+small+molecule-drug+conjugates%3A+opportunities+and+challenges+for+the+development+of+selective+anticancer+cytotoxic+agents&doi=10.1021%2Facs.jmedchem.5b00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents</span></div><div class="casAuthors">Casi, Giulio; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8751-8761</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose escalation to therapeutically active regimens.  In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the neoplastic mass.  For many years, the availability of ligands, capable of selective internalization into tumor cells, has been considered to be an essential requirement for the development of targeted cytotoxics.  This assumption, however, has recently been challenged on the basis of therapeutic data obtained with noninternalizing drug conjugates.  Moreover, quant. evaluations of the tumor targeting properties of antibodies and of small org. ligands have provided new insights for the implementation of optimal strategies for the development of targeted cytotoxics.  In this article, we highlight opportunities and challenges assocd. with the clin. and industrial development of antibody-drug conjugates and small mol.-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFQV1Ekvuz8rVg90H21EOLACvtfcHk0ljvwzxSHyMk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVagurzO&md5=24614e4825cbfe408e0b875db1826e68</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00457%26sid%3Dliteratum%253Aachs%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DAntibody-Drug%2520Conjugates%2520and%2520small%2520molecule-drug%2520conjugates%253A%2520opportunities%2520and%2520challenges%2520for%2520the%2520development%2520of%2520selective%2520anticancer%2520cytotoxic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8751%26epage%3D61%26doi%3D10.1021%2Facs.jmedchem.5b00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span>RDKit,
2020.09.1 version: Open-Source Cheminformatics Software. <a href="https://www.rdkit.org" class="extLink">https://www.rdkit.org</a>. (accessed
2020-08-07).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RDKit%2C%0A2020.09.1+version%3A+Open-Source+Cheminformatics+Software.+https%3A%2F%2Fwww.rdkit.org.+%28accessed%0A2020-08-07%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lig8RP492Sgaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachhav, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajanna, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">U.S. FDA approved drugs from 2015–June 2020: a perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2339</span>– <span class="NLM_lpage">2381</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01786</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01786" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltVyrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=2339-2381&author=P.+Bhutaniauthor=G.+Joshiauthor=N.+Rajaauthor=N.+Bachhavauthor=P.+K.+Rajannaauthor=H.+Bhutaniauthor=A.+T.+Paulauthor=R.+Kumar&title=U.S.+FDA+approved+drugs+from+2015%E2%80%93June+2020%3A+a+perspective&doi=10.1021%2Facs.jmedchem.0c01786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. FDA Approved Drugs from 2015-June 2020: A Perspective</span></div><div class="casAuthors">Bhutani, Priyadeep; Joshi, Gaurav; Raja, Nivethitha; Bachhav, Namrata; Rajanna, Prabhakar K.; Bhutani, Hemant; Paul, Atish T.; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2339-2381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present work, we report compilation and anal. of 245 drugs, including small and macromols. approved by the U.  S. FDA from 2015 until June 2020.  Nearly 29% of the drugs were approved for the treatment of various types of cancers.  Other major therapeutic areas of focus were infectious diseases (14%); neurol. conditions (12%); and genetic, metabolic, and cardiovascular disorders (7-8% each).  Itemization of the approved drugs according to the year of approval, sponsor, target, chem. class, major drug-metabolizing enzyme(s), route of administration/elimination, and drug-drug interaction liability (perpetrator or/and victim) is presented and discussed.  An effort has been made to analyze the pharmacophores to identity the structural (e.g., arom., heterocycle, and aliph.), elemental (e.g., boron, sulfur, fluorine, phosphorus, and deuterium), and functional group (e.g., nitro drugs) diversity among the approved drugs.  Further, descriptor-based chem. space anal. of FDA approved drugs and several strategies utilized for optimizing metab. leading to their discoveries have been emphasized.  Finally, an anal. of drug-likeness for the approved drugs is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTyUH9SM6PbVg90H21EOLACvtfcHk0lig8RP492Sgaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltVyrsLs%253D&md5=476a6161406118f193f2bca000cbd20d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26aulast%3DBhutani%26aufirst%3DP.%26aulast%3DJoshi%26aufirst%3DG.%26aulast%3DRaja%26aufirst%3DN.%26aulast%3DBachhav%26aufirst%3DN.%26aulast%3DRajanna%26aufirst%3DP.%2BK.%26aulast%3DBhutani%26aufirst%3DH.%26aulast%3DPaul%26aufirst%3DA.%2BT.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DU.S.%2520FDA%2520approved%2520drugs%2520from%25202015%25E2%2580%2593June%25202020%253A%2520a%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D2339%26epage%3D2381%26doi%3D10.1021%2Facs.jmedchem.0c01786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Sun, L.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Kongsted, J.</span>; <span class="NLM_string-name">Poongavanam, V.</span>; <span class="NLM_string-name">Zhan, P.</span>; <span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the medicinal chemistry of single boron atom-containing compounds</span>.  <i>Acta Pharm. Sin. B</i> [Online early access]. <span class="NLM_year" style="font-weight: bold;">2021</span><span class="refDoi"> DOI: 10.1016/j.apsb.2021.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.apsb.2021.01.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=S.+Song&author=P.+Gao&author=L.+Sun&author=D.+Kang&author=J.+Kongsted&author=V.+Poongavanam&author=P.+Zhan&author=X.+Liu&title=Recent+developments+in+the+medicinal+chemistry+of+single+boron+atom-containing+compounds&doi=10.1016%2Fj.apsb.2021.01.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2021.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2021.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DS.%26atitle%3DRecent%2520developments%2520in%2520the%2520medicinal%2520chemistry%2520of%2520single%2520boron%2520atom-containing%2520compounds%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2021%26doi%3D10.1016%2Fj.apsb.2021.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, G. F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Boron in drug design: Recent advances in the development of new therapeutic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.ejmech.2019.06.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31288128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=791-804&author=G.+F.+S.+Fernandesauthor=W.+A.+Dennyauthor=J.+L.+Dos+Santos&title=Boron+in+drug+design%3A+Recent+advances+in+the+development+of+new+therapeutic+agents&doi=10.1016%2Fj.ejmech.2019.06.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Boron in drug design: Recent advances in the development of new therapeutic agents</span></div><div class="casAuthors">Fernandes, Guilherme Felipe Santos; Denny, William Alexander; Dos Santos, Jean Leandro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Advances in the field of boron chem. have expanded the application of this element in Medicinal Chem.  Boron-contg. compds. represent a new class for medicinal chemists to use in their drug designs.  Bortezomib, a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-contg. compds. After its approval, two other boron-contg. compds. have been approved, tavaborole for the treatment of onychomycosis and crisaborole for the treatment of mild to moderate atopic dermatitis.  A no. of boron-contg. compds. have been described and evaluated for a plethora of therapeutic applications.  The present review is intended to highlight the recent advances related to boron-contg. compds. and their therapeutic applications.  Here, we focused only in those most biol. active compds. with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNneApZtw8C7Vg90H21EOLACvtfcHk0ljoDX_o6nlozg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE&md5=52c7677a4b6213be8a03b48c3981bba4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.092%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DG.%2BF.%2BS.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DBoron%2520in%2520drug%2520design%253A%2520Recent%2520advances%2520in%2520the%2520development%2520of%2520new%2520therapeutic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.ejmech.2019.06.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, D. S.</span></span> <span> </span><span class="NLM_article-title">Quest for novel chemical entities through incorporation of silicon in drug scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3779</span>– <span class="NLM_lpage">3798</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3779-3798&author=R.+Rameshauthor=D.+S.+Reddy&title=Quest+for+novel+chemical+entities+through+incorporation+of+silicon+in+drug+scaffolds&doi=10.1021%2Facs.jmedchem.7b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds</span></div><div class="casAuthors">Ramesh, Remya; Reddy, D. Srinivasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3779-3798</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to optimize a lead mol. for further development, bioisosteric replacements are generally adopted as one of the strategies.  Silicon appears to be the right choice as a carbon isostere because of the similarity in chem. properties.  Silicon can be strategically introduced in a mol. to modulate its druglike properties, providing medicinal chemists with an unconventional strategy for replacing a carbon atom.  Silicon can also be introduced to replace other heteroatoms and can act as a surrogate of functional groups such as olefin and amide as well.  The present Perspective focuses on the opportunities that silicon incorporation offers in drug discovery, with an emphasis on case studies where introduction of silicon has created a benefit over its analog.  We have tried to highlight all the recent developments in the field and briefly discuss the challenges assocd. with them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjk4JZC1BTKLVg90H21EOLACvtfcHk0ljoDX_o6nlozg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM&md5=fa3da0fddb955d156d410eb68030e78a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00718%26sid%3Dliteratum%253Aachs%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26atitle%3DQuest%2520for%2520novel%2520chemical%2520entities%2520through%2520incorporation%2520of%2520silicon%2520in%2520drug%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3779%26epage%3D3798%26doi%3D10.1021%2Facs.jmedchem.7b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleemiss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvinage, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaspina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleemiss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puylaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staubitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzschentke, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dringen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, J.</span></span> <span> </span><span class="NLM_article-title">Sila-ibuprofen</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12614</span>– <span class="NLM_lpage">12622</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00813</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00813" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCrtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12614-12622&author=F.+Kleemissauthor=A.+Justiesauthor=D.+Duvinageauthor=P.+Watermannauthor=E.+Ehrkeauthor=K.+Sugimotoauthor=M.+Fugelauthor=L.+A.+Malaspinaauthor=A.+Dittmerauthor=T.+Kleemissauthor=P.+Puylaertauthor=N.+R.+Kingauthor=A.+Staubitzauthor=T.+M.+Tzschentkeauthor=R.+Dringenauthor=S.+Grabowskyauthor=J.+Beckmann&title=Sila-ibuprofen&doi=10.1021%2Facs.jmedchem.0c00813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Sila-Ibuprofen</span></div><div class="casAuthors">Kleemiss, Florian; Justies, Aileen; Duvinage, Daniel; Watermann, Patrick; Ehrke, Eric; Sugimoto, Kunihisa; Fugel, Malte; Malaspina, Lorraine A.; Dittmer, Anneke; Kleemiss, Torsten; Puylaert, Pim; King, Nelly R.; Staubitz, Anne; Tzschentke, Thomas M.; Dringen, Ralf; Grabowsky, Simon; Beckmann, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12614-12622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, characterization, biol. activity and toxicol. of sila-ibuprofen, a Si deriv. of the most common nonsteroidal antiinflammatory drug, is reported.  Key improvements compared to ibuprofen are a four times higher soly. in physiol. media and a lower melting enthalpy, which were attributed to the C-Si switch.  The improved soly. is of interest for post-surgical i.v. administration.  A potential for pain relief is rationalized via inhibition expts. of cyclooxygenases I and II (COX-I and COX-II) as well as via a set of newly developed methods that combine mol. dynamics, quantum chem. and quantum crystallog.  The binding affinity of sila-ibuprofen to COX-I and COX-II is quantified in terms of London dispersion and electrostatic interactions in the active receptor site.  This study shows not only the potential of sila-ibuprofen for medicinal application, but also improves the authors' understanding of the mechanism of action of the inhibition process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz0jUeMYjPDbVg90H21EOLACvtfcHk0ljoDX_o6nlozg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCrtbvI&md5=2d57e497c4fbda852ddbd52583328cdd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00813%26sid%3Dliteratum%253Aachs%26aulast%3DKleemiss%26aufirst%3DF.%26aulast%3DJusties%26aufirst%3DA.%26aulast%3DDuvinage%26aufirst%3DD.%26aulast%3DWatermann%26aufirst%3DP.%26aulast%3DEhrke%26aufirst%3DE.%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DFugel%26aufirst%3DM.%26aulast%3DMalaspina%26aufirst%3DL.%2BA.%26aulast%3DDittmer%26aufirst%3DA.%26aulast%3DKleemiss%26aufirst%3DT.%26aulast%3DPuylaert%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DN.%2BR.%26aulast%3DStaubitz%26aufirst%3DA.%26aulast%3DTzschentke%26aufirst%3DT.%2BM.%26aulast%3DDringen%26aufirst%3DR.%26aulast%3DGrabowsky%26aufirst%3DS.%26aulast%3DBeckmann%26aufirst%3DJ.%26atitle%3DSila-ibuprofen%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12614%26epage%3D12622%26doi%3D10.1021%2Facs.jmedchem.0c00813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Applications of deuterium in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5276</span>– <span class="NLM_lpage">5297</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5276-5297&author=T.+Piraliauthor=M.+Serafiniauthor=S.+Cargninauthor=A.+A.+Genazzani&title=Applications+of+deuterium+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.8b01808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of deuterium in medicinal chemistry</span></div><div class="casAuthors">Pirali, Tracey; Serafini, Marta; Cargnin, Sarah; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5276-5297</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of deuteration in medicinal chem. has exploded in the past years, and the FDA has recently approved the first deuterium-labeled drug.  Precision deuteration goes beyond the pure and simple amelioration of the pharmacokinetic parameters of a drug and might provide an opportunity when facing problems in terms of metab.-mediated toxicity, drug interactions, and low bioactivation.  The use of deuterium is even broader, offering the opportunity to lower the degree of epimerization, reduce the dose of coadministered boosters, and discover compds. where deuterium is the basis for the mechanism of action.  Nevertheless, designing, synthesizing, and developing a successful deuterated drug is far from straightforward, and the translation from concept to practice is often unpredictable.  This Perspective provides an overview of the recent developments of deuteration, with a focus on deuterated clin. candidates, and highlights both opportunities and challenges of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ICy0AH9zGLVg90H21EOLACvtfcHk0li8RFZ4oEQe1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D&md5=1ce58dbff268894dc319bfc00a1ae01f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01808%26sid%3Dliteratum%253Aachs%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DApplications%2520of%2520deuterium%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5276%26epage%3D5297%26doi%3D10.1021%2Facs.jmedchem.8b01808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">A primer of deuterium in drug design</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2039</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.4155%2Ffmc-2019-0183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31538524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKis7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2039-2042&author=S.+Cargninauthor=M.+Serafiniauthor=T.+Pirali&title=A+primer+of+deuterium+in+drug+design&doi=10.4155%2Ffmc-2019-0183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A primer of deuterium in drug design</span></div><div class="casAuthors">Cargnin, Sarah; Serafini, Marta; Pirali, Tracey</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2039-2042</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discusses about role of deuterated compounds, heavy and nonradioactive isotope of hydrogen in clinical development and effects of deuteration incorporation in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnDF9mfxcU77Vg90H21EOLACvtfcHk0li8RFZ4oEQe1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKis7fN&md5=2c7c1c4a9820456566886af749d28068</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0183%26sid%3Dliteratum%253Aachs%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DA%2520primer%2520of%2520deuterium%2520in%2520drug%2520design%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2039%26epage%3D2042%26doi%3D10.4155%2Ffmc-2019-0183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span> <span> </span><span class="NLM_article-title">A decade of deuteration in medicinal chemistry</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1016/bs.armc.2017.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fbs.armc.2017.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOlsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=519-542&author=J.+F.+Liuauthor=S.+L.+Harbesonauthor=C.+L.+Brummelauthor=R.+Tungauthor=R.+Silvermanauthor=D.+Doller&title=A+decade+of+deuteration+in+medicinal+chemistry&doi=10.1016%2Fbs.armc.2017.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of deuteration in medicinal chemistry</span></div><div class="casAuthors">Liu, Julie F.; Harbeson, Scott L.; Brummel, Christopher L.; Tung, Roger; Silverman, Robert; Doller, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-542</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The use of deuterium to drive DIEs and favorably alter pharmacokinetics and metab. in drug discovery has accelerated in the last decade.  The first major wave of patent applications came from small biotechnol. organizations and were aimed at improving pharmacokinetic properties of marketed drugs or enhancing properties offailed drug candidates.  A substantial no. of patent applications were published beginning in 2006, and the deuterium chem. patent estate continues to expand.  Deuterated drug candidates have progressed from early patent filings to successful proof-of-concept human studies, including the first FDA-approved deuterated drug.  The use of DIEs in drug design has expanded, and now deuteration of drug candidates and tool compds., including imaging ligands, has become a welcome instrument in the arsenal of medicinal chemists.  It is expected that experimentation with strategic introduction of deuterium into the structures of org. compds. will continue to increase and may enable the future development ofa variety ofnovel drugs and chem. tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRWRQHDkKt5LVg90H21EOLACvtfcHk0li8RFZ4oEQe1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOlsrvF&md5=18499ed5ccfb021913c4dea9e51946b7</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fbs.armc.2017.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.armc.2017.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DTung%26aufirst%3DR.%26aulast%3DSilverman%26aufirst%3DR.%26aulast%3DDoller%26aufirst%3DD.%26atitle%3DA%2520decade%2520of%2520deuteration%2520in%2520medicinal%2520chemistry%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2017%26volume%3D50%26spage%3D519%26epage%3D542%26doi%3D10.1016%2Fbs.armc.2017.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using deuterium in drug discovery: leaving the label in the drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+deuterium+in+drug+discovery%3A+leaving+the+label+in+the+drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0li8RFZ4oEQe1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520deuterium%2520in%2520drug%2520discovery%253A%2520leaving%2520the%2520label%2520in%2520the%2520drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="note"><p class="first last">A hydrogen-bearing molecule can potentially exist in several deuterated forms. For example, the d<sub>9</sub>-analogue of ivacaftor has been named deutivacaftor, but a d<sub>18</sub>-analogue was also reported; therefore, it is possible that, in the future, a prefix alongside the suffix <i>deu</i>- will be added to identify the presence of more than one deuterated analogue of a hydrogenated molecule.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of dosimertinib, a highly potent, selective, and orally efficacious deuterated EGFR targeting clinical candidate for the treatment of non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">925</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c02005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c02005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtlWks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=925-937&author=Y.+Mengauthor=B.+Yuauthor=H.+Huangauthor=Y.+Pengauthor=E.+Liauthor=Y.+Yaoauthor=C.+Songauthor=W.+Yuauthor=K.+Zhuauthor=K.+Wangauthor=D.+Yiauthor=J.+Duauthor=J.+Chang&title=Discovery+of+dosimertinib%2C+a+highly+potent%2C+selective%2C+and+orally+efficacious+deuterated+EGFR+targeting+clinical+candidate+for+the+treatment+of+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.0c02005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Meng, Yonggang; Yu, Bin; Huang, He; Peng, Youmei; Li, Ertong; Yao, Yongfang; Song, Chuanjun; Yu, Wenquan; Zhu, Kaikai; Wang, Kai; Yi, Dongxu; Du, Jinfa; Chang, Junbiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">925-937</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clin. benefits and is now a std.-of-care therapy for advanced EGFR mutation-pos. non-small-cell lung cancer (NSCLC).  However, AZ5104, a primary toxic metabolite of osimertinib, has caused unwanted toxicities.  To address this unmet medical need, we initiated an iterative program focusing on structural optimizations of osimertinib and preclin. characterization, leading to the discovery of a highly potent, selective, and orally efficacious deuterated EGFR-targeting clin. candidate, dosimertinib.  Preclin. studies revealed that dosimertinib demonstrated robust in vivo antitumor efficacy and favorable PK profiles, but with lower toxicity than osimertinib.  These preclin. data support further clin. development of dosimertinib for the treatment of NSCLC.  Dosimertinib has received official approval in China to initiate the phase I clin. trial (registration nos.: CXHL2000060 and CXHL2000061).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyJIlEhtJqX7Vg90H21EOLACvtfcHk0lj8Xs1lroFWdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtlWks74%253D&md5=e5d35658715f7ae6aa3817a2bf7dd4db</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DYi%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520dosimertinib%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520deuterated%2520EGFR%2520targeting%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D925%26epage%3D937%26doi%3D10.1021%2Facs.jmedchem.0c02005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span> <span> </span><span class="NLM_article-title">Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4506</span>– <span class="NLM_lpage">4506</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.4506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1200%2FJCO.2020.38.15_suppl.4506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=4506-4506&author=F.+Biauthor=S.+Qinauthor=S.+Guauthor=Y.+Baiauthor=Z.+Chenauthor=Z.+Wangauthor=J.+Yingauthor=Y.+Luauthor=Z.+Mengauthor=H.+Panauthor=P.+Yangauthor=H.+Zhangauthor=X.+Chenauthor=A.+Xuauthor=X.+Liuauthor=Q.+Mengauthor=L.+Wuauthor=F.+Chen&title=Donafenib+versus+sorafenib+as+first-line+therapy+in+advanced+hepatocellular+carcinoma%3A+An+open-label%2C+randomized%2C+multicenter+phase+II%2FIII+trial&doi=10.1200%2FJCO.2020.38.15_suppl.4506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.4506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.4506%26sid%3Dliteratum%253Aachs%26aulast%3DBi%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYing%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DF.%26atitle%3DDonafenib%2520versus%2520sorafenib%2520as%2520first-line%2520therapy%2520in%2520advanced%2520hepatocellular%2520carcinoma%253A%2520An%2520open-label%252C%2520randomized%252C%2520multicenter%2520phase%2520II%252FIII%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D4506%26epage%3D4506%26doi%3D10.1200%2FJCO.2020.38.15_suppl.4506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">Sulfur containing scaffolds in drugs: Synthesis and application in medicinal chemistry</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150915111741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.2174%2F1568026615666150915111741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=26369815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlClu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1200-1216&author=M.+Fengauthor=B.+Tangauthor=S.+H.+Liangauthor=X.+Jiang&title=Sulfur+containing+scaffolds+in+drugs%3A+Synthesis+and+application+in+medicinal+chemistry&doi=10.2174%2F1568026615666150915111741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry</span></div><div class="casAuthors">Feng, Minghao; Tang, Bingqing; Liang, Steven H.; Jiang, Xuefeng</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1200-1216</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The impact of the development of sulfur therapeutics is instrumental to the evolution of the pharmaceutical industry.  Sulfur-derived functional groups can be found in a broad range of pharmaceuticals and natural products.  For centuries, sulfur continues to maintain its status as the dominating heteroatom integrated into a set of 362 sulfur-contg. FDA approved drugs (besides oxygen or nitrogen) through the present.  Sulfonamides, thioethers, sulfones and Penicillin are the most common scaffolds in sulfur contg. drugs, which are well studied both on synthesis and application during the past decades.  In this review, these four moieties in pharmaceuticals and recent advances in the synthesis of the corresponding core scaffolds are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHURkv9s2oTLVg90H21EOLACvtfcHk0lj8Xs1lroFWdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlClu7w%253D&md5=d1ee22514ac37b3869919eef6d945c03</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150915111741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150915111741%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%26atitle%3DSulfur%2520containing%2520scaffolds%2520in%2520drugs%253A%2520Synthesis%2520and%2520application%2520in%2520medicinal%2520chemistry%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1200%26epage%3D1216%26doi%3D10.2174%2F1568026615666150915111741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L.</span></span> <span> </span><span class="NLM_article-title">Advanced squamous cell carcinoma of the lung: current treatment approaches and the role of afatinib</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">9305</span>– <span class="NLM_lpage">9321</span>, <span class="refDoi"> DOI: 10.2147/OTT.S250446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.2147%2FOTT.S250446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=33061419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKru7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=9305-9321&author=E.+S.+Santosauthor=L.+Hart&title=Advanced+squamous+cell+carcinoma+of+the+lung%3A+current+treatment+approaches+and+the+role+of+afatinib&doi=10.2147%2FOTT.S250446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Advanced squamous cell carcinoma of thelung: current treatment approaches and therole of afatinib</span></div><div class="casAuthors">Santos, Edgardo S.; Hart, Lowell</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9305-9321</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Options for the treatment of squamous cell lung carcinoma expanded in recent years with the introduction of the immune checkpoint inhibitors into routine clin. practice in both the first- and second-line settings but are still limited.  As a result, pembrolizumab, given either alone or in combination with platinum-based chemotherapy, is now a std. first-line treatment for squamous cell lung cancer.  However, few options exist once patients have progressed on immune checkpoint inhibitors and chemotherapy.  In this setting, the irreversible ErbB family blocker, afatinib, has a potential role as second or subsequent therapy for some patients.  The Phase III LUX-Lung 8 study demonstrated that afatinib significantly prolonged progression-free and overall survival compared with erlotinib in patients with squamous cell lung carcinoma.  Notably, retrospective, ad-hoc biomarker analyses of a subset of patients from LUX-Lung 8 suggested that patients with ErbB family mutations derived particular benefit from afatinib, esp. those with ErbB2 (HER2) mutations.  Afatinib has a manageable and predictable safety profile, and adverse events can be managed with the use of a tolerability-guided dose modification protocol.  Until more data are available, afatinib could be considered as a potential second-line treatment option for patients who have progressed on combined pembrolizumab and platinum-based chemotherapy and are ineligible for more established second-line options, or as a third-line option in patients who have received first-line immunotherapy, and second-line chemotherapy or chemotherapy and antiangiogenesis therapy.  However, further data are required to support the use of afatinib following immunotherapy.  Given that treatment options are limited in both of these settings, investigating an agent with an entirely new mechanism of action is warranted.  If available, mol. anal. to identify ErbB family mutations or the use of proteomic profiling could help to further isolate patients who are likely to derive the most benefit from afatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhUMl0owMc7Vg90H21EOLACvtfcHk0lgiHQHZTVfcqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKru7fN&md5=44e0e3bc9672393429d100a58ebe92c3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2147%2FOTT.S250446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S250446%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DE.%2BS.%26aulast%3DHart%26aufirst%3DL.%26atitle%3DAdvanced%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520lung%253A%2520current%2520treatment%2520approaches%2520and%2520the%2520role%2520of%2520afatinib%26jtitle%3DOncoTargets%2520Ther.%26date%3D2020%26volume%3D13%26spage%3D9305%26epage%3D9321%26doi%3D10.2147%2FOTT.S250446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">PCI-32765, the first BTK (Bruton’s tyrosine kinase) inhibitor in clinical trials</span>. <i>Curr. Hematol. Malig. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s11899-012-0147-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2Fs11899-012-0147-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=23296407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1-6&author=J.+R.+Brown&title=PCI-32765%2C+the+first+BTK+%28Bruton%E2%80%99s+tyrosine+kinase%29+inhibitor+in+clinical+trials&doi=10.1007%2Fs11899-012-0147-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials</span></div><div class="casAuthors">Brown Jennifer R</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ibrutinib is a potent covalent kinase inhibitor that targets BTK.  BTK, or Bruton's tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia.  Ibrutinib has modest cytotoxicity against CLL cells in vitro but also blocks trophic stimuli from the microenvironment.  As with other inhibitors of the BCR pathway, ibrutinib causes rapid nodal reduction and response associated with rapid increase in lymphocytosis, which then returns to baseline over time.  The ORR of ibrutinib in relapsed refractory CLL is 67 % with PFS 88 % at 15 months.  In a cohort of untreated patients 65 years and over, the estimated 15 month PFS is 96 %.  Registration trials have been initiated, and the difficult task that remains is to determine where in the course of CLL therapy this drug will have the greatest impact and benefit for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmwv_ITNl9Dxgd2Wuil24tfW6udTcc2eaxEzIihCuR7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D&md5=c64d7d8fa5d40a79ad029c9fb34248c3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs11899-012-0147-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-012-0147-9%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DPCI-32765%252C%2520the%2520first%2520BTK%2520%2528Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2529%2520inhibitor%2520in%2520clinical%2520trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2013%26volume%3D8%26spage%3D1%26epage%3D6%26doi%3D10.1007%2Fs11899-012-0147-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1093%2Fannonc%2Fmdw129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=26961148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1165-1170&author=A.+Yver&title=Osimertinib+%28AZD9291%29%E2%80%94a+science-driven%2C+collaborative+approach+to+rapid+drug+design+and+development&doi=10.1093%2Fannonc%2Fmdw129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development</span></div><div class="casAuthors">Yver A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1165-1170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTcfXYyifUoEewzGPswiWOfW6udTcc2eaxEzIihCuR7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D&md5=903bbb3edf2d109af352ef0354e4bca6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw129%26sid%3Dliteratum%253Aachs%26aulast%3DYver%26aufirst%3DA.%26atitle%3DOsimertinib%2520%2528AZD9291%2529%25E2%2580%2594a%2520science-driven%252C%2520collaborative%2520approach%2520to%2520rapid%2520drug%2520design%2520and%2520development%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D1165%26epage%3D1170%26doi%3D10.1093%2Fannonc%2Fmdw129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span>To calculate
p<i>K</i><sub>a</sub> values, the p<i>K</i><sub>a</sub> plugin of Marvin’s cxcalc program was used. Marvin
20.19.0, ChemAxon: <a href="https://www.chemaxon.com" class="extLink">https://www.chemaxon.com</a> (accessed 2020-08-07).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=To+calculate%0ApKa+values%2C+the+pKa+plugin+of+Marvin%E2%80%99s+cxcalc+program+was+used.+Marvin%0A20.19.0%2C+ChemAxon%3A+https%3A%2F%2Fwww.chemaxon.com+%28accessed+2020-08-07%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, W. P.</span></span> <span> </span><span class="NLM_article-title">Acidic and basic drugs in medicinal chemistry: A perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9701</span>– <span class="NLM_lpage">9717</span>, <span class="refDoi"> DOI: 10.1021/jm501000a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501000a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOnt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9701-9717&author=P.+S.+Charifsonauthor=W.+P.+Walters&title=Acidic+and+basic+drugs+in+medicinal+chemistry%3A+A+perspective&doi=10.1021%2Fjm501000a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Acidic and Basic Drugs in Medicinal Chemistry: A Perspective</span></div><div class="casAuthors">Charifson, Paul S.; Walters, W. Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9701-9717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The acid/base properties of a mol. are among the most fundamental for drug action.  However, they are often overlooked in a prospective design manner unless it has been established that a certain ionization state (e.g., quaternary base or presence of a carboxylic acid) appears to be required for activity.  In medicinal chem. optimization programs it is relatively common to attenuate basicity to circumvent undesired effects such as lack of biol. selectivity or safety risks such as hERG or phospholipidosis.  However, teams may not prospectively explore a range of carefully chosen compd. pKa values as part of an overall chem. strategy or design hypothesis.  This review summarizes the potential advantages and disadvantages of both acidic and basic drugs and provides some new analyses based on recently available public data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDorb0LfJ8PrVg90H21EOLACvtfcHk0lgiHQHZTVfcqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOnt7jN&md5=51a3cb91be42ddd1a784afe737c64c60</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm501000a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501000a%26sid%3Dliteratum%253Aachs%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DWalters%26aufirst%3DW.%2BP.%26atitle%3DAcidic%2520and%2520basic%2520drugs%2520in%2520medicinal%2520chemistry%253A%2520A%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9701%26epage%3D9717%26doi%3D10.1021%2Fjm501000a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alves, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedykh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokshyna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuz’min, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span> <span> </span><span class="NLM_article-title">Alarms about structural alerts</span>. <i>Green Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4348</span>– <span class="NLM_lpage">4360</span>, <span class="refDoi"> DOI: 10.1039/C6GC01492E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2FC6GC01492E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28503093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOntrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=4348-4360&author=V.+Alvesauthor=E.+Muratovauthor=S.+Capuzziauthor=R.+Politiauthor=Y.+Lowauthor=R.+Bragaauthor=A.+V.+Zakharovauthor=A.+Sedykhauthor=E.+Mokshynaauthor=S.+Faragauthor=C.+Andradeauthor=V.+Kuz%E2%80%99minauthor=D.+Fourchesauthor=A.+Tropsha&title=Alarms+about+structural+alerts&doi=10.1039%2FC6GC01492E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Alarms about structural alerts</span></div><div class="casAuthors">Alves, Vinicius M.; Muratov, Eugene N.; Capuzzi, Stephen J.; Politi, Regina; Low, Yen; Braga, Rodolpho C.; Zakharov, Alexey V.; Sedykh, Alexander; Mokshyna, Elena; Farag, Sherif; Andrade, Carolina H.; Kuz'min, Victor E.; Fourches, Denis; Tropsha, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Green Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4348-4360</span>CODEN:
                <span class="NLM_cas:coden">GRCHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9262</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Structural alerts are widely accepted in chem. toxicol. and regulatory decision support as a simple, transparent means to flag potential chem. hazards or group compds. into categories for read-across.  However, there is a growing concern that alerts disproportionally flag chems. as toxic, which questions their reliability as toxicity markers.  Conversely, rigorously developed, properly validated statistical QSAR models can accurately, reliably predict the toxicity of a chem.; however, their use in regulatory toxicol. has been hampered by a lack of transparency and interpretability.  This work demonstrated that contrary to the common perception of QSAR models as black boxes, they can identify statistically significant chem. substructures (QSAR-based alerts) which influence toxicity.  The authors show using case studies, that the mere presence of structural alerts in a chem., irresp. of the derivation method (expert- or QSAR-based), should be perceived only as hypotheses of possible toxicol. effect.  A new approach is proposed which synergistically integrates structural alerts and rigorously validated QSAR models for a more transparent, accurate safety assessment of new chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXku_XrUJZDbVg90H21EOLACvtfcHk0lhu9C_m5v-g3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOntrrE&md5=73fac6acfc2a5a5ad5b79bdd554cbca3</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1039%2FC6GC01492E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6GC01492E%26sid%3Dliteratum%253Aachs%26aulast%3DAlves%26aufirst%3DV.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DCapuzzi%26aufirst%3DS.%26aulast%3DPoliti%26aufirst%3DR.%26aulast%3DLow%26aufirst%3DY.%26aulast%3DBraga%26aufirst%3DR.%26aulast%3DZakharov%26aufirst%3DA.%2BV.%26aulast%3DSedykh%26aufirst%3DA.%26aulast%3DMokshyna%26aufirst%3DE.%26aulast%3DFarag%26aufirst%3DS.%26aulast%3DAndrade%26aufirst%3DC.%26aulast%3DKuz%25E2%2580%2599min%26aufirst%3DV.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DTropsha%26aufirst%3DA.%26atitle%3DAlarms%2520about%2520structural%2520alerts%26jtitle%3DGreen%2520Chem.%26date%3D2016%26volume%3D18%26spage%3D4348%26epage%3D4360%26doi%3D10.1039%2FC6GC01492E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gampe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, V. A.</span></span> <span> </span><span class="NLM_article-title">Curse or cure? A perspective on the developability of aldehydes as active pharmaceutical ingredients</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">14357</span>– <span class="NLM_lpage">14381</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVWhs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=14357-14381&author=C.+Gampeauthor=V.+A.+Verma&title=Curse+or+cure%3F+A+perspective+on+the+developability+of+aldehydes+as+active+pharmaceutical+ingredients&doi=10.1021%2Facs.jmedchem.0c01177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients</span></div><div class="casAuthors">Gampe, Christian; Verma, Vishal A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14357-14381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a dichotomy between the increasing utility of aldehydes as tool mols. that bind to "undruggable" protein sites and the designation of the aldehyde functional group as a structural alert by the medicinal chem. community.  Herein we compile information about pharmacol. active aldehydes that are being used in humans.  We summarize the learnings from these data, discuss advantages and challenges assocd. with aldehydes, and derive strategies for the successful development of aldehydes within drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppz1oqp1WGV7Vg90H21EOLACvtfcHk0lhu9C_m5v-g3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVWhs7vE&md5=4696123fdaba8f20895bb11f2b78ff84</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01177%26sid%3Dliteratum%253Aachs%26aulast%3DGampe%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DV.%2BA.%26atitle%3DCurse%2520or%2520cure%253F%2520A%2520perspective%2520on%2520the%2520developability%2520of%2520aldehydes%2520as%2520active%2520pharmaceutical%2520ingredients%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D14357%26epage%3D14381%26doi%3D10.1021%2Facs.jmedchem.0c01177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mäder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattner, L.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines as rising stars in modern drug discovery? Current status and perspective on an emerging functional group in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">14243</span>– <span class="NLM_lpage">14275</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00960</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00960" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB38bivV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=14243-14275&author=P.+M%C3%A4derauthor=L.+Kattner&title=Sulfoximines+as+rising+stars+in+modern+drug+discovery%3F+Current+status+and+perspective+on+an+emerging+functional+group+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.0c00960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry</span></div><div class="casAuthors">Mader Patrick; Kattner Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14243-14275</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sulfoximines have been largely disregarded in medicinal chemistry for a long time.  However, recently, they have risen to the apparent level of stardom on the drug discovery scene.  Considering the outstanding properties of sulfoximines, this versatile functional group has advanced to implementation in several drug discovery programs.  Currently, this fashionable functional group can be found in various hit-to-lead and lead optimization studies in early stages and in several compounds currently in clinical trials.  Herein, we review recent developments to demonstrate the scope and limitations of this interesting and versatile functional group in medicinal chemistry and drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4vGCH7PqQvJ6KlWarZTAzfW6udTcc2eY6K4-Csneairntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bivV2isQ%253D%253D&md5=8013be4218e0f70c3b1e02601681f3fd</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00960%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4der%26aufirst%3DP.%26aulast%3DKattner%26aufirst%3DL.%26atitle%3DSulfoximines%2520as%2520rising%2520stars%2520in%2520modern%2520drug%2520discovery%253F%2520Current%2520status%2520and%2520perspective%2520on%2520an%2520emerging%2520functional%2520group%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D14243%26epage%3D14275%26doi%3D10.1021%2Facs.jmedchem.0c00960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A. D. G.</span></span> <span> </span><span class="NLM_article-title">Rings in drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5845</span>– <span class="NLM_lpage">5859</span>, <span class="refDoi"> DOI: 10.1021/jm4017625</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5845-5859&author=R.+D.+Taylorauthor=M.+MacCossauthor=A.+D.+G.+Lawson&title=Rings+in+drugs&doi=10.1021%2Fjm4017625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Rings in Drugs</span></div><div class="casAuthors">Taylor, Richard D.; MacCoss, Malcolm; Lawson, Alastair D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5845-5859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We have analyzed the rings, ring systems, and frameworks in drugs listed in the FDA Orange Book to understand the frequency, time-lines, mol. property space, and the application of these rings in different therapeutic areas and target classes.  This anal. shows that there are only 351 ring systems and 1197 frameworks in drugs that came onto the market before 2013.  Furthermore, on av. six new ring systems enter drug space each year and approx. 28% of new drugs contain a new ring system.  Moreover, it is very unusual for a drug to contain more than one new ring system and the majority of the most frequently used ring systems (83%) were first used in drugs developed prior to 1983.  These observations give insight into the chem. novelty of drugs and potentially efficient ways to assess compd. libraries and develop compds. from hit identification to lead optimization and beyond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_e_L4z4XCrVg90H21EOLACvtfcHk0liqfheoUIXLHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D&md5=c84ce84b8698eb6fad38fa82b0ab4912</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm4017625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017625%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%2BD.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DLawson%26aufirst%3DA.%2BD.%2BG.%26atitle%3DRings%2520in%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5845%26epage%3D5859%26doi%3D10.1021%2Fjm4017625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="note"><p class="first last">Steroid core substructures that were grouped are the following: hexadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthrene; 2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthrene; 7,8,9,11,12,13,14,15,16,17-decahydro-6<i>H</i>-cyclopenta[<i>a</i>]phenanthrene; 6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthren-3(2<i>H</i>)-one; 6,7,8,11,12,13,14,15,16,17-decahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthren-3(2<i>H</i>)-one; 6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3<i>H</i>-cyclopenta[<i>a</i>]phenanthren-3-one.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span>; <span class="NLM_string-name">Pirali, T.</span>; <span class="NLM_string-name">Tron, G. C.</span></span> <span> </span><span class="NLM_article-title">Click 1,2,3-triazoles in drug discovery and development: from the flask to the clinic?</span> <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, [Online early access].<span class="refDoi"> DOI: 10.1016/bs.aihch.2020.10.001</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fbs.aihch.2020.10.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Serafini&author=T.+Pirali&author=G.+C.+Tron&title=Click+1%2C2%2C3-triazoles+in+drug+discovery+and+development%3A+from+the+flask+to+the+clinic%3F&doi=10.1016%2Fbs.aihch.2020.10.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fbs.aihch.2020.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.aihch.2020.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26atitle%3DClick%25201%252C2%252C3-triazoles%2520in%2520drug%2520discovery%2520and%2520development%253A%2520from%2520the%2520flask%2520to%2520the%2520clinic%253F%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D2020%26doi%3D10.1016%2Fbs.aihch.2020.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J.-M.</span>; <span class="NLM_string-name">Sippl, W.</span></span> <span> </span><span class="NLM_article-title">Homo and Heterodimer Ligands the Twin Drug Approach</span>. In  <i>The Practice of Medicinal Chemistry</i><i>,</i> <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">414</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2FB978-0-12-374194-3.00018-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=380-414&author=J.-M.+Contreras&author=W.+Sipplauthor=C.+G.+Wermuth&title=The+Practice+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-374194-3.00018-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-374194-3.00018-4%26sid%3Dliteratum%253Aachs%26aulast%3DContreras%26aufirst%3DJ.-M.%26atitle%3DHomo%2520and%2520Heterodimer%2520Ligands%2520the%2520Twin%2520Drug%2520Approach%26btitle%3DThe%2520Practice%2520of%2520Medicinal%2520Chemistry%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26pub%3DElsevier%26date%3D2008%26spage%3D380%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreone, P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of daclatasvir in hepatitis C: an overview</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2016.00038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.14218%2FJCTH.2016.00038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28097103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC1c7mslSqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=336-344&author=N.+Gamalauthor=S.+Gittoauthor=P.+Andreone&title=Efficacy+and+safety+of+daclatasvir+in+hepatitis+C%3A+an+overview&doi=10.14218%2FJCTH.2016.00038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview</span></div><div class="casAuthors">Gamal Nesrine; Gitto Stefano; Andreone Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">336-344</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a growing public health concern, with 184 million people infected worldwide.  During the past decade, interferon has been the backbone of HCV treatment, even though it remains far from ideal.  The latest development of the new direct antivirals has drastically changed the treatment approach for chronic hepatitis C (CHC).  Inhibitors of the HCV NS5A region have garnered remarkable interest among treating physicians, due to their high potency and favourable safety profile.  In particular, treatment with daclatasvir (DCV) has yielded high rates of vriologic response in patients infected with genotype (Gt) 1 and Gt 3, when used in combination with other antivirals of a different class, such as sofosbuvir.  Although few data are available for DCV treatment of the other Gts, the results in patients with Gt 2 and Gt 4 infection appear promising, as do those for unique patient populations.  NS5A-resistant viral variants can pre-exist or emerge after treatment failure for the HCV NS5A inhibitors.  Nonetheless, DCV-resistant viral variants continue to be sensitive to interferon and other classes of antivirals such as NS3/4A and NS5B inhibitors.  Herein, we aimed to provide an overview of the current knowledge about DCV in the treatment of CHC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIlu-VdjyoXRWfpMXQLRstfW6udTcc2eaEH36WfnuyuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7mslSqsA%253D%253D&md5=9a82491790340af8fdd774ee06128421</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2016.00038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2016.00038%26sid%3Dliteratum%253Aachs%26aulast%3DGamal%26aufirst%3DN.%26aulast%3DGitto%26aufirst%3DS.%26aulast%3DAndreone%26aufirst%3DP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520daclatasvir%2520in%2520hepatitis%2520C%253A%2520an%2520overview%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2016%26volume%3D4%26spage%3D336%26epage%3D344%26doi%3D10.14218%2FJCTH.2016.00038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flisiak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flisiak-Jackiewicz, M.</span></span> <span> </span><span class="NLM_article-title">Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1080/17474124.2017.1309284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1080%2F17474124.2017.1309284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28317409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1Slsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=559-567&author=R.+Flisiakauthor=M.+Flisiak-Jackiewicz&title=Ombitasvir+and+paritaprevir+boosted+with+ritonavir+and+combined+with+dasabuvir+for+chronic+hepatitis+C&doi=10.1080%2F17474124.2017.1309284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C</span></div><div class="casAuthors">Flisiak, Robert; Flisiak-Jackiewicz, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-567</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Hepatitis C is a leading cause of cirrhosis and hepatocellular carcinoma responsible for almost 700,000 deaths worldwide annually.  Until 2014, management of HCV infections was based on interferon alfa contg. regimens, with efficacy of 40-70% and a high adverse event rate.  Interferon-free therapeutic options improved sustained viral response (SVR) rate to >90% and safety profile to placebo-like levels.:.  This article describes all-oral regimen consisting of three direct acting antivirals (DAA) - ombitasvir (OBV), paritaprevir (PTV) and dasabuvir (DSV), which in clin. practice is boosted with ritonavir (r) and sometimes with ribavirin (RBV).  This combination is registered for treatment of patients infected with HCV genotype 1 and 4.  We focused on the regimen characteristics, pharmacokinetics, risk of resistance as well as efficacy and safety in clin. trials and real world studies.:.  Combination of OBV/PTV/r±DSV±RBV provides SVR rate of about 95% and good safety profile even in patients with compensated liver cirrhosis and failure with previous therapy.  Currently it should be of particular value in areas with a predominance of genotype 1b infections.  Due to the complexity and risk of drug to drug interactions, it will probably be replaced in coming few years with pangenotypic combinations of next generation DAAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEip3CV8OzerVg90H21EOLACvtfcHk0lhrOrz2ycRqlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1Slsrw%253D&md5=805164f84b6755b5561b7a7a53f0aabd</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1080%2F17474124.2017.1309284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2017.1309284%26sid%3Dliteratum%253Aachs%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DFlisiak-Jackiewicz%26aufirst%3DM.%26atitle%3DOmbitasvir%2520and%2520paritaprevir%2520boosted%2520with%2520ritonavir%2520and%2520combined%2520with%2520dasabuvir%2520for%2520chronic%2520hepatitis%2520C%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D11%26spage%3D559%26epage%3D567%26doi%3D10.1080%2F17474124.2017.1309284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2020.00078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.14218%2FJCTH.2020.00078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=33604263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB3snmtVektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2021&pages=125-132&author=X.+Liuauthor=P.+Hu&title=Efficacy+and+safety+of+glecaprevir%2Fpibrentasvir+in+patients+with+chronic+HCV+infection&doi=10.14218%2FJCTH.2020.00078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection</span></div><div class="casAuthors">Liu Xiaoqing; Hu Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-132</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease, including decompensated cirrhosis and hepatocellular carcinoma.  Over 95% of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved for patients with HCV infection.  The glecaprevir/pibrentasvir (G/P) regimen has some features that distinguish it from others and is the only 8-week regimen approved for treatment-naive patients and patients experienced in regimens containing (peg)interferon, ribavirin, and/or sofosbuvir, without an HCV NS3/4A protease inhibitor or NS5A inhibitor (except those with genotype 3).  This review aims to summarize the efficacy and safety of G/P in HCV-infected patients from clinic trials and real-world studies, including those who have historically been considered difficult to cure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT11y4N919DkQwxfk_AGB-EfW6udTcc2eaeWmEYoByrurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3snmtVektA%253D%253D&md5=b8caa6359e28bdf2cc5529ee40b1d2d9</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2020.00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2020.00078%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520glecaprevir%252Fpibrentasvir%2520in%2520patients%2520with%2520chronic%2520HCV%2520infection%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2021%26volume%3D9%26spage%3D125%26epage%3D132%26doi%3D10.14218%2FJCTH.2020.00078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Kügelgen, I.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of P2Y receptors</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2019.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.brainresbull.2019.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=30922852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntVSnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2019&pages=12-24&author=I.+von%0AK%C3%BCgelgen&title=Pharmacology+of+P2Y+receptors&doi=10.1016%2Fj.brainresbull.2019.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of P2Y receptors</span></div><div class="casAuthors">von Kuegelgen, Ivar</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-24</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides.  There are eight mammalian P2Y receptor subtypes divided into two subgroups (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) and (P2Y12, P2Y13, and P2Y14).  The P2Y receptors are expressed in various cell types and play important roles in physiol. and pathophysiol. including inflammatory responses and neuropathic pain.  The antagonism of P2Y12 receptors is used in pharmacotherapy for the prevention and therapy of cardiovascular events.  The nucleoside analog ticagrelor and active metabolites of the thienopyridine compds. ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y12 receptors and reduce thereby platelet aggregation.  The P2Y2 receptor agonist diquafosol is used for the treatment of the dry eye syndrome.  The P2Y receptor subtypes differ in their amino acid sequences, their pharmacol. profiles and their signaling transduction pathways.  Recently, selective receptor ligands have been developed for all subtypes.  The published crystal structures of the human P2Y1 and P2Y12 receptors as well as receptor models will facilitate the development of novel drugs for pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWCjAgvzCJbVg90H21EOLACvtfcHk0lhrOrz2ycRqlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntVSnt78%253D&md5=d4c1f902c903cb4c500419cf4ec26f18</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2019.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2019.03.010%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26atitle%3DPharmacology%2520of%2520P2Y%2520receptors%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2019%26volume%3D151%26spage%3D12%26epage%3D24%26doi%3D10.1016%2Fj.brainresbull.2019.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marc, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boitard, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balavoine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Targeting brain aminopeptidase A: a new strategy for the treatment of hypertension and heart failure</span>. <i>Can. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/j.cjca.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.cjca.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=32389345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB38vltVOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=721-731&author=Y.+Marcauthor=S.+E.+Boitardauthor=F.+Balavoineauthor=M.+Aziziauthor=C.+Llorens-Cortes&title=Targeting+brain+aminopeptidase+A%3A+a+new+strategy+for+the+treatment+of+hypertension+and+heart+failure&doi=10.1016%2Fj.cjca.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure</span></div><div class="casAuthors">Marc Yannick; Boitard Solene Emmanuelle; Balavoine Fabrice; Azizi Michel; Llorens-Cortes Catherine</div><div class="citationInfo"><span class="NLM_cas:title">The Canadian journal of cardiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-731</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pathophysiology of heart failure (HF) and hypertension are thought to involve brain renin-angiotensin system (RAS) hyperactivity.  Angiotensin III, a key effector peptide in the brain RAS, provides tonic stimulatory control over blood pressure (BP) in hypertensive rats.  Aminopeptidase A (APA), the enzyme responsible for generating brain angiotensin III, constitutes a potential therapeutic target for hypertension treatment.  We focus here on studies of RB150/firibastat, the first prodrug of the specific and selective APA inhibitor EC33 able to cross the blood-brain barrier.  We consider its development from therapeutic target discovery to clinical trials of the prodrug.  After oral administration, firibastat crosses the gastrointestinal and blood-brain barriers.  On arrival in the brain, it is cleaved to generate EC33, which inhibits brain APA activity, lowering BP in various experimental models of hypertension.  Firibastat was clinically and biologically well tolerated, even at high doses, in phase I trials conducted in healthy human subjects.  It was then shown to decrease BP effectively in patients of various ethnic origins with hypertension in phase II trials.  Brain RAS hyperactivity leads to excessive sympathetic activity, which can contribute to HF after myocardial infarction (MI).  Chronic treatment with oral firibastat (4 or 8 weeks after MI) has been shown to normalize brain APA activity in mice.  This effect is accompanied by a normalization of brain RAS and sympathetic activities, reducing cardiac fibrosis and hypertrophy and preventing cardiac dysfunction.  Firibastat may therefore represent a novel therapeutic advance in the clinical management of patients with hypertension and potentially with HF after MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpbZaRLxgQnftos8R3JUhXfW6udTcc2eaeWmEYoByrurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vltVOlsw%253D%253D&md5=8e4b47550cf40efe1b16eceb466203e0</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.cjca.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cjca.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DMarc%26aufirst%3DY.%26aulast%3DBoitard%26aufirst%3DS.%2BE.%26aulast%3DBalavoine%26aufirst%3DF.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DTargeting%2520brain%2520aminopeptidase%2520A%253A%2520a%2520new%2520strategy%2520for%2520the%2520treatment%2520of%2520hypertension%2520and%2520heart%2520failure%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2020%26volume%3D36%26spage%3D721%26epage%3D731%26doi%3D10.1016%2Fj.cjca.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainusso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coarfa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenbekova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yustein, J. T.</span></span> <span> </span><span class="NLM_article-title">Tegavivint and the β-catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1093/jnci/djz026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1093%2Fjnci%2Fdjz026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=30793158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCgtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2019&pages=1216-1227&author=M.+Nomuraauthor=N.+Rainussoauthor=Y.+C.+Leeauthor=B.+Dawsonauthor=C.+Coarfaauthor=R.+Hanauthor=J.+L.+Larsonauthor=R.+Shuckauthor=L.+Kurenbekovaauthor=J.+T.+Yustein&title=Tegavivint+and+the+%CE%B2-catenin%2FALDH+axis+in+chemotherapy-resistant+and+metastatic+osteosarcoma&doi=10.1093%2Fjnci%2Fdjz026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Tegavivint and the β-catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma</span></div><div class="casAuthors">Nomura, Motonari; Rainusso, Nino; Lee, Yi-Chien; Dawson, Brian; Coarfa, Cristian; Han, Ruolan; Larson, Jeffrey L.; Shuck, Ryan; Kurenbekova, Lyazat; Yustein, Jason T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1216-1227</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">1460-2105</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background : The Wnt/β-catenin pathway is closely assocd. with osteosarcoma (OS) development and metastatic progression.  We investigated the antitumor activity of Tegavivint, a novel β-catenin/transducin β-like protein 1 (TBL1) inhibitor, against OS employing in vitro, ex vivo, and in vivo cell line and patient-derived xenograft (PDX) models that recapitulate high risk disease.  Methods : The antitumor efficacy of Tegavivint was evaluated in vitro using established OS and PDX-derived cell lines.  Use of an ex vivo three-dimensional pulmonary metastasis assay assessed targeting of β-catenin activity during micro- and macrometastatic development.  The in vivo activity of Tegavivint was evaluated using chemoresistant and metastatic OS PDX models.  Gene and protein expression were quantified by quant. Reverse transcription polymerase chain reaction or immunoblot anal.  Bone integrity was detd. via microCT.  All statistical tests were two-sided.  Results : Tegavivint exhibited antiproliferative activity against OS cells in vitro and actively reduced micro- and macrometastatic development ex vivo.  Multiple OS PDX tumors (n = 3), including paired patient primary and lung metastatic tumors with inherent chemoresistance, were suppressed by Tegavivint in vivo.  We identified that metastatic lung OS cell lines (n = 2) exhibited increased stem cell signatures, including enhanced concomitant aldehyde dehydrogenase (ALDH1) and β-catenin expression and downstream activity, which were suppressed by Tegavivint (ALDH1: control group, mean relative mRNA expression = 1.00, 95% confidence interval [CI] = 0.68 to 1.22 vs Tegavivint group, mean = 0.011, 95% CI = 0.0012 to 0.056, P <.001; β-catenin: control group, mean relative mRNA expression = 1.00, 95% CI = 0.71 to 1.36 vs Tegavivint group, mean = 0.45, 95% CI = 0.36 to 0.52, P <.001).  ALDH1high PDX-derived lung OS cells, which demonstrated enhanced metastatic potential compared with ALDHlow cells in vivo, were sensitive to Tegavivint.  Toxicity studies revealed decreased bone d. in male Tegavivint-treated mice (n = 4 mice per group).  Conclusions: Tegavivint is a promising therapeutic agent for advanced stages of OS via its targeting of the β-catenin/ALDH1 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBg4QrTFdBQrVg90H21EOLACvtfcHk0lilFddnebqVdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCgtL7E&md5=49bca45ea03e3de9b56051ba0cc3b238</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjz026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjz026%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DM.%26aulast%3DRainusso%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DDawson%26aufirst%3DB.%26aulast%3DCoarfa%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DLarson%26aufirst%3DJ.%2BL.%26aulast%3DShuck%26aufirst%3DR.%26aulast%3DKurenbekova%26aufirst%3DL.%26aulast%3DYustein%26aufirst%3DJ.%2BT.%26atitle%3DTegavivint%2520and%2520the%2520%25CE%25B2-catenin%252FALDH%2520axis%2520in%2520chemotherapy-resistant%2520and%2520metastatic%2520osteosarcoma%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2019%26volume%3D111%26spage%3D1216%26epage%3D1227%26doi%3D10.1093%2Fjnci%2Fdjz026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynadier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheshwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bette-Bobillo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran Van Ba, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penarete-Vargas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraisse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerdan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, H.</span></span> <span> </span><span class="NLM_article-title">Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">2263</span>– <span class="NLM_lpage">2276</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01966.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1111%2Fj.1476-5381.2012.01966.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=22471905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1artL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=2263-2276&author=S.+Weinauthor=M.+Maynadierauthor=Y.+Bordatauthor=J.+Perezauthor=S.+Maheshwariauthor=P.+Bette-Bobilloauthor=C.+Tran+Van+Baauthor=D.+Penarete-Vargasauthor=L.+Fraisseauthor=R.+Cerdanauthor=H.+Vial&title=Transport+and+pharmacodynamics+of+albitiazolium%2C+an+antimalarial+drug+candidate&doi=10.1111%2Fj.1476-5381.2012.01966.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate</span></div><div class="casAuthors">Wein, S.; Maynadier, M.; Bordat, Y.; Perez, J.; Maheshwari, S.; Bette-Bobillo, P.; Ba, C. Tran Van; Penarete-Vargas, D.; Fraisse, L.; Cerdan, R.; Vial, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2263-2276</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Choline analogs, a new type of antimalarials, exert potent in vitro and in vivo antimalarial activity.  This has given rise to albitiazolium, which is currently in phase II clin. trials to cure severe malaria.  Here we dissected its mechanism of action step by step from choline entry into the infected erythrocyte to its effect on phosphatidylcholine (PC) biosynthesis.  Exptl. Approach We biochem. unravelled the transport and enzymic steps that mediate de novo synthesis of PC and elucidated how albitiazolium enters the intracellular parasites and affects the PC biosynthesis.  Key results Choline entry into Plasmodium falciparum-infected erythrocytes is achieved both by the remnant erythrocyte choline carrier and by parasite-induced new permeability pathways (NPP), while parasite entry involves a poly-specific cation transporter.  Albitiazolium specifically prevented choline incorporation into its end-product PC, and its antimalarial activity was strongly antagonized by choline.  Albitiazolium entered the infected erythrocyte mainly via a furosemide-sensitive NPP and was transported into the parasite by a poly-specific cation carrier.  Albitiazolium competitively inhibited choline entry via the parasite-derived cation transporter and also, at a much higher concn., affected each of the three enzymes conducting de novo synthesis of PC.  Conclusions and Implications Inhibition of choline entry into the parasite appears to be the primary mechanism by which albitiazolium exerts its potent antimalarial effect.  However, the pharmacol. response to albitiazolium involves mol. interactions with different steps of the de novo PC biosynthesis pathway, which would help to delay the development of resistance to this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8v0mm2kzEirVg90H21EOLACvtfcHk0lilFddnebqVdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1artL3J&md5=33f6d2d296ba6d7e2179db90f97666eb</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01966.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01966.x%26sid%3Dliteratum%253Aachs%26aulast%3DWein%26aufirst%3DS.%26aulast%3DMaynadier%26aufirst%3DM.%26aulast%3DBordat%26aufirst%3DY.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DMaheshwari%26aufirst%3DS.%26aulast%3DBette-Bobillo%26aufirst%3DP.%26aulast%3DTran%2BVan%2BBa%26aufirst%3DC.%26aulast%3DPenarete-Vargas%26aufirst%3DD.%26aulast%3DFraisse%26aufirst%3DL.%26aulast%3DCerdan%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DH.%26atitle%3DTransport%2520and%2520pharmacodynamics%2520of%2520albitiazolium%252C%2520an%2520antimalarial%2520drug%2520candidate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D2263%26epage%3D2276%26doi%3D10.1111%2Fj.1476-5381.2012.01966.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pepys, M. B.</span></span> <span> </span><span class="NLM_article-title">The pentraxins 1975–2018: serendipity, diagnostics and drugs</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2382</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.02382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.3389%2Ffimmu.2018.02382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=30459761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2382&author=M.+B.+Pepys&title=The+pentraxins+1975%E2%80%932018%3A+serendipity%2C+diagnostics+and+drugs&doi=10.3389%2Ffimmu.2018.02382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The Pentraxins 1975-2018: serendipity, diagnostics and drugs</span></div><div class="casAuthors">Pepys, Mark. B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2382/1-2382/18</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The phylogenetically ancient, pentraxin family of plasma proteins, comprises C-reactive protein (CRP) and serum amyloid P component (SAP) in humans and the homologous proteins in other species.  They are composed of five, identical, non-covalently assocd. protomers arranged with cyclic pentameric symmetry in a disk-like configuration.  Each protomer has a calcium dependent site that mediates the particular specific ligand binding responsible for all the rigorously established functional properties of these proteins.  No genetic deficiency of either human CRP or SAP has been reported, nor even any sequence polymorphism in the proteins themselves.  Although their actual functions in humans are therefore unknown, gene deletion studies in mice demonstrate that both proteins can contribute to innate immunity.  CRP is the classical human acute phase protein, routinely measured in clin. practice worldwide to monitor disease activity.  Human SAP, which is not an acute phase protein, is a universal constituent of all human amyloid deposits as a result of its avid specific binding to amyloid fibrils of all types.  SAP thereby contributes to amyloid formation and persistence in vivo.  Whole body radiolabeled SAP scintigraphy safely and non-invasively localizes and quantifies systemic amyloid deposits, and has transformed understanding of the natural history of amyloidosis and its response to treatment.  Human SAP is also a therapeutic target, both in amyloidosis and Alzheimer's disease.  Our drug, miridesap, depletes SAP from the blood and the brain and is currently being tested in the DESPIAD clin. trial in Alzheimer's disease.  Meanwhile, the obligate therapeutic partnership of miridesap, to deplete circulating SAP, and dezamizumab, a humanized monoclonal anti-SAP antibody that targets residual SAP in amyloid deposits, produces unprecedented removal of amyloid from the tissues and improves organ function.  Human CRP binds to dead and damaged cells in vivo and activates complement and this can exacerbate pre-existing tissue damage.  The adverse effects of CRP are completely abrogated by compds. that block its binding to autologous ligands and we are developing CRP inhibitor drugs.  The present personal and crit. perspective on the pentraxins reports, for the first time, the key role of serendipity in our work since 1975.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjsPRQBKCnfLVg90H21EOLACvtfcHk0lilFddnebqVdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCksro%253D&md5=62b716c18714e7dd224107dfcbb50c8d</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02382%26sid%3Dliteratum%253Aachs%26aulast%3DPepys%26aufirst%3DM.%2BB.%26atitle%3DThe%2520pentraxins%25201975%25E2%2580%25932018%253A%2520serendipity%252C%2520diagnostics%2520and%2520drugs%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D2382%26doi%3D10.3389%2Ffimmu.2018.02382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voß, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klewer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-W.</span></span> <span> </span><span class="NLM_article-title">Chemically induced dimerization: reversible and spatiotemporal control of protein function in cells</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2015.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.cbpa.2015.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=26431673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2gsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=194-201&author=S.+Vo%C3%9Fauthor=L.+Klewerauthor=Y.-W.+Wu&title=Chemically+induced+dimerization%3A+reversible+and+spatiotemporal+control+of+protein+function+in+cells&doi=10.1016%2Fj.cbpa.2015.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced dimerization: reversible and spatiotemporal control of protein function in cells</span></div><div class="casAuthors">Voss, Stephanie; Klewer, Laura; Wu, Yao-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">194-201</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Small-mol. perturbation of biol. systems is able to tackle biol. problems that are not accessible by classical genetic interference methods.  Chem. induced dimerization (CID) has been used as a valuable tool to study various biol. processes.  Recent years have seen tremendous progress in the development of orthogonal and reversible CID systems.  These new systems allow control over protein function with unprecedented precision and spatiotemporal resoln.  While the primary application of CID has been on dissecting signal transductions, new emerging approaches have extended the scope of this technique to elucidating membrane and protein trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGX6DErfWByLVg90H21EOLACvtfcHk0ljm-BiF_wyeow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2gsb%252FI&md5=40daffc34a882fd4bbc1aad5a6496b1c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DVo%25C3%259F%26aufirst%3DS.%26aulast%3DKlewer%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.-W.%26atitle%3DChemically%2520induced%2520dimerization%253A%2520reversible%2520and%2520spatiotemporal%2520control%2520of%2520protein%2520function%2520in%2520cells%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D28%26spage%3D194%26epage%3D201%26doi%3D10.1016%2Fj.cbpa.2015.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonpavde, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMannis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethammagari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancsak, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapteva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, K. M.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1357</span>, <span class="refDoi"> DOI: 10.1007/s00262-017-2027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2Fs00262-017-2027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28608115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGlu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1345-1357&author=G.+Sonpavdeauthor=J.+D.+McMannisauthor=Y.+Baiauthor=M.+R.+Seethammagariauthor=J.+M.+C.+Bullauthor=V.+Hawkinsauthor=T.+K.+Dancsakauthor=N.+Laptevaauthor=J.+M.+Levittauthor=A.+Moseleyauthor=D.+M.+Spencerauthor=K.+M.+Slawin&title=Phase+I+trial+of+antigen-targeted+autologous+dendritic+cell-based+vaccine+with+in+vivo+activation+of+inducible+CD40+for+advanced+prostate+cancer&doi=10.1007%2Fs00262-017-2027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer</span></div><div class="casAuthors">Sonpavde, Guru; McMannis, John D.; Bai, Yu; Seethammagari, Mamatha R.; Bull, Joan M. C.; Hawkins, Victoria; Dancsak, Theresa K.; Lapteva, Natasha; Levitt, Jonathan M.; Moseley, Annemarie; Spencer, David M.; Slawin, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1345-1357</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting cell (APC) vaccine in men with metastatic castration-resistant prostate cancer (mCRPC).  To manuf. BPX101, APCs collected in a single leukapheresis were transduced with adenoviral vector Ad5f35 encoding inducible human (ih)-CD40, followed by incubation with protein PA001, which contains the extracellular domain of human prostate-specific membrane antigen.  The ih-CD40 represents a modified chimeric version of the dendritic cell (DC) co-stimulatory mol., CD40, which responds to a bioinert membrane-permeable activating dimerizer drug, rimiducid (AP1903), permitting temporally controlled, lymphoid-localized, DC-specific activation.  Eighteen men with progressive mCRPC following ≤1 prior chemotherapy regimen were enrolled to evaluate three doses of BPX101 (4 × 106, 12.5 × 106 and 25 × 106 cells) administered intradermally every 2-4 wk followed by rimiducid (0.4 mg/kg) i.v. (IV) infusion 24 h after each BPX101 dose.  There were no dose-limiting toxicities.  Immune upregulation as well as anti-tumor activity was obsd. with PSA declines, objective tumor regressions and robust efficacy of post-trial therapy.  This novel antigen-targeted and in vivo activated immunotherapy platform may warrant further development as monotherapy and as a component of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPqUDTm2BizLVg90H21EOLACvtfcHk0ljm-BiF_wyeow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGlu77P&md5=cd625f66250e778611a43b50db4c68dd</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs00262-017-2027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-017-2027-6%26sid%3Dliteratum%253Aachs%26aulast%3DSonpavde%26aufirst%3DG.%26aulast%3DMcMannis%26aufirst%3DJ.%2BD.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DSeethammagari%26aufirst%3DM.%2BR.%26aulast%3DBull%26aufirst%3DJ.%2BM.%2BC.%26aulast%3DHawkins%26aufirst%3DV.%26aulast%3DDancsak%26aufirst%3DT.%2BK.%26aulast%3DLapteva%26aufirst%3DN.%26aulast%3DLevitt%26aufirst%3DJ.%2BM.%26aulast%3DMoseley%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26atitle%3DPhase%2520I%2520trial%2520of%2520antigen-targeted%2520autologous%2520dendritic%2520cell-based%2520vaccine%2520with%2520in%2520vivo%2520activation%2520of%2520inducible%2520CD40%2520for%2520advanced%2520prostate%2520cancer%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2017%26volume%3D66%26spage%3D1345%26epage%3D1357%26doi%3D10.1007%2Fs00262-017-2027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryde, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span> <span> </span><span class="NLM_article-title">Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">710</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1021/bi0264770</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0264770" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=710-717&author=L.+O.+Gerlachauthor=J.+S.+Jakobsenauthor=K.+P.+Jensenauthor=M.+R.+Rosenkildeauthor=R.+T.+Skerljauthor=U.+Rydeauthor=G.+J.+Bridgerauthor=T.+W.+Schwartz&title=Metal+ion+enhanced+binding+of+AMD3100+to+Asp262+in+the+CXCR4+receptor&doi=10.1021%2Fbi0264770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Metal Ion Enhanced Binding of AMD3100 to Asp262 in the CXCR4 Receptor</span></div><div class="casAuthors">Gerlach, Lars Ole; Jakobsen, Janus S.; Jensen, Kasper P.; Rosenkilde, Mette R.; Skerlj, Renato T.; Ryde, Ulf; Bridger, Gary J.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">710-717</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The affinity of AMD3100, a sym. nonpeptide antagonist composed of two 1,4,8,11-tetraazacyclotetradecane (cyclam) rings connected through a 1,4-dimethylene(phenylene) linker to the CXCR4 chemokine receptor was increased 7, 36, and 50-fold, resp., by incorporation of the following: Cu2+, Zn2+, or Ni2+ into the cyclam rings of the compd.  The rank order of the transition metal ions correlated with the calcd. binding energy between free acetate and the metal ions coordinated in a cyclam ring.  Construction of AMD3100 substituted with only a single Cu2+ or Ni2+ ion demonstrated that the increase in binding affinity of the metal ion substituted bicyclam is achieved through an enhanced interaction of just one of the ring systems.  Mutational anal. of potential metal ion binding residues in the main ligand binding crevice of the CXCR4 receptor showed that although binding of the bicyclam is dependent on both Asp171 and Asp262, the enhancing effect of the metal ion was selectively eliminated by substitution of Asp262 located at the extracellular end of TM-VI.  It is concluded that the increased binding affinity of the metal ion substituted AMD3100 is obtained through enhanced interaction of one of the cyclam ring systems with the carboxylate group of Asp262.  It is suggested that this occurs through a strong concomitant interaction of one of the oxygen's directly with the metal ion and the other oxygen to one of the nitrogens of the cyclam ring through a hydrogen bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomGEp4uVdAELVg90H21EOLACvtfcHk0ljm-BiF_wyeow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktw%253D%253D&md5=a555971cbc1f0c31dfa72f4325090ed7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fbi0264770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0264770%26sid%3Dliteratum%253Aachs%26aulast%3DGerlach%26aufirst%3DL.%2BO.%26aulast%3DJakobsen%26aufirst%3DJ.%2BS.%26aulast%3DJensen%26aufirst%3DK.%2BP.%26aulast%3DRosenkilde%26aufirst%3DM.%2BR.%26aulast%3DSkerlj%26aufirst%3DR.%2BT.%26aulast%3DRyde%26aufirst%3DU.%26aulast%3DBridger%26aufirst%3DG.%2BJ.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DMetal%2520ion%2520enhanced%2520binding%2520of%2520AMD3100%2520to%2520Asp262%2520in%2520the%2520CXCR4%2520receptor%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D710%26epage%3D717%26doi%3D10.1021%2Fbi0264770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vo, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2013.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.jinorgbio.2013.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=24176921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWjt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2014&pages=69-73&author=N.+H.+Voauthor=Z.+Xiaauthor=J.+Hankoauthor=T.+Yunauthor=S.+Bloomauthor=J.+Shenauthor=K.+Koyaauthor=L.+Sunauthor=S.+Chen&title=Synthesis%2C+crystallographic+characterization+and+electrochemical+property+of+a+copper%28II%29+complex+of+the+anticancer+agent+elesclomol&doi=10.1016%2Fj.jinorgbio.2013.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol</span></div><div class="casAuthors">Vo, Nha Huu; Xia, Zhiqiang; Hanko, Jason; Yun, Tong; Bloom, Steve; Shen, Jianhua; Koya, Keizo; Sun, Lijun; Chen, Shoujun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-73</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Elesclomol is a novel anticancer agent that was evaluated in a no. of late stage clin. trials.  A new and convenient synthesis of elesclomol and its Cu complex is described.  X-ray crystallog. characterization and the electrochem. properties of the elesclomol Cu(II) complex are discussed.  The Cu(II) cation is coordinated in a highly distorted square-planar geometry to each of the S and amide N atoms of elesclomol.  Electrochem. measurements demonstrate that the complex undergoes a reversible 1-electron redn. at biol. accessible potentials.  In contrast the free elesclomol is found electrochem. inactive.  This evidence is in strong support of the mechanism of action the authors proposed for the anticancer activity of elesclomol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXVMYuAXC35bVg90H21EOLACvtfcHk0lhFjSny5Orjqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWjt7fM&md5=a653d8f8ff02d67ad6e8030b4106266f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2013.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2013.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DVo%26aufirst%3DN.%2BH.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DHanko%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DT.%26aulast%3DBloom%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DSynthesis%252C%2520crystallographic%2520characterization%2520and%2520electrochemical%2520property%2520of%2520a%2520copper%2528II%2529%2520complex%2520of%2520the%2520anticancer%2520agent%2520elesclomol%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D130%26spage%3D69%26epage%3D73%26doi%3D10.1016%2Fj.jinorgbio.2013.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-Lucio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">The many roles of molecular complexity in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.drudis.2016.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=27575998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=120-126&author=O.+M%C3%A9ndez-Lucioauthor=J.+L.+Medina-Franco&title=The+many+roles+of+molecular+complexity+in+drug+discovery&doi=10.1016%2Fj.drudis.2016.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of molecular complexity in drug discovery</span></div><div class="casAuthors">Mendez-Lucio, Oscar; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-126</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mol. complexity is becoming a crucial concept in drug discovery.  It has been assocd. with target selectivity, success in progressing into clin. development and compd. safety, among other factors.  Multiple metrics have been developed to quantify mol. complexity and explore complexity-property relationships.  However, there is no general agreement regarding how to measure this mol. feature.  Herein, we have surveyed the many roles of mol. complexity in drug discovery discussing in a crit. manner different quantification methods.  Through the anal. of various ref. compd. databases, common pitfalls and workarounds of the quantification of mol. complexity are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyZIwgtqVak7Vg90H21EOLACvtfcHk0lhFjSny5Orjqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P&md5=f731baf9298ee3b0f0c341970a990841</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Lucio%26aufirst%3DO.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520many%2520roles%2520of%2520molecular%2520complexity%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D120%26epage%3D126%26doi%3D10.1016%2Fj.drudis.2016.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, T.</span></span> <span> </span><span class="NLM_article-title">An additive definition of molecular complexity</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC28nosl2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=462-470&author=T.+B%C3%B6ttcher&title=An+additive+definition+of+molecular+complexity&doi=10.1021%2Facs.jcim.5b00723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">An Additive Definition of Molecular Complexity</span></div><div class="casAuthors">Bottcher Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">462-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A framework for molecular complexity is established that is based on information theory and consistent with chemical knowledge.  The resulting complexity index Cm is derived from abstracting the information content of a molecule by the degrees of freedom in the microenvironments on a per-atom basis, allowing the molecular complexity to be calculated in a simple and additive way.  This index allows the complexity of any molecule to be universally assessed and is sensitive to stereochemistry, heteroatoms, and symmetry.  The performance of this complexity index is evaluated and compared against the current state of the art.  Its additive character gives consistent values also for very large molecules and supports direct comparisons of chemical reactions.  Finally, this approach may provide a useful tool for medicinal chemistry in drug design and lead selection, as demonstrated by correlating molecular complexities of antibiotics with compound-specific parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWHp0vsfcWMRLDWw4HIq2sfW6udTcc2ebH2GLFEJFWi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nosl2quw%253D%253D&md5=c549b38908b24a36e6f6c6ac1419a8fc</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00723%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DT.%26atitle%3DAn%2520additive%2520definition%2520of%2520molecular%2520complexity%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D462%26epage%3D470%26doi%3D10.1021%2Facs.jcim.5b00723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivanenkov, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagribelnyy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aladinskiy, V. A.</span></span> <span> </span><span class="NLM_article-title">Are we opening the door to a new era of medicinal chemistry or being collapsed to a chemical singularity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10026</span>– <span class="NLM_lpage">10043</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKksbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10026-10043&author=Y.+A.+Ivanenkovauthor=B.+A.+Zagribelnyyauthor=V.+A.+Aladinskiy&title=Are+we+opening+the+door+to+a+new+era+of+medicinal+chemistry+or+being+collapsed+to+a+chemical+singularity%3F&doi=10.1021%2Facs.jmedchem.9b00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?</span></div><div class="casAuthors">Ivanenkov, Yan A.; Zagribelnyy, Bogdan A.; Aladinskiy, Vladimir A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10026-10043</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The paradigm of "drug-like-ness" dramatically altered the behavior of the medicinal chem. community for a long time.  In recent years, scientists have empirically found a significant increase in key properties of drugs that have moved structures closer to the periphery or the outside of the rule-of-five "cage".  Herein, we show that for the past decade, the no. of mols. claimed in patent records by major pharmaceutical companies has dramatically decreased, which may lead to a "chem. singularity".  New compds. contg. fragments with increased 3D complexity are generally larger, slightly more lipophilic, and more polar.  A core difference between this study and recently published papers is that we consider the nature and quality of sp3-rich frameworks rather than sp3 count.  We introduce the original descriptor MCE-18, which stands for medicinal chem. evolution, 2018, and this measure can effectively score mols. by novelty in terms of their cumulative sp3 complexity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvBxU8FqJprLVg90H21EOLACvtfcHk0ljPvvQZv7LKqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKksbjJ&md5=369fdff9d9018714e982d7bfe6125109</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00004%26sid%3Dliteratum%253Aachs%26aulast%3DIvanenkov%26aufirst%3DY.%2BA.%26aulast%3DZagribelnyy%26aufirst%3DB.%2BA.%26aulast%3DAladinskiy%26aufirst%3DV.%2BA.%26atitle%3DAre%2520we%2520opening%2520the%2520door%2520to%2520a%2520new%2520era%2520of%2520medicinal%2520chemistry%2520or%2520being%2520collapsed%2520to%2520a%2520chemical%2520singularity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10026%26epage%3D10043%26doi%3D10.1021%2Facs.jmedchem.9b00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0ljPvvQZv7LKqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span> <span> </span><span class="NLM_article-title">What do medicinal chemists actually make? A 50-year retrospective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6405</span>– <span class="NLM_lpage">6416</span>, <span class="refDoi"> DOI: 10.1021/jm200504p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200504p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6405-6416&author=W.+P.+Waltersauthor=J.+Greenauthor=J.+R.+Weissauthor=M.+A.+Murcko&title=What+do+medicinal+chemists+actually+make%3F+A+50-year+retrospective&doi=10.1021%2Fjm200504p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">What Do Medicinal Chemists Actually Make? A 50-Year Retrospective</span></div><div class="casAuthors">Walters, W. Patrick; Green, Jeremy; Weiss, Jonathan R.; Murcko, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6405-6416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the dramatically increasing costs of pharmaceutical R&D productivity, as measured by the no. of new drugs approved each year, has languished during the past decade.  Many different explanations have been proposed to account for this decline, such as increasing regulatory scrutiny, the inherent inefficiency of very large organizations, the pursuit of highly speculative targets identified from genomics, and more objective decision-making about advancing marginal compds. into latest age clin. trials.  Another factor often cited to help explain low pharmaceutical productivity is that, paradoxically, many compds. synthesized by medicinal chemists are not "druglike", at least as measured by various criteria.  The authors discuss the past, present and perspectives in the development of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg5xuF4wHqKrVg90H21EOLACvtfcHk0ljPvvQZv7LKqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O&md5=33109f9d55967be0d34f377f433621e4</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm200504p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200504p%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DW.%2BP.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DJ.%2BR.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DWhat%2520do%2520medicinal%2520chemists%2520actually%2520make%253F%2520A%252050-year%2520retrospective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6405%26epage%3D6416%26doi%3D10.1021%2Fjm200504p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raymer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span> <span> </span><span class="NLM_article-title">Lead-like drugs: a perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10375</span>– <span class="NLM_lpage">10384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2is73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10375-10384&author=B.+Raymerauthor=S.+K.+Bhattacharya&title=Lead-like+drugs%3A+a+perspective&doi=10.1021%2Facs.jmedchem.8b00407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Lead-like Drugs: A Perspective</span></div><div class="casAuthors">Raymer, Brian; Bhattacharya, Samit K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10375-10384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lead-like drugs, or drugs below mol. wt. 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chem. practice.  To examine the recent state-of-the-art in lead-like drug discovery, we surveyed recent drug approvals from 2011 to 2017 and top 200 prescribed medications, as well as provide case studies on recently approved lead-like drugs.  Many of these recent drugs are close analogs of previously known drugs or natural substrates, with a key focus of their medicinal chem. optimization being the choice of a low mol. wt. starting point and maintaining low mol. wt. during the optimization.  However, the identification of low mol. wt. starting points may be limited by the availability of suitable low mol. wt. screening sets.  To increase the discovery rate of lead-like drugs, we suggest an increased focus on inclusion and prosecution of lead-like starting points in screening libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqDUrWKytt_7Vg90H21EOLACvtfcHk0ljPvvQZv7LKqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2is73O&md5=e9fc17d69c7d671459fdaf77d6721829</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00407%26sid%3Dliteratum%253Aachs%26aulast%3DRaymer%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DLead-like%2520drugs%253A%2520a%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10375%26epage%3D10384%26doi%3D10.1021%2Facs.jmedchem.8b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lghTBf5gLgQYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lghTBf5gLgQYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kombo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallapragada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speake, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S.</span></span> <span> </span><span class="NLM_article-title">3D molecular descriptors important for clinical success</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1021/ci300445e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300445e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=327-342&author=D.+C.+Komboauthor=K.+Tallapragadaauthor=R.+Jainauthor=J.+Chewningauthor=A.+A.+Mazurovauthor=J.+D.+Speakeauthor=T.+A.+Hauserauthor=S.+Toler&title=3D+molecular+descriptors+important+for+clinical+success&doi=10.1021%2Fci300445e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">3D Molecular Descriptors Important for Clinical Success</span></div><div class="casAuthors">Kombo, David C.; Tallapragada, Kartik; Jain, Rachit; Chewning, Joseph; Mazurov, Anatoly A.; Speake, Jason D.; Hauser, Terry A.; Toler, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-342</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacokinetic and safety profiles of clin. drug candidates are greatly influenced by their requisite physicochem. properties.  In particular, it has been shown that 2D mol. descriptors such as fraction of Sp3 carbon atoms (Fsp3) and no. of stereo centers correlate with clin. success.  Using the proteomic off-target hit rate of nicotinic ligands, we found that shape-based 3D descriptors such as the radius of gyration and shadow indexes discriminate off-target promiscuity better than do Fsp3 and the no. of stereo centers.  We have deduced the relevant descriptor values required for a ligand to be nonpromiscuous.  Investigating the MDL Drug Data Report (MDDR) database as compds. move from the preclin. stage toward the market, we have found that these shape-based 3D descriptors predict clin. success of compds. at preclin. and phase1 stages vs compds. withdrawn from the market better than do Fsp3 and LogD.  Further, these computed 3D mol. descriptors correlate well with exptl. obsd. soly., which is among well-known physicochem. properties that drive clin. success.  We also found that about 84% of launched drugs satisfy either Shadow index or Fsp3 criteria, whereas withdrawn and discontinued compds. fail to meet the same criteria.  Our studies suggest that spherical compds. (rather than their elongated counterparts) with a minimal no. of arom. rings may exhibit a high propensity to advance from clin. trials to market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRhBgMppmbbVg90H21EOLACvtfcHk0lghTBf5gLgQYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE&md5=c750cdc150c2ba3626d98e2eea8c3144</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fci300445e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300445e%26sid%3Dliteratum%253Aachs%26aulast%3DKombo%26aufirst%3DD.%2BC.%26aulast%3DTallapragada%26aufirst%3DK.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DChewning%26aufirst%3DJ.%26aulast%3DMazurov%26aufirst%3DA.%2BA.%26aulast%3DSpeake%26aufirst%3DJ.%2BD.%26aulast%3DHauser%26aufirst%3DT.%2BA.%26aulast%3DToler%26aufirst%3DS.%26atitle%3D3D%2520molecular%2520descriptors%2520important%2520for%2520clinical%2520success%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D327%26epage%3D342%26doi%3D10.1021%2Fci300445e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span> </span><span class="NLM_article-title">FDA’s policy
statement for the development of new stereoisomeric
drugs</span>.  <i>Chirality</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume">4</span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1002/chir.530040513</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1002%2Fchir.530040513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1354468" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%E2%80%99s+policy%0Astatement+for+the+development+of+new+stereoisomeric%0Adrugs.+Chirality+1992%2C+4%2C+338%E2%80%93340+10.1002%2Fchir.530040513."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fchir.530040513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchir.530040513%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%25E2%2580%2599s%2520policy%250Astatement%2520for%2520the%2520development%2520of%2520new%2520stereoisomeric%250Adrugs%26jtitle%3DChirality%26date%3D1992%26volume%3D4%26spage%3D338%26epage%3D340%26doi%3D10.1002%2Fchir.530040513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">U.S. Food & Drug Administration</span>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs</a> (accessed 2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+%26+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fdevelopment-new-stereoisomeric-drugs+%28accessed+2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span> <span> </span><span class="NLM_article-title">From racemates to single enantiomers - Chiral synthetic drugs over the last 20 years</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1007/128_2006_072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2F128_2006_072" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2006&pages=273-299&author=H.+Murakami&title=From+racemates+to+single+enantiomers+-+Chiral+synthetic+drugs+over+the+last+20+years&doi=10.1007%2F128_2006_072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2F128_2006_072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F128_2006_072%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DH.%26atitle%3DFrom%2520racemates%2520to%2520single%2520enantiomers%2520-%2520Chiral%2520synthetic%2520drugs%2520over%2520the%2520last%252020%2520years%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2006%26volume%3D269%26spage%3D273%26epage%3D299%26doi%3D10.1007%2F128_2006_072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Opportunities for tapping into three-dimensional chemical space through a quaternary carbon</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">13291</span>– <span class="NLM_lpage">13315</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13291-13315&author=T.+T.+Talele&title=Opportunities+for+tapping+into+three-dimensional+chemical+space+through+a+quaternary+carbon&doi=10.1021%2Facs.jmedchem.0c00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13291-13315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron.  The spirocyclic quaternary carbon positioned at the center of a bioactive mol. offers conformational rigidity, which in turn reduces the penalty for conformational entropy.  The quaternary carbon is a predominant feature of natural product structures and has been assocd. with more effective and selective binding to target proteins compared to planar compds. with a high sp2 count.  The presence of a quaternary carbon stereocenter allows the exploration of novel chem. space to obtain new mols. with enhanced three-dimensionality.  These characteristics, coupled to an increasing awareness to develop sp3-rich mols., boosted utility of quaternary carbon stereocenters in bioactive compds.  It is hoped that this Perspective will inspire the chemist to utilize quaternary carbon stereocenters to enhance potency, selectivity, and other drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMfj5wUL80Z7Vg90H21EOLACvtfcHk0ljB4w_h902Q5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL&md5=4aebceb05cdc84702ea15908488a4e58</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DOpportunities%2520for%2520tapping%2520into%2520three-dimensional%2520chemical%2520space%2520through%2520a%2520quaternary%2520carbon%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D13291%26epage%3D13315%26doi%3D10.1021%2Facs.jmedchem.0c00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar’in, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic scaffolds in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=150-183&author=K.+Hiesingerauthor=D.+Dar%E2%80%99inauthor=E.+Proschakauthor=M.+Krasavin&title=Spirocyclic+scaffolds+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.0c01473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic Scaffolds in Medicinal Chemistry</span></div><div class="casAuthors">Hiesinger, Kerstin; Dar'in, Dmitry; Proschak, Ewgenij; Krasavin, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-183</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates.  The increasing interest in less planar bioactive compds. has given rise to the development of synthetic methodologies for the prepn. of spirocyclic scaffolds.  In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems.  The impact of spirocycles on potency and selectivity, including the aspect of stereochem., is discussed.  Furthermore, we examine the changes in physicochem. properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compds. to their nonspirocyclic counterparts.  In conclusion, the value of spirocyclic scaffolds in medicinal chem. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxeu8qelbAWbVg90H21EOLACvtfcHk0ljB4w_h902Q5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K&md5=b584a88a9ee65ed93277c946262de216</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26aulast%3DHiesinger%26aufirst%3DK.%26aulast%3DDar%25E2%2580%2599in%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DKrasavin%26aufirst%3DM.%26atitle%3DSpirocyclic%2520scaffolds%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D150%26epage%3D183%26doi%3D10.1021%2Facs.jmedchem.0c01473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. R.</span>; <span class="NLM_string-name">Di Fruscia, P.</span>; <span class="NLM_string-name">Lucas, S. C. C.</span>; <span class="NLM_string-name">Michaelides, I. N.</span>; <span class="NLM_string-name">Nelson, J. E.</span>; <span class="NLM_string-name">Storer, R. I.</span>; <span class="NLM_string-name">Whitehurst, B. C.</span></span> <span> </span><span class="NLM_article-title">Put a ring on it: application of small aliphatic rings in medicinal chemistry</span>.  <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, [Online early access].<span class="refDoi"> DOI: 10.1039/D0MD00370K</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2FD0MD00370K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=M.+R.+Bauer&author=P.+Di+Fruscia&author=S.+C.+C.+Lucas&author=I.+N.+Michaelides&author=J.+E.+Nelson&author=R.+I.+Storer&author=B.+C.+Whitehurst&title=Put+a+ring+on+it%3A+application+of+small+aliphatic+rings+in+medicinal+chemistry&doi=10.1039%2FD0MD00370K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1039%2FD0MD00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0MD00370K%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DM.%2BR.%26atitle%3DPut%2520a%2520ring%2520on%2520it%253A%2520application%2520of%2520small%2520aliphatic%2520rings%2520in%2520medicinal%2520chemistry%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2021%26doi%3D10.1039%2FD0MD00370K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4443</span>– <span class="NLM_lpage">4458</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4443-4458&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Analysis+of+past+and+present+synthetic+methodologies+on+medicinal+chemistry%3A+where+have+all+the+new+reactions+gone%3F&doi=10.1021%2Facs.jmedchem.5b01409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4443-4458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  An anal. of chem. reactions used in current medicinal chem. (2014), three decades ago (1984), and in natural product total synthesis has been conducted.  The anal. revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and 1990s (Suzuki-Miyaura and Buchwald-Hartwig).  This suggests an inherent high bar of impact for new synthetic reactions in drug discovery.  The most frequently used reactions were amide bond formation, Suzuki-Miyaura coupling, and SNAr reactions, most likely due to com. availability of reagents, high chemoselectivity, and a pressure on delivery.  The authors show that these practices result in overpopulation of certain types of mol. shapes to the exclusion of others using simple PMI plots.  The authors hope that these results will help catalyze improvements in integration of new synthetic methodologies as well as new library design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLWvt5DxktAbVg90H21EOLACvtfcHk0lhqYgL3AM1byw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM&md5=fd56ba8418f6d4e8c271f4e977ee2a93</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01409%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DAnalysis%2520of%2520past%2520and%2520present%2520synthetic%2520methodologies%2520on%2520medicinal%2520chemistry%253A%2520where%2520have%2520all%2520the%2520new%2520reactions%2520gone%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4443%26epage%3D4458%26doi%3D10.1021%2Facs.jmedchem.5b01409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhqYgL3AM1byw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajiness, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence oral drug-like behavior</span>. <i>Curr. Opin. Drug Discovery Devel.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=15338956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvFOms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=470-477&author=M.+S.+Lajinessauthor=M.+Viethauthor=J.+Erickson&title=Molecular+properties+that+influence+oral+drug-like+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties that influence oral drug-like behavior</span></div><div class="casAuthors">Lajiness, Michael S.; Vieth, Michal; Erickson, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-477</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Pharmaceutical companies are constantly racing to discover the next therapeutic blockbuster.  The consensus in the industry is to focus on compds. that are by some measure drug-like, but to do this effectively a no. of questions must be answered.  For example, how should drug-like be defined and how might this definition be used to enhance drug discovery.  Has the field moved beyond Lipinski's seminal 'rule-of-five' observations.  This review offers a working definition of oral drug-likeness, describes various approaches used in its characterization and discusses its appropriate use.  The authors will focus primarily on the use of computed mol. properties that attempt to predict the oral drug-like behavior of compds. and propose guidelines for the use of observations and trends established in existing datasets to support drug discovery efforts.  In particular, this review will demonstrate how trends in simple properties of the data can be used prospectively to compare and prioritize groups of compds., chem. libraries and different chem. series with greater reliability than for predicting drug-likeness of single compds.  It is the authors' belief, however, that properties or descriptors that will completely sep. drug-like space from non-drug-like space are unlikely to be found; the focus should instead lie on overall distributions of drug-like and non-drug-like compds. in the property space that tend to overlap significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTz2SN5eShpLVg90H21EOLACvtfcHk0lhqYgL3AM1byw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvFOms70%253D&md5=7c2d8d16a3d7338da189f26ccade6219</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLajiness%26aufirst%3DM.%2BS.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DErickson%26aufirst%3DJ.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520oral%2520drug-like%2520behavior%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2004%26volume%3D7%26spage%3D470%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':[],'ref27':[],'ref28':[],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b','cit32c'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':[],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':[],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Use of stems, prefixes, infixes, and suffixes in INNs. The definitions of the stems in the figure are the official definitions that can be found in the stem book.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of the five SCEs present in list p124 devoted to drugs potentially of use in the COVID pandemic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. INNs issued between 2000 and 2021. Categories composed of less than 10 substances were excluded from the figure (two inorganics and three mixtures), while the same were included in the calculation of the percentage of approved INNs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Probability of INN approval from the year of publication on the recommended INN list.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Representative structures of SCEs that are conjugated with mAbs. Payloads that are part of approved ADCs are highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Frequency of the most common stems in period A (blue; 2000–2011: <i>N</i> = 1038) and period B (orange; 2012–2021: <i>N</i> = 980).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Frequency of elements beyond CHON in SCEs in period A (blue; 2000–2011: <i>N</i> = 1038) and period B (orange; 2012–2021: <i>N</i> = 980). In the INN lists, four molecules are listed as containing sodium, but a visual inspection revealed that this indicates the salified molecule. These molecules were thereby excluded from the figure. Numbers in parentheses refer to the relative ranking of elements in FDA-approved drugs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> *<i>The occurrence of each element group refers to the number of SCEs containing at least one</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. INN molecules containing unconventional elements. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue, and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. INN deuterated molecules. EMA, FDA, or PMDA approved SCEs are highlighted in blue. The numbers in brackets indicate the rINN list and the year in which the molecule was published. <i>*To avoid a proliferation of stems and definitions, the WHO uses broad categories. Deucravacitinib well exemplifies that this choice is not flawless and might result in grouping molecules with distinct features. Indeed, both the stem (-citinib) and the definition place this drug as a Janus kinase (JAK) inhibitor, although the drug has been designed and developed as a specific inhibitor of TYK2, one of the four protein members of the JAK family (the others being JAK1, JAK2, and JAK3)</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Frequency of selected functional groups in SCEs in period A (blue; 2000–2011: <i>N</i> = 1038) and period B (orange; 2012–2021: <i>N</i> = 980). <i>*The occurrence of each functional group refers to the number of SCEs containing at least one</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Distribution of neutral, acid, basic, and zwitterionic SCEs in period A (2000–2011: <i>N</i> = 1038) and period B (2012–2021: <i>N</i> = 980). <i>* To define the acid/base properties of the SCEs, their ionization state at pH 7.4 was considered</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures of selected SCEs-containing α,β-unsaturated amide, aldehyde, or sulfoximine. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Frequency of selected ring systems in SCEs in period A (blue; 2000–2011: <i>N</i> = 994) and period B (orange; 2012–2021: <i>N</i> = 955). Numbers in parentheses refer to the relative ranking of ring systems in FDA-approved drugs.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a><i>The occurrence of each ring system was determined by counting the number of SCEs containing at least one</i>. *Steroids were grouped<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a>, while in Taylor et al. they were subdivided, considering the different ring systems. With our methodology, steroids would have risen to second place in Taylor et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures of selected symmetric compounds. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue, and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of the 12 SCEs with MW below 150 Da. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue, and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published. It is interesting to note that, at times, the INN does not reflect the common name by which a compound is known (which in the case of tramiprosate would be homotaurine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Median MW and mean Fsp<sup>3</sup> in period A (2000–2011: <i>N</i> = 1038) and period B (2012–2021: <i>N</i> = 980) and (B) per year; number of spirocycles (C) in periods A and B and (D) per year and number of SCE-containing small cycles (E) in periods A and B and (F) per year. <i>*The occurrence of spiro and small cycles refers to the number of SCEs containing at least one. Benzofused systems were excluded from the count of spiro compounds. Lactones and lactams were excluded from the count of small cycles</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/medium/jm1c00181_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Selected SCEs containing spirocyclic scaffolds and small rings. EMA-, FDA-, or PMDA-approved SCEs are highlighted in blue and molecules found to be approved by other agencies are highlighted in green. The numbers in brackets indicate the rINN list and the year in which the molecule was published.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00181/20210415/images/large/jm1c00181_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00181&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41135" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41135" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 91 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> Wikipedia. <a href="https://en.wikipedia.org/wiki/List_of_languages_by_total_number_of_speakers" class="extLink">https://en.wikipedia.org/wiki/List_of_languages_by_total_number_of_speakers</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Wikipedia.+https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FList_of_languages_by_total_number_of_speakers+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <i>Ethnologue: Languages of the World</i><i>,</i> <span class="NLM_edition">23</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D. M.</span>, <span class="NLM_string-name">Simons, G. F.</span>, <span class="NLM_string-name">Fennig, C. D.</span></span>, Eds; <span class="NLM_publisher-name">SIL International</span>: <span class="NLM_publisher-loc">Dallas, TX</span>, <span class="NLM_year">2020</span>. Online version: <a href="http://www.ethnologue.com" class="extLink">http://www.ethnologue.com</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=D.+M.+Eberhard&author=G.+F.+Simons&author=C.+D.+Fennig&title=Ethnologue%3A+Languages+of+the+World"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DEthnologue%253A%2520Languages%2520of%2520the%2520World%26aulast%3DEberhard%26aufirst%3DD.%2BM.%26pub%3DSIL%2520International%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">World Health
Organization</span>. <a href="https://apps.who.int/iris/bitstream/handle/10665/86211/WHA3.11_eng.pdf" class="extLink">https://apps.who.int/iris/bitstream/handle/10665/86211/WHA3.11_eng.pdf</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization.+https%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F86211%2FWHA3.11_eng.pdf+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. K.</span></span> <span> </span><span class="NLM_article-title">“Where name and image meet”–the argument for “adrenaline”</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1136/bmj.320.7233.506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1136%2Fbmj.320.7233.506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10678871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BD3c7ktlKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2000&pages=506-509&author=J.+K.+Aronson&title=%E2%80%9CWhere+name+and+image+meet%E2%80%9D%E2%80%93the+argument+for+%E2%80%9Cadrenaline%E2%80%9D&doi=10.1136%2Fbmj.320.7233.506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">"Where name and image meet"--the argument for "adrenaline"</span></div><div class="casAuthors">Aronson J K</div><div class="citationInfo"><span class="NLM_cas:title">BMJ (Clinical research ed.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">7233</span>),
    <span class="NLM_cas:pages">506-9</span>
        ISSN:<span class="NLM_cas:issn">0959-8138</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsSZkL2tiuY_h3YQQtAhNufW6udTcc2eYbgfp5cnkyarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7ktlKhtQ%253D%253D&md5=0a8fb7303156e6dff7b72b571672f61d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1136%2Fbmj.320.7233.506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.320.7233.506%26sid%3Dliteratum%253Aachs%26aulast%3DAronson%26aufirst%3DJ.%2BK.%26atitle%3D%25E2%2580%259CWhere%2520name%2520and%2520image%2520meet%25E2%2580%259D%25E2%2580%2593the%2520argument%2520for%2520%25E2%2580%259Cadrenaline%25E2%2580%259D%26jtitle%3DBMJ.%26date%3D2000%26volume%3D320%26spage%3D506%26epage%3D509%26doi%3D10.1136%2Fbmj.320.7233.506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. K.</span></span> <span> </span><span class="NLM_article-title">Medication errors resulting from the confusion of drug names</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1517/14740338.3.3.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1517%2F14740338.3.3.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=15155145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ovVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=167-172&author=J.+K.+Aronson&title=Medication+errors+resulting+from+the+confusion+of+drug+names&doi=10.1517%2F14740338.3.3.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Medication errors resulting from the confusion of drug names</span></div><div class="casAuthors">Aronson Jeffrey K</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug safety</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-72</span>
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    </div><div class="casAbstract">If drug names are similar, errors can occur.  Problems arise when different drugs have similar names (whether proprietary or non-proprietary), when formulations with the same brand name contain different drugs, when the same drug is marketed in formulations with different names, and when drug names are abbreviated.  The risk of errors could be reduced by some simple precautions at different stages of drug development, prescribing, supply, and administration.  Regulatory authorities and manufacturers should maintain their vigilance when naming new drugs and formulations, and should be prepared to change names if errors occur.  Before they write an unfamiliar name on a prescription, prescribers should check what they are prescribing and what other medications the patient is taking (patients should be familiar with their medicines), and pharmacists should check patients' medicines.  At all times there should be good communication among those who prescribe, supply, and administer medicines, and those who take them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUm9ReelARjwqdek-gHSrIfW6udTcc2eYbgfp5cnkyarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ovVSnsg%253D%253D&md5=1221787ce9905ec262e78cfd8effe146</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14740338.3.3.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.3.3.167%26sid%3Dliteratum%253Aachs%26aulast%3DAronson%26aufirst%3DJ.%2BK.%26atitle%3DMedication%2520errors%2520resulting%2520from%2520the%2520confusion%2520of%2520drug%2520names%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2004%26volume%3D3%26spage%3D167%26epage%3D172%26doi%3D10.1517%2F14740338.3.3.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Personal Care Products Council</span>. <a href="https://www.personalcarecouncil.org/resources/inci/" class="extLink">https://www.personalcarecouncil.org/resources/inci/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Personal+Care+Products+Council.+https%3A%2F%2Fwww.personalcarecouncil.org%2Fresources%2Finci%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinclair, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olliaro, P. L.</span></span> <span> </span><span class="NLM_article-title">Drugs for treating urinary schistosomiasis</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">CD000053</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD000053.pub3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1002%2F14651858.CD000053.pub3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=CD000053&author=C.+V.+Kramerauthor=F.+Zhangauthor=D.+Sinclairauthor=P.+L.+Olliaro&title=Drugs+for+treating+urinary+schistosomiasis&doi=10.1002%2F14651858.CD000053.pub3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD000053.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD000053.pub3%26sid%3Dliteratum%253Aachs%26aulast%3DKramer%26aufirst%3DC.%2BV.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DSinclair%26aufirst%3DD.%26aulast%3DOlliaro%26aufirst%3DP.%2BL.%26atitle%3DDrugs%2520for%2520treating%2520urinary%2520schistosomiasis%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2014%26volume%3D8%26spage%3DCD000053%26doi%3D10.1002%2F14651858.CD000053.pub3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/medicines/services/inn/inn_expert_group/en/" class="extLink">https://www.who.int/medicines/services/inn/inn_expert_group/en/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fservices%2Finn%2Finn_expert_group%2Fen%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">World Health
Organization</span>. <a href="https://www.who.int/medicines/services/inn/publication/en/" class="extLink">https://www.who.int/medicines/services/inn/publication/en/</a> (accessed
2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health%0AOrganization.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fservices%2Finn%2Fpublication%2Fen%2F+%28accessed%0A2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span>Stem Book
2018. <a href="https://www.who.int/publications/i/item/who-emp-rht-tsn-2018-1" class="extLink">https://www.who.int/publications/i/item/who-emp-rht-tsn-2018-1</a> (accessed 2021-01-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Stem+Book%0A2018.+https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fwho-emp-rht-tsn-2018-1+%28accessed+2021-01-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span>Radical
Book 2015. <a href="https://www.who.int/medicines/services/inn/RadicalBook2015.pdf?ua=1" class="extLink">https://www.who.int/medicines/services/inn/RadicalBook2015.pdf?ua=1</a> (accessed 2021-01-27).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Radical%0ABook+2015.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fservices%2Finn%2FRadicalBook2015.pdf%3Fua%3D1+%28accessed+2021-01-27%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López
de la Rica Manjavacas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mignot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balocco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span> <span> </span><span class="NLM_article-title">The INN global nomenclature of biological medicines: A continuous challenge</span>. <i>Biologicals</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.biologicals.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.biologicals.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31130314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB3M7pvFSksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=15-23&author=J.+S.+Robertsonauthor=W.+K.+Chuiauthor=A.+A.+Genazzaniauthor=S.+F.+Malanauthor=A.+L%C3%B3pez%0Ade+la+Rica+Manjavacasauthor=G.+Mignotauthor=R.+Thorpeauthor=R.+Baloccoauthor=M.+Rizzi&title=The+INN+global+nomenclature+of+biological+medicines%3A+A+continuous+challenge&doi=10.1016%2Fj.biologicals.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The INN global nomenclature of biological medicines: A continuous challenge</span></div><div class="casAuthors">Robertson James S; Thorpe Robin; Chui Wai-Keung; Genazzani Armando A; Malan Sarel F; Lopez de la Rica Manjavacas Ana; Mignot Gilles; Balocco Raffaella; Rizzi Menico</div><div class="citationInfo"><span class="NLM_cas:title">Biologicals : journal of the International Association of Biological Standardization</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Medicines are assigned International Nonproprietary Names (INN) by the World Health Organization (WHO), pursuing the aim to increase patient safety.  Following scientific developments in drug discovery and biotechnology, the number of biological medicines is constantly growing and a surge in INN applications for them has been observed.  Pharmacologically active biological substances have a complex structure and mechanism of action posing new challenges in selecting names that appropriately reflect such properties.  As a consequence, existing nomenclature naming schemes may need to be revised and new ones developed.  This review reports on the recently implemented policies for naming fusion proteins, monoclonal antibodies, advanced therapy substances that cover gene and cell therapy, virus-based therapies as well as vaccines and vaccine-like substances.  Different approaches, based on the use of a one-word versus a two-word naming scheme, have been developed for different categories of biological substances highlighting a major and still not completely resolved issue, i.e. how to assign a name that is both informative, short and euphonic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSFdG8dheR5wWRJ3OJdH_qfW6udTcc2ea5Y7BtHNqfIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7pvFSksQ%253D%253D&md5=4ce97e0a760415c62c858a8bab02bf20</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.biologicals.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biologicals.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BS.%26aulast%3DChui%26aufirst%3DW.%2BK.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26aulast%3DMalan%26aufirst%3DS.%2BF.%26aulast%3DL%25C3%25B3pez%2Bde%2Bla%2BRica%2BManjavacas%26aufirst%3DA.%26aulast%3DMignot%26aufirst%3DG.%26aulast%3DThorpe%26aufirst%3DR.%26aulast%3DBalocco%26aufirst%3DR.%26aulast%3DRizzi%26aufirst%3DM.%26atitle%3DThe%2520INN%2520global%2520nomenclature%2520of%2520biological%2520medicines%253A%2520A%2520continuous%2520challenge%26jtitle%3DBiologicals%26date%3D2019%26volume%3D60%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.biologicals.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span> </span><span class="NLM_article-title">School of International Non-proprietary
Names</span>. <a href="https://extranet.who.int/soinn/" class="extLink">https://extranet.who.int/soinn/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=School+of+International+Non-proprietary%0ANames.+https%3A%2F%2Fextranet.who.int%2Fsoinn%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DSchool%2520of%2520International%2520Non-proprietary%250ANames" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">World Health Organization</span>. <a href="https://www.who.int/medicines/publications/druginformation/innlists/en/" class="extLink">https://www.who.int/medicines/publications/druginformation/innlists/en/</a> (accessed 2020-12-21).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+https%3A%2F%2Fwww.who.int%2Fmedicines%2Fpublications%2Fdruginformation%2Finnlists%2Fen%2F+%28accessed+2020-12-21%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A survey of the structures of US FDA approved combination drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4311</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01610</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01610" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4265-4311&author=P.+Dasauthor=M.+D.+Delostauthor=M.+H.+Qureshiauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=A+survey+of+the+structures+of+US+FDA+approved+combination+drugs&doi=10.1021%2Facs.jmedchem.8b01610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Structures of US FDA Approved Combination Drugs</span></div><div class="casAuthors">Das, Pradipta; Delost, Michael D.; Qureshi, Munaum H.; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4265-4311</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Combination drugs are an important class of US FDA approved pharmaceuticals.  These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s.  In this Perspective, we report the first comprehensive compilation and anal. of US FDA approved combination drugs, from the first approval in 1943 through 2018.  Our database contains 419 combination drugs, which are represented by 328 unique small mol. structures.  Breakdown of these drugs according to disease category, structure, combination compn., and year of approval is presented as well as the top 24 most commonly used small mol. combination drug components.  For frequently used small mol. components, we present "relationship diagrams" to aid in the visualization of the many drug combinations these structures are part of.  The main body contains 10 disease-focused sections wherein every small mol. component utilized as part of a combination for each disease category is displayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8XxgcuwxFEbVg90H21EOLACvtfcHk0liL92cjHVmhbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Citb7J&md5=caeeef6298591e300a93782176e87ab8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01610%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DP.%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DQureshi%26aufirst%3DM.%2BH.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520survey%2520of%2520the%2520structures%2520of%2520US%2520FDA%2520approved%2520combination%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4265%26epage%3D4311%26doi%3D10.1021%2Facs.jmedchem.8b01610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two decades under the influence of the rule of five and the changing properties of approved oral drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+decades+under+the+influence+of+the+rule+of+five+and+the+changing+properties+of+approved+oral+drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0liL92cjHVmhbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520decades%2520under%2520the%2520influence%2520of%2520the%2520rule%2520of%2520five%2520and%2520the%2520changing%2520properties%2520of%2520approved%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delost, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">From oxiranes to oligomers: Architectures of U.S. FDA approved pharmaceuticals containing oxygen heterocycles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10996</span>– <span class="NLM_lpage">11020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00876</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10996-11020&author=M.+D.+Delostauthor=D.+T.+Smithauthor=B.+J.+Andersonauthor=J.+T.+Njardarson&title=From+oxiranes+to+oligomers%3A+Architectures+of+U.S.+FDA+approved+pharmaceuticals+containing+oxygen+heterocycles&doi=10.1021%2Facs.jmedchem.8b00876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles</span></div><div class="casAuthors">Delost, Michael D.; Smith, David T.; Anderson, Benton J.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10996-11020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals.  Anal. of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals contg. at least one oxygen heterocycle.  Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five.  The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-contg. heterocycles.  For each section, all oxygen heterocycle-contg. drugs are presented along with a brief discussion about structural and drug application patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor-PzQmLXoGbVg90H21EOLACvtfcHk0lhm3T7iFtjdlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7nE&md5=18f3979c80513bfbbc263dd5945c63f0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00876%26sid%3Dliteratum%253Aachs%26aulast%3DDelost%26aufirst%3DM.%2BD.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DAnderson%26aufirst%3DB.%2BJ.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DFrom%2520oxiranes%2520to%2520oligomers%253A%2520Architectures%2520of%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%2520containing%2520oxygen%2520heterocycles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10996%26epage%3D11020%26doi%3D10.1021%2Facs.jmedchem.8b00876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of US FDA-approved drugs containing sulfur atoms</span>. <i>Top Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">5</span>, <span class="refDoi"> DOI: 10.1007/s41061-018-0184-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2Fs41061-018-0184-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=29356979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjtVWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2018&pages=5&author=K.+A.+Scottauthor=J.+T.+Njardarson&title=Analysis+of+US+FDA-approved+drugs+containing+sulfur+atoms&doi=10.1007%2Fs41061-018-0184-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of US FDA-Approved Drugs Containing Sulfur Atoms</span></div><div class="casAuthors">Scott Kevin A; Njardarson Jon T; Scott Kevin A</div><div class="citationInfo"><span class="NLM_cas:title">Topics in current chemistry (Cham)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn">2365-0869</span>.
    </div><div class="casAbstract">In this review, we discuss all sulfur-containing FDA-approved drugs and their structures.  The second section of the review is dedicated to structural analysis and is divided into 14 subsections, each focusing on one type of sulfur-containing moiety.  A concise graphical representation of each class features drugs that are organized on the basis of structural similarity, evolutionary relevance, and medical indication.  This review offers a unique and comprehensive overview of the structural features of all sulfur-containing FDA-approved drugs to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX4OluBMto4cULxIEhxUjPfW6udTcc2eZ0cojYfTf9TLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjtVWksA%253D%253D&md5=2dcb48e2346e2d3df04fa1c24e3d6dfe</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs41061-018-0184-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs41061-018-0184-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520US%2520FDA-approved%2520drugs%2520containing%2520sulfur%2520atoms%26jtitle%3DTop%2520Curr.%2520Chem.%26date%3D2018%26volume%3D376%26spage%3D5%26doi%3D10.1007%2Fs41061-018-0184-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the rule of 5: Lessons learned from AbbVie’s drugs and compound collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&author=D.+A.+DeGoeyauthor=H.+J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+rule+of+5%3A+Lessons+learned+from+AbbVie%E2%80%99s+drugs+and+compound+collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0lhm3T7iFtjdlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520rule%2520of%25205%253A%2520Lessons%2520learned%2520from%2520AbbVie%25E2%2580%2599s%2520drugs%2520and%2520compound%2520collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+U.S.+FDA+approved+pharmaceuticals&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0lhfJeMIhEa-IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Beyond C, H, O, and N! Analysis of the elemental composition of U.S. FDA approved drug architectures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9764</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/jm501105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9764-9773&author=B.+R.+Smithauthor=C.+M.+Eastmanauthor=J.+T.+Njardarson&title=Beyond+C%2C+H%2C+O%2C+and+N%21+Analysis+of+the+elemental+composition+of+U.S.+FDA+approved+drug+architectures&doi=10.1021%2Fjm501105n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond C, H, O, and N! Analysis of the Elemental Composition of U.S. FDA Approved Drug Architectures</span></div><div class="casAuthors">Smith, Brandon R.; Eastman, Candice M.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9764-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The diversity of elements among U.S.  Food and Drug Administration (FDA) approved pharmaceuticals is analyzed and reported, with a focus on atoms other than carbon, hydrogen, oxygen, and nitrogen.  Our anal. reveals that sulfur, chlorine, fluorine, and phosphorous represent about 90% of elemental substitutions, with sulfur being the fifth most used element followed closely by chlorine, then fluorine and finally phosphorous in the eighth place.  The remaining 10% of substitutions are represented by 16 other elements of which bromine, iodine, and iron occur most frequently.  The most detailed parts of our anal. are focused on chlorinated drugs as a function of approval date, disease condition, chlorine attachment, and structure.  To better aid our chlorine drug analyses, a new poster showcasing the structures of chlorinated pharmaceuticals was created specifically for this study.  Phosphorus, bromine, and iodine contg. drugs are analyzed closely as well, followed by a discussion about other elements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLwTieDN1HbVg90H21EOLACvtfcHk0lhfJeMIhEa-IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1WlurbL&md5=95e1ab686ba41c63070059ad0987ff6c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm501105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501105n%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DEastman%26aufirst%3DC.%2BM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DBeyond%2520C%252C%2520H%252C%2520O%252C%2520and%2520N%2521%2520Analysis%2520of%2520the%2520elemental%2520composition%2520of%2520U.S.%2520FDA%2520approved%2520drug%2520architectures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9764%26epage%3D9773%26doi%3D10.1021%2Fjm501105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2842</span>, <span class="refDoi"> DOI: 10.1021/jm401375q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+design+and+discovery&doi=10.1021%2Fjm401375q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0lhfJeMIhEa-IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842%26doi%3D10.1021%2Fjm401375q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellaire, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, B. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A Structural analysis of the FDA Green Book-approved veterinary drugs and roles in human medicine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">15449</span>– <span class="NLM_lpage">15482</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2iu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=15449-15482&author=K.+A.+Scottauthor=M.+H.+Qureshiauthor=P.+B.+Coxauthor=C.+M.+Marshallauthor=B.+C.+Bellaireauthor=M.+Wilcoxauthor=B.+A.+R.+Stuartauthor=J.+T.+Njardarson&title=A+Structural+analysis+of+the+FDA+Green+Book-approved+veterinary+drugs+and+roles+in+human+medicine&doi=10.1021%2Facs.jmedchem.0c01502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine</span></div><div class="casAuthors">Scott, Kevin A.; Qureshi, M. Haziq; Cox, Philip B.; Marshall, Christopher M.; Bellaire, Bailey C.; Wilcox, Michael; Stuart, Bradey A. R.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15449-15482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The FDA Green Book is a list of all drug products that have been approved by the FDA for use in veterinary medicine.  The Green Book, as published, lacks structural information corresponding to approved drugs.  To address this gap, we have compiled the structural data for all FDA Green Book drugs approved through the end of 2019.  Herein we discuss the relevance of this data set to human drugs in the context of structural classes and physicochem. properties.  Anal. reveals that physicochem. properties are highly optimized and consistent with a high probability of favorable drug metab. and pharmacokinetic properties, including good oral bioavailability for most compds.  We provide a detailed anal. of this data set organized on the basis of structure and function.  Slightly over half (51%) of vet drugs are also approved in human medicine.  Combination drugs are biologics are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGJ3v34Bzi-7Vg90H21EOLACvtfcHk0lhfJeMIhEa-IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2iu7zL&md5=bfccb59426934314de5e774431af78ea</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01502%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DK.%2BA.%26aulast%3DQureshi%26aufirst%3DM.%2BH.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DMarshall%26aufirst%3DC.%2BM.%26aulast%3DBellaire%26aufirst%3DB.%2BC.%26aulast%3DWilcox%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DB.%2BA.%2BR.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520Structural%2520analysis%2520of%2520the%2520FDA%2520Green%2520Book-approved%2520veterinary%2520drugs%2520and%2520roles%2520in%2520human%2520medicine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D15449%26epage%3D15482%26doi%3D10.1021%2Facs.jmedchem.0c01502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Essential medicinal chemistry of essential medicines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10170</span>– <span class="NLM_lpage">10187</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00415</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00415" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotl2qt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10170-10187&author=M.+Serafiniauthor=S.+Cargninauthor=A.+Massarottiauthor=T.+Piraliauthor=A.+A.+Genazzani&title=Essential+medicinal+chemistry+of+essential+medicines&doi=10.1021%2Facs.jmedchem.0c00415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Essential Medicinal Chemistry of Essential Medicines</span></div><div class="casAuthors">Serafini, Marta; Cargnin, Sarah; Massarotti, Alberto; Pirali, Tracey; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10170-10187</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Since 1977, the World Health Organization publishes a list of essential medicines, i.e., those that satisfy the priority health care needs of the population and are selected with regard to disease prevalence and public health relevance, evidence of clin. efficacy, and safety, as well as comparative costs and cost-effectiveness.  The Essential Medicines List (EML) is an invaluable tool for all countries to select those medicines that have an excellent risk/benefit ratio and that are reputed to be of pivotal importance to health.  In the present perspective, we describe the chem. compn. and the main features of the small mols. that are included in the EML, spanning from their origin, to their stereochem. and measure of drug-likeness.  Most and foremost, we wish to disseminate the importance of the EML, which can be both a helpful teaching tool in an ever-expanding world of medicines and an inspiration for those involved in pharmaceutical R&D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9SxMf0szdPrVg90H21EOLACvtfcHk0lgEUq4vV_eNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotl2qt74%253D&md5=db1e89fcc1eac121a5c23af2b063bb3a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00415%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DEssential%2520medicinal%2520chemistry%2520of%2520essential%2520medicines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10170%26epage%3D10187%26doi%3D10.1021%2Facs.jmedchem.0c00415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, J.</span></span> <span> </span><span class="NLM_article-title">The most common functional groups in bioactive molecules and how their popularity has evolved over time</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8408</span>– <span class="NLM_lpage">8418</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00754</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00754" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8408-8418&author=P.+Ertlauthor=E.+Altmannauthor=J.+McKenna&title=The+most+common+functional+groups+in+bioactive+molecules+and+how+their+popularity+has+evolved+over+time&doi=10.1021%2Facs.jmedchem.0c00754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Most Common Functional Groups in Bioactive Molecules and How Their Popularity Has Evolved over Time</span></div><div class="casAuthors">Ertl, Peter; Altmann, Eva; McKenna, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8408-8418</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of functional groups (FGs), sets of connected atoms that can det. the intrinsic reactivity of the parent mol. and in part are responsible for the overall properties of the mol., form a foundation within modern medicinal chem.  In this Article, we analyze the occurrence of various FGs in mols. described in the medicinal chem. literature over the last 40 years and show how their development and utilization over time has varied.  The popularity of various FGs has not evolved randomly, but instead, clear patterns of use are evident.  Various factors influencing these patterns, including the introduction of new synthetic methods, novel techniques, and strategies applied in drug discovery and the better knowledge of mol. properties affecting the success of candidate development, are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6iMIvgb6l7Vg90H21EOLACvtfcHk0lgEUq4vV_eNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurjO&md5=17fc5a390c5642ab234c0fa7202f7a74</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00754%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DAltmann%26aufirst%3DE.%26aulast%3DMcKenna%26aufirst%3DJ.%26atitle%3DThe%2520most%2520common%2520functional%2520groups%2520in%2520bioactive%2520molecules%2520and%2520how%2520their%2520popularity%2520has%2520evolved%2520over%2520time%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8408%26epage%3D8418%26doi%3D10.1021%2Facs.jmedchem.0c00754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Where do recent small molecule clinical development candidates come from?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Where+do+recent+small+molecule+clinical+development+candidates+come+from%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0lgEUq4vV_eNWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DWhere%2520do%2520recent%2520small%2520molecule%2520clinical%2520development%2520candidates%2520come%2520from%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">These substances have been labeled with an asterisk in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00181/suppl_file/jm1c00181_si_001.xlsx" class="ext-link">Supporting Information</a> database, since their proposed INNs were submitted by WHO several years before their publication in the rINN list.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">On the one hand, the category of biologicals includes proteins, including those in which some amino acid residues have been modified, low molecular weight heparins, purified hormones, and small peptides. On the other hand, when a short peptide (up to four-five amino acids) was present in an otherwise SCE (e.g., vintafolide, r69;2013), this substance was inserted in the SCE category. Note that the number of mAbs is slightly overestimated, as often, in the same rINN list, the applicant applied for the mAb itself together with a second application for the relative conjugate (30 examples in the analyzed lists). Pegylation, indicated as either the prefix “peg” or the suffix “pegol”, has not been considered in the classification of the substances. RNA/DNA-based therapies broadly comprise antisense, siRNA, and mRNA-based therapies. Advanced therapies comprise gene and cell therapies, oncolytic viruses, or bacteria. The category of veterinary drugs has been compiled following the indication reported in the proposed INN volumes, and not on chemical or biological structures, but it must be recognized that also drugs not specifically categorized as veterinary during the INN application process may be then developed for veterinary use. Surprisingly, the lists also include a few sunscreens, possibly because these are not considered cosmetic ingredients for the U.S. legislation.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="note"><p class="first last">Belzupacap sarotalocan is described in list p122 as “A modified human papillomavirus (HPV) type 16-derived empty nanoparticle, 55 nm in diameter conjugated to approximately 200 molecules of a phthalocyanine-based photosensitizer (sarotalocan group). Each nanoparticle is comprised of 72 capsomeres, made of 5 molecules of modified viral capsid protein L1 [P78 > R, T176 > N, D273 > T, N285 > T, S288 > N, T353 > P, T389 > S] and one molecule of viral capsid protein L2”.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span> </span><span class="NLM_article-title">FDA-approved
drugs</span>. <a href="https://www.accessdata.fda.gov/scripts/cder/daf/" class="extLink">https://www.accessdata.fda.gov/scripts/cder/daf/</a> (accessed 2020-09-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA-approved%0Adrugs.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2F+%28accessed+2020-09-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DFDA-approved%250Adrugs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span> </span><span class="NLM_article-title">EMA EPARs for human
and veterinary medicines</span>. <a href="https://www.ema.europa.eu/en/medicines/download-medicine-data" class="extLink">https://www.ema.europa.eu/en/medicines/download-medicine-data</a> (accessed 2020-09-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EMA+EPARs+for+human%0Aand+veterinary+medicines.+https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fmedicines%2Fdownload-medicine-data+%28accessed+2020-09-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEMA%2520EPARs%2520for%2520human%250Aand%2520veterinary%2520medicines" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span> </span><span class="NLM_article-title">PMDA-approved drugs</span>. <a href="https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html" class="extLink">https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html</a> (accessed 2020-09-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PMDA-approved+drugs.+https%3A%2F%2Fwww.pmda.go.jp%2Fenglish%2Freview-services%2Freviews%2Fapproved-information%2Fdrugs%2F0002.html+%28accessed+2020-09-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPMDA-approved%2520drugs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">To this aim, we used the following Web sites and databases:</p></div><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <a href="http://adisinsight.springer.com" class="extLink">adisinsight.springer.com</a> (accessed 2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+adisinsight.springer.com+%28accessed+2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <a href="http://www.wikipedia.org" class="extLink">www.wikipedia.org</a> (accessed
2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+www.wikipedia.org+%28accessed%0A2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span> <a href="http://newdrugapprovals.org" class="extLink">newdrugapprovals.org</a> (accessed
2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+newdrugapprovals.org+%28accessed%0A2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bargh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isidro-Llobet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Cleavable linkers in antibody-drug conjugates</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4361</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1039/C8CS00676H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2FC8CS00676H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31294429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=4361-4374&author=J.+D.+Barghauthor=A.+Isidro-Llobetauthor=J.+S.+Parkerauthor=D.+R.+Spring&title=Cleavable+linkers+in+antibody-drug+conjugates&doi=10.1039%2FC8CS00676H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Cleavable linkers in antibody-drug conjugates</span></div><div class="casAuthors">Bargh, Jonathan D.; Isidro-Llobet, Albert; Parker, Jeremy S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4361-4374</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Antibody-Drug Conjugates (ADCs) are now established as a major class of therapeutics for the clin. treatment of cancer.  The properties of the linker between the antibody and the payload are proven to be crit. to the success of an ADC.  Although ADC linkers can be 'non-cleavable', the vast majority of ADCs in clin. development have specific release mechanisms to allow controlled linker cleavage at the target site and are thus termed 'cleavable'.  In recent years, the development of new methods of drug release from ADCs has continued in parallel to the deepening understanding of the biol. processes underlying the mechanisms of action of pre-existing technologies.  This review summarises the advances in the field of cleavable linker technologies for ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvG2Xk9IvLpLVg90H21EOLACvtfcHk0lhj9nafaypy8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGgu77M&md5=bc73619319b21c2b85e3d613ca72f778</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1039%2FC8CS00676H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00676H%26sid%3Dliteratum%253Aachs%26aulast%3DBargh%26aufirst%3DJ.%2BD.%26aulast%3DIsidro-Llobet%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DCleavable%2520linkers%2520in%2520antibody-drug%2520conjugates%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26spage%3D4361%26epage%3D4374%26doi%3D10.1039%2FC8CS00676H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Drug Conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8751</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVagurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8751-61&author=G.+Casiauthor=D.+Neri&title=Antibody-Drug+Conjugates+and+small+molecule-drug+conjugates%3A+opportunities+and+challenges+for+the+development+of+selective+anticancer+cytotoxic+agents&doi=10.1021%2Facs.jmedchem.5b00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents</span></div><div class="casAuthors">Casi, Giulio; Neri, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8751-8761</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Conventional cancer chemotherapy heavily relies on the use of cytotoxic agents, which typically do not preferentially localize at the tumor site and cause toxicity to normal organs, preventing dose escalation to therapeutically active regimens.  In principle, antibodies and other ligands could be used for the selective pharmacodelivery of cytotoxic agents to the neoplastic mass.  For many years, the availability of ligands, capable of selective internalization into tumor cells, has been considered to be an essential requirement for the development of targeted cytotoxics.  This assumption, however, has recently been challenged on the basis of therapeutic data obtained with noninternalizing drug conjugates.  Moreover, quant. evaluations of the tumor targeting properties of antibodies and of small org. ligands have provided new insights for the implementation of optimal strategies for the development of targeted cytotoxics.  In this article, we highlight opportunities and challenges assocd. with the clin. and industrial development of antibody-drug conjugates and small mol.-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFQV1Ekvuz8rVg90H21EOLACvtfcHk0lhj9nafaypy8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVagurzO&md5=24614e4825cbfe408e0b875db1826e68</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00457%26sid%3Dliteratum%253Aachs%26aulast%3DCasi%26aufirst%3DG.%26aulast%3DNeri%26aufirst%3DD.%26atitle%3DAntibody-Drug%2520Conjugates%2520and%2520small%2520molecule-drug%2520conjugates%253A%2520opportunities%2520and%2520challenges%2520for%2520the%2520development%2520of%2520selective%2520anticancer%2520cytotoxic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8751%26epage%3D61%26doi%3D10.1021%2Facs.jmedchem.5b00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span>RDKit,
2020.09.1 version: Open-Source Cheminformatics Software. <a href="https://www.rdkit.org" class="extLink">https://www.rdkit.org</a>. (accessed
2020-08-07).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=RDKit%2C%0A2020.09.1+version%3A+Open-Source+Cheminformatics+Software.+https%3A%2F%2Fwww.rdkit.org.+%28accessed%0A2020-08-07%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lhj9nafaypy8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachhav, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajanna, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">U.S. FDA approved drugs from 2015–June 2020: a perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">2339</span>– <span class="NLM_lpage">2381</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01786</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01786" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3MXltVyrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=2339-2381&author=P.+Bhutaniauthor=G.+Joshiauthor=N.+Rajaauthor=N.+Bachhavauthor=P.+K.+Rajannaauthor=H.+Bhutaniauthor=A.+T.+Paulauthor=R.+Kumar&title=U.S.+FDA+approved+drugs+from+2015%E2%80%93June+2020%3A+a+perspective&doi=10.1021%2Facs.jmedchem.0c01786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. FDA Approved Drugs from 2015-June 2020: A Perspective</span></div><div class="casAuthors">Bhutani, Priyadeep; Joshi, Gaurav; Raja, Nivethitha; Bachhav, Namrata; Rajanna, Prabhakar K.; Bhutani, Hemant; Paul, Atish T.; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2339-2381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present work, we report compilation and anal. of 245 drugs, including small and macromols. approved by the U.  S. FDA from 2015 until June 2020.  Nearly 29% of the drugs were approved for the treatment of various types of cancers.  Other major therapeutic areas of focus were infectious diseases (14%); neurol. conditions (12%); and genetic, metabolic, and cardiovascular disorders (7-8% each).  Itemization of the approved drugs according to the year of approval, sponsor, target, chem. class, major drug-metabolizing enzyme(s), route of administration/elimination, and drug-drug interaction liability (perpetrator or/and victim) is presented and discussed.  An effort has been made to analyze the pharmacophores to identity the structural (e.g., arom., heterocycle, and aliph.), elemental (e.g., boron, sulfur, fluorine, phosphorus, and deuterium), and functional group (e.g., nitro drugs) diversity among the approved drugs.  Further, descriptor-based chem. space anal. of FDA approved drugs and several strategies utilized for optimizing metab. leading to their discoveries have been emphasized.  Finally, an anal. of drug-likeness for the approved drugs is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTyUH9SM6PbVg90H21EOLACvtfcHk0lj8pS4C5-i2aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXltVyrsLs%253D&md5=476a6161406118f193f2bca000cbd20d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26aulast%3DBhutani%26aufirst%3DP.%26aulast%3DJoshi%26aufirst%3DG.%26aulast%3DRaja%26aufirst%3DN.%26aulast%3DBachhav%26aufirst%3DN.%26aulast%3DRajanna%26aufirst%3DP.%2BK.%26aulast%3DBhutani%26aufirst%3DH.%26aulast%3DPaul%26aufirst%3DA.%2BT.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DU.S.%2520FDA%2520approved%2520drugs%2520from%25202015%25E2%2580%2593June%25202020%253A%2520a%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D2339%26epage%3D2381%26doi%3D10.1021%2Facs.jmedchem.0c01786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span>; <span class="NLM_string-name">Gao, P.</span>; <span class="NLM_string-name">Sun, L.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Kongsted, J.</span>; <span class="NLM_string-name">Poongavanam, V.</span>; <span class="NLM_string-name">Zhan, P.</span>; <span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the medicinal chemistry of single boron atom-containing compounds</span>.  <i>Acta Pharm. Sin. B</i> [Online early access]. <span class="NLM_year" style="font-weight: bold;">2021</span><span class="refDoi"> DOI: 10.1016/j.apsb.2021.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.apsb.2021.01.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=S.+Song&author=P.+Gao&author=L.+Sun&author=D.+Kang&author=J.+Kongsted&author=V.+Poongavanam&author=P.+Zhan&author=X.+Liu&title=Recent+developments+in+the+medicinal+chemistry+of+single+boron+atom-containing+compounds&doi=10.1016%2Fj.apsb.2021.01.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2021.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2021.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DS.%26atitle%3DRecent%2520developments%2520in%2520the%2520medicinal%2520chemistry%2520of%2520single%2520boron%2520atom-containing%2520compounds%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2021%26doi%3D10.1016%2Fj.apsb.2021.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, G. F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos Santos, J. L.</span></span> <span> </span><span class="NLM_article-title">Boron in drug design: Recent advances in the development of new therapeutic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.ejmech.2019.06.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31288128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=791-804&author=G.+F.+S.+Fernandesauthor=W.+A.+Dennyauthor=J.+L.+Dos+Santos&title=Boron+in+drug+design%3A+Recent+advances+in+the+development+of+new+therapeutic+agents&doi=10.1016%2Fj.ejmech.2019.06.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Boron in drug design: Recent advances in the development of new therapeutic agents</span></div><div class="casAuthors">Fernandes, Guilherme Felipe Santos; Denny, William Alexander; Dos Santos, Jean Leandro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Advances in the field of boron chem. have expanded the application of this element in Medicinal Chem.  Boron-contg. compds. represent a new class for medicinal chemists to use in their drug designs.  Bortezomib, a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-contg. compds. After its approval, two other boron-contg. compds. have been approved, tavaborole for the treatment of onychomycosis and crisaborole for the treatment of mild to moderate atopic dermatitis.  A no. of boron-contg. compds. have been described and evaluated for a plethora of therapeutic applications.  The present review is intended to highlight the recent advances related to boron-contg. compds. and their therapeutic applications.  Here, we focused only in those most biol. active compds. with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNneApZtw8C7Vg90H21EOLACvtfcHk0lj8pS4C5-i2aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtleju7fE&md5=52c7677a4b6213be8a03b48c3981bba4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.092%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DG.%2BF.%2BS.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDos%2BSantos%26aufirst%3DJ.%2BL.%26atitle%3DBoron%2520in%2520drug%2520design%253A%2520Recent%2520advances%2520in%2520the%2520development%2520of%2520new%2520therapeutic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.ejmech.2019.06.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, D. S.</span></span> <span> </span><span class="NLM_article-title">Quest for novel chemical entities through incorporation of silicon in drug scaffolds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3779</span>– <span class="NLM_lpage">3798</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3779-3798&author=R.+Rameshauthor=D.+S.+Reddy&title=Quest+for+novel+chemical+entities+through+incorporation+of+silicon+in+drug+scaffolds&doi=10.1021%2Facs.jmedchem.7b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds</span></div><div class="casAuthors">Ramesh, Remya; Reddy, D. Srinivasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3779-3798</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to optimize a lead mol. for further development, bioisosteric replacements are generally adopted as one of the strategies.  Silicon appears to be the right choice as a carbon isostere because of the similarity in chem. properties.  Silicon can be strategically introduced in a mol. to modulate its druglike properties, providing medicinal chemists with an unconventional strategy for replacing a carbon atom.  Silicon can also be introduced to replace other heteroatoms and can act as a surrogate of functional groups such as olefin and amide as well.  The present Perspective focuses on the opportunities that silicon incorporation offers in drug discovery, with an emphasis on case studies where introduction of silicon has created a benefit over its analog.  We have tried to highlight all the recent developments in the field and briefly discuss the challenges assocd. with them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjk4JZC1BTKLVg90H21EOLACvtfcHk0lj8pS4C5-i2aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1KnsbvM&md5=fa3da0fddb955d156d410eb68030e78a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00718%26sid%3Dliteratum%253Aachs%26aulast%3DRamesh%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DD.%2BS.%26atitle%3DQuest%2520for%2520novel%2520chemical%2520entities%2520through%2520incorporation%2520of%2520silicon%2520in%2520drug%2520scaffolds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3779%26epage%3D3798%26doi%3D10.1021%2Facs.jmedchem.7b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleemiss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvinage, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malaspina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleemiss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puylaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staubitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzschentke, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dringen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, J.</span></span> <span> </span><span class="NLM_article-title">Sila-ibuprofen</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12614</span>– <span class="NLM_lpage">12622</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00813</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00813" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCrtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12614-12622&author=F.+Kleemissauthor=A.+Justiesauthor=D.+Duvinageauthor=P.+Watermannauthor=E.+Ehrkeauthor=K.+Sugimotoauthor=M.+Fugelauthor=L.+A.+Malaspinaauthor=A.+Dittmerauthor=T.+Kleemissauthor=P.+Puylaertauthor=N.+R.+Kingauthor=A.+Staubitzauthor=T.+M.+Tzschentkeauthor=R.+Dringenauthor=S.+Grabowskyauthor=J.+Beckmann&title=Sila-ibuprofen&doi=10.1021%2Facs.jmedchem.0c00813"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Sila-Ibuprofen</span></div><div class="casAuthors">Kleemiss, Florian; Justies, Aileen; Duvinage, Daniel; Watermann, Patrick; Ehrke, Eric; Sugimoto, Kunihisa; Fugel, Malte; Malaspina, Lorraine A.; Dittmer, Anneke; Kleemiss, Torsten; Puylaert, Pim; King, Nelly R.; Staubitz, Anne; Tzschentke, Thomas M.; Dringen, Ralf; Grabowsky, Simon; Beckmann, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12614-12622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, characterization, biol. activity and toxicol. of sila-ibuprofen, a Si deriv. of the most common nonsteroidal antiinflammatory drug, is reported.  Key improvements compared to ibuprofen are a four times higher soly. in physiol. media and a lower melting enthalpy, which were attributed to the C-Si switch.  The improved soly. is of interest for post-surgical i.v. administration.  A potential for pain relief is rationalized via inhibition expts. of cyclooxygenases I and II (COX-I and COX-II) as well as via a set of newly developed methods that combine mol. dynamics, quantum chem. and quantum crystallog.  The binding affinity of sila-ibuprofen to COX-I and COX-II is quantified in terms of London dispersion and electrostatic interactions in the active receptor site.  This study shows not only the potential of sila-ibuprofen for medicinal application, but also improves the authors' understanding of the mechanism of action of the inhibition process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz0jUeMYjPDbVg90H21EOLACvtfcHk0ljLBCi5SBmUlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCrtbvI&md5=2d57e497c4fbda852ddbd52583328cdd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00813%26sid%3Dliteratum%253Aachs%26aulast%3DKleemiss%26aufirst%3DF.%26aulast%3DJusties%26aufirst%3DA.%26aulast%3DDuvinage%26aufirst%3DD.%26aulast%3DWatermann%26aufirst%3DP.%26aulast%3DEhrke%26aufirst%3DE.%26aulast%3DSugimoto%26aufirst%3DK.%26aulast%3DFugel%26aufirst%3DM.%26aulast%3DMalaspina%26aufirst%3DL.%2BA.%26aulast%3DDittmer%26aufirst%3DA.%26aulast%3DKleemiss%26aufirst%3DT.%26aulast%3DPuylaert%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DN.%2BR.%26aulast%3DStaubitz%26aufirst%3DA.%26aulast%3DTzschentke%26aufirst%3DT.%2BM.%26aulast%3DDringen%26aufirst%3DR.%26aulast%3DGrabowsky%26aufirst%3DS.%26aulast%3DBeckmann%26aufirst%3DJ.%26atitle%3DSila-ibuprofen%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12614%26epage%3D12622%26doi%3D10.1021%2Facs.jmedchem.0c00813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Applications of deuterium in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5276</span>– <span class="NLM_lpage">5297</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5276-5297&author=T.+Piraliauthor=M.+Serafiniauthor=S.+Cargninauthor=A.+A.+Genazzani&title=Applications+of+deuterium+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.8b01808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of deuterium in medicinal chemistry</span></div><div class="casAuthors">Pirali, Tracey; Serafini, Marta; Cargnin, Sarah; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5276-5297</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of deuteration in medicinal chem. has exploded in the past years, and the FDA has recently approved the first deuterium-labeled drug.  Precision deuteration goes beyond the pure and simple amelioration of the pharmacokinetic parameters of a drug and might provide an opportunity when facing problems in terms of metab.-mediated toxicity, drug interactions, and low bioactivation.  The use of deuterium is even broader, offering the opportunity to lower the degree of epimerization, reduce the dose of coadministered boosters, and discover compds. where deuterium is the basis for the mechanism of action.  Nevertheless, designing, synthesizing, and developing a successful deuterated drug is far from straightforward, and the translation from concept to practice is often unpredictable.  This Perspective provides an overview of the recent developments of deuteration, with a focus on deuterated clin. candidates, and highlights both opportunities and challenges of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ICy0AH9zGLVg90H21EOLACvtfcHk0ljLBCi5SBmUlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKjtw%253D%253D&md5=1ce58dbff268894dc319bfc00a1ae01f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01808%26sid%3Dliteratum%253Aachs%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DApplications%2520of%2520deuterium%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5276%26epage%3D5297%26doi%3D10.1021%2Facs.jmedchem.8b01808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cargnin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">A primer of deuterium in drug design</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2039</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.4155%2Ffmc-2019-0183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=31538524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKis7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2039-2042&author=S.+Cargninauthor=M.+Serafiniauthor=T.+Pirali&title=A+primer+of+deuterium+in+drug+design&doi=10.4155%2Ffmc-2019-0183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A primer of deuterium in drug design</span></div><div class="casAuthors">Cargnin, Sarah; Serafini, Marta; Pirali, Tracey</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2039-2042</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article discusses about role of deuterated compounds, heavy and nonradioactive isotope of hydrogen in clinical development and effects of deuteration incorporation in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnDF9mfxcU77Vg90H21EOLACvtfcHk0lh3e1ufHS8XAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKis7fN&md5=2c7c1c4a9820456566886af749d28068</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0183%26sid%3Dliteratum%253Aachs%26aulast%3DCargnin%26aufirst%3DS.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DA%2520primer%2520of%2520deuterium%2520in%2520drug%2520design%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2039%26epage%3D2042%26doi%3D10.4155%2Ffmc-2019-0183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doller, D.</span></span> <span> </span><span class="NLM_article-title">A decade of deuteration in medicinal chemistry</span>. <i>Annu. Rep. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1016/bs.armc.2017.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fbs.armc.2017.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFOlsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=519-542&author=J.+F.+Liuauthor=S.+L.+Harbesonauthor=C.+L.+Brummelauthor=R.+Tungauthor=R.+Silvermanauthor=D.+Doller&title=A+decade+of+deuteration+in+medicinal+chemistry&doi=10.1016%2Fbs.armc.2017.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A decade of deuteration in medicinal chemistry</span></div><div class="casAuthors">Liu, Julie F.; Harbeson, Scott L.; Brummel, Christopher L.; Tung, Roger; Silverman, Robert; Doller, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Reports in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519-542</span>CODEN:
                <span class="NLM_cas:coden">ARMCBI</span>;
        ISSN:<span class="NLM_cas:issn">0065-7743</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The use of deuterium to drive DIEs and favorably alter pharmacokinetics and metab. in drug discovery has accelerated in the last decade.  The first major wave of patent applications came from small biotechnol. organizations and were aimed at improving pharmacokinetic properties of marketed drugs or enhancing properties offailed drug candidates.  A substantial no. of patent applications were published beginning in 2006, and the deuterium chem. patent estate continues to expand.  Deuterated drug candidates have progressed from early patent filings to successful proof-of-concept human studies, including the first FDA-approved deuterated drug.  The use of DIEs in drug design has expanded, and now deuteration of drug candidates and tool compds., including imaging ligands, has become a welcome instrument in the arsenal of medicinal chemists.  It is expected that experimentation with strategic introduction of deuterium into the structures of org. compds. will continue to increase and may enable the future development ofa variety ofnovel drugs and chem. tools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRWRQHDkKt5LVg90H21EOLACvtfcHk0lh3e1ufHS8XAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOlsrvF&md5=18499ed5ccfb021913c4dea9e51946b7</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fbs.armc.2017.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.armc.2017.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DTung%26aufirst%3DR.%26aulast%3DSilverman%26aufirst%3DR.%26aulast%3DDoller%26aufirst%3DD.%26atitle%3DA%2520decade%2520of%2520deuteration%2520in%2520medicinal%2520chemistry%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2017%26volume%3D50%26spage%3D519%26epage%3D542%26doi%3D10.1016%2Fbs.armc.2017.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using deuterium in drug discovery: leaving the label in the drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+deuterium+in+drug+discovery%3A+leaving+the+label+in+the+drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0lh3e1ufHS8XAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520deuterium%2520in%2520drug%2520discovery%253A%2520leaving%2520the%2520label%2520in%2520the%2520drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="note"><p class="first last">A hydrogen-bearing molecule can potentially exist in several deuterated forms. For example, the d<sub>9</sub>-analogue of ivacaftor has been named deutivacaftor, but a d<sub>18</sub>-analogue was also reported; therefore, it is possible that, in the future, a prefix alongside the suffix <i>deu</i>- will be added to identify the presence of more than one deuterated analogue of a hydrogenated molecule.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of dosimertinib, a highly potent, selective, and orally efficacious deuterated EGFR targeting clinical candidate for the treatment of non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">925</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c02005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c02005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtlWks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=925-937&author=Y.+Mengauthor=B.+Yuauthor=H.+Huangauthor=Y.+Pengauthor=E.+Liauthor=Y.+Yaoauthor=C.+Songauthor=W.+Yuauthor=K.+Zhuauthor=K.+Wangauthor=D.+Yiauthor=J.+Duauthor=J.+Chang&title=Discovery+of+dosimertinib%2C+a+highly+potent%2C+selective%2C+and+orally+efficacious+deuterated+EGFR+targeting+clinical+candidate+for+the+treatment+of+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.0c02005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Meng, Yonggang; Yu, Bin; Huang, He; Peng, Youmei; Li, Ertong; Yao, Yongfang; Song, Chuanjun; Yu, Wenquan; Zhu, Kaikai; Wang, Kai; Yi, Dongxu; Du, Jinfa; Chang, Junbiao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">925-937</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clin. benefits and is now a std.-of-care therapy for advanced EGFR mutation-pos. non-small-cell lung cancer (NSCLC).  However, AZ5104, a primary toxic metabolite of osimertinib, has caused unwanted toxicities.  To address this unmet medical need, we initiated an iterative program focusing on structural optimizations of osimertinib and preclin. characterization, leading to the discovery of a highly potent, selective, and orally efficacious deuterated EGFR-targeting clin. candidate, dosimertinib.  Preclin. studies revealed that dosimertinib demonstrated robust in vivo antitumor efficacy and favorable PK profiles, but with lower toxicity than osimertinib.  These preclin. data support further clin. development of dosimertinib for the treatment of NSCLC.  Dosimertinib has received official approval in China to initiate the phase I clin. trial (registration nos.: CXHL2000060 and CXHL2000061).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyJIlEhtJqX7Vg90H21EOLACvtfcHk0ligtHoev0pWrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtlWks74%253D&md5=e5d35658715f7ae6aa3817a2bf7dd4db</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DYi%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520dosimertinib%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520deuterated%2520EGFR%2520targeting%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D925%26epage%3D937%26doi%3D10.1021%2Facs.jmedchem.0c02005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span> <span> </span><span class="NLM_article-title">Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">4506</span>– <span class="NLM_lpage">4506</span>, <span class="refDoi"> DOI: 10.1200/JCO.2020.38.15_suppl.4506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1200%2FJCO.2020.38.15_suppl.4506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=4506-4506&author=F.+Biauthor=S.+Qinauthor=S.+Guauthor=Y.+Baiauthor=Z.+Chenauthor=Z.+Wangauthor=J.+Yingauthor=Y.+Luauthor=Z.+Mengauthor=H.+Panauthor=P.+Yangauthor=H.+Zhangauthor=X.+Chenauthor=A.+Xuauthor=X.+Liuauthor=Q.+Mengauthor=L.+Wuauthor=F.+Chen&title=Donafenib+versus+sorafenib+as+first-line+therapy+in+advanced+hepatocellular+carcinoma%3A+An+open-label%2C+randomized%2C+multicenter+phase+II%2FIII+trial&doi=10.1200%2FJCO.2020.38.15_suppl.4506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.4506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.4506%26sid%3Dliteratum%253Aachs%26aulast%3DBi%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYing%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DF.%26atitle%3DDonafenib%2520versus%2520sorafenib%2520as%2520first-line%2520therapy%2520in%2520advanced%2520hepatocellular%2520carcinoma%253A%2520An%2520open-label%252C%2520randomized%252C%2520multicenter%2520phase%2520II%252FIII%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D4506%26epage%3D4506%26doi%3D10.1200%2FJCO.2020.38.15_suppl.4506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">Sulfur containing scaffolds in drugs: Synthesis and application in medicinal chemistry</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1200</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150915111741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.2174%2F1568026615666150915111741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=26369815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlClu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=1200-1216&author=M.+Fengauthor=B.+Tangauthor=S.+H.+Liangauthor=X.+Jiang&title=Sulfur+containing+scaffolds+in+drugs%3A+Synthesis+and+application+in+medicinal+chemistry&doi=10.2174%2F1568026615666150915111741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry</span></div><div class="casAuthors">Feng, Minghao; Tang, Bingqing; Liang, Steven H.; Jiang, Xuefeng</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1200-1216</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The impact of the development of sulfur therapeutics is instrumental to the evolution of the pharmaceutical industry.  Sulfur-derived functional groups can be found in a broad range of pharmaceuticals and natural products.  For centuries, sulfur continues to maintain its status as the dominating heteroatom integrated into a set of 362 sulfur-contg. FDA approved drugs (besides oxygen or nitrogen) through the present.  Sulfonamides, thioethers, sulfones and Penicillin are the most common scaffolds in sulfur contg. drugs, which are well studied both on synthesis and application during the past decades.  In this review, these four moieties in pharmaceuticals and recent advances in the synthesis of the corresponding core scaffolds are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHURkv9s2oTLVg90H21EOLACvtfcHk0ligtHoev0pWrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlClu7w%253D&md5=d1ee22514ac37b3869919eef6d945c03</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150915111741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150915111741%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DLiang%26aufirst%3DS.%2BH.%26aulast%3DJiang%26aufirst%3DX.%26atitle%3DSulfur%2520containing%2520scaffolds%2520in%2520drugs%253A%2520Synthesis%2520and%2520application%2520in%2520medicinal%2520chemistry%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D1200%26epage%3D1216%26doi%3D10.2174%2F1568026615666150915111741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L.</span></span> <span> </span><span class="NLM_article-title">Advanced squamous cell carcinoma of the lung: current treatment approaches and the role of afatinib</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">9305</span>– <span class="NLM_lpage">9321</span>, <span class="refDoi"> DOI: 10.2147/OTT.S250446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.2147%2FOTT.S250446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=33061419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKru7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=9305-9321&author=E.+S.+Santosauthor=L.+Hart&title=Advanced+squamous+cell+carcinoma+of+the+lung%3A+current+treatment+approaches+and+the+role+of+afatinib&doi=10.2147%2FOTT.S250446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Advanced squamous cell carcinoma of thelung: current treatment approaches and therole of afatinib</span></div><div class="casAuthors">Santos, Edgardo S.; Hart, Lowell</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9305-9321</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Options for the treatment of squamous cell lung carcinoma expanded in recent years with the introduction of the immune checkpoint inhibitors into routine clin. practice in both the first- and second-line settings but are still limited.  As a result, pembrolizumab, given either alone or in combination with platinum-based chemotherapy, is now a std. first-line treatment for squamous cell lung cancer.  However, few options exist once patients have progressed on immune checkpoint inhibitors and chemotherapy.  In this setting, the irreversible ErbB family blocker, afatinib, has a potential role as second or subsequent therapy for some patients.  The Phase III LUX-Lung 8 study demonstrated that afatinib significantly prolonged progression-free and overall survival compared with erlotinib in patients with squamous cell lung carcinoma.  Notably, retrospective, ad-hoc biomarker analyses of a subset of patients from LUX-Lung 8 suggested that patients with ErbB family mutations derived particular benefit from afatinib, esp. those with ErbB2 (HER2) mutations.  Afatinib has a manageable and predictable safety profile, and adverse events can be managed with the use of a tolerability-guided dose modification protocol.  Until more data are available, afatinib could be considered as a potential second-line treatment option for patients who have progressed on combined pembrolizumab and platinum-based chemotherapy and are ineligible for more established second-line options, or as a third-line option in patients who have received first-line immunotherapy, and second-line chemotherapy or chemotherapy and antiangiogenesis therapy.  However, further data are required to support the use of afatinib following immunotherapy.  Given that treatment options are limited in both of these settings, investigating an agent with an entirely new mechanism of action is warranted.  If available, mol. anal. to identify ErbB family mutations or the use of proteomic profiling could help to further isolate patients who are likely to derive the most benefit from afatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhUMl0owMc7Vg90H21EOLACvtfcHk0lg6iugp87HQ6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKru7fN&md5=44e0e3bc9672393429d100a58ebe92c3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2147%2FOTT.S250446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S250446%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DE.%2BS.%26aulast%3DHart%26aufirst%3DL.%26atitle%3DAdvanced%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520lung%253A%2520current%2520treatment%2520approaches%2520and%2520the%2520role%2520of%2520afatinib%26jtitle%3DOncoTargets%2520Ther.%26date%3D2020%26volume%3D13%26spage%3D9305%26epage%3D9321%26doi%3D10.2147%2FOTT.S250446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">PCI-32765, the first BTK (Bruton’s tyrosine kinase) inhibitor in clinical trials</span>. <i>Curr. Hematol. Malig. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s11899-012-0147-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2Fs11899-012-0147-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=23296407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1-6&author=J.+R.+Brown&title=PCI-32765%2C+the+first+BTK+%28Bruton%E2%80%99s+tyrosine+kinase%29+inhibitor+in+clinical+trials&doi=10.1007%2Fs11899-012-0147-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials</span></div><div class="casAuthors">Brown Jennifer R</div><div class="citationInfo"><span class="NLM_cas:title">Current hematologic malignancy reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ibrutinib is a potent covalent kinase inhibitor that targets BTK.  BTK, or Bruton's tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia.  Ibrutinib has modest cytotoxicity against CLL cells in vitro but also blocks trophic stimuli from the microenvironment.  As with other inhibitors of the BCR pathway, ibrutinib causes rapid nodal reduction and response associated with rapid increase in lymphocytosis, which then returns to baseline over time.  The ORR of ibrutinib in relapsed refractory CLL is 67 % with PFS 88 % at 15 months.  In a cohort of untreated patients 65 years and over, the estimated 15 month PFS is 96 %.  Registration trials have been initiated, and the difficult task that remains is to determine where in the course of CLL therapy this drug will have the greatest impact and benefit for patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmwv_ITNl9Dxgd2Wuil24tfW6udTcc2eamMRG8Mfnya7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3nsVKjsw%253D%253D&md5=c64d7d8fa5d40a79ad029c9fb34248c3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs11899-012-0147-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11899-012-0147-9%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DPCI-32765%252C%2520the%2520first%2520BTK%2520%2528Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2529%2520inhibitor%2520in%2520clinical%2520trials%26jtitle%3DCurr.%2520Hematol.%2520Malig.%2520Rep.%26date%3D2013%26volume%3D8%26spage%3D1%26epage%3D6%26doi%3D10.1007%2Fs11899-012-0147-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1093%2Fannonc%2Fmdw129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=26961148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1165-1170&author=A.+Yver&title=Osimertinib+%28AZD9291%29%E2%80%94a+science-driven%2C+collaborative+approach+to+rapid+drug+design+and+development&doi=10.1093%2Fannonc%2Fmdw129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development</span></div><div class="casAuthors">Yver A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1165-1170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTcfXYyifUoEewzGPswiWOfW6udTcc2eamMRG8Mfnya7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D&md5=903bbb3edf2d109af352ef0354e4bca6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw129%26sid%3Dliteratum%253Aachs%26aulast%3DYver%26aufirst%3DA.%26atitle%3DOsimertinib%2520%2528AZD9291%2529%25E2%2580%2594a%2520science-driven%252C%2520collaborative%2520approach%2520to%2520rapid%2520drug%2520design%2520and%2520development%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D1165%26epage%3D1170%26doi%3D10.1093%2Fannonc%2Fmdw129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span>To calculate
p<i>K</i><sub>a</sub> values, the p<i>K</i><sub>a</sub> plugin of Marvin’s cxcalc program was used. Marvin
20.19.0, ChemAxon: <a href="https://www.chemaxon.com" class="extLink">https://www.chemaxon.com</a> (accessed 2020-08-07).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=To+calculate%0ApKa+values%2C+the+pKa+plugin+of+Marvin%E2%80%99s+cxcalc+program+was+used.+Marvin%0A20.19.0%2C+ChemAxon%3A+https%3A%2F%2Fwww.chemaxon.com+%28accessed+2020-08-07%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, W. P.</span></span> <span> </span><span class="NLM_article-title">Acidic and basic drugs in medicinal chemistry: A perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9701</span>– <span class="NLM_lpage">9717</span>, <span class="refDoi"> DOI: 10.1021/jm501000a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501000a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOnt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9701-9717&author=P.+S.+Charifsonauthor=W.+P.+Walters&title=Acidic+and+basic+drugs+in+medicinal+chemistry%3A+A+perspective&doi=10.1021%2Fjm501000a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Acidic and Basic Drugs in Medicinal Chemistry: A Perspective</span></div><div class="casAuthors">Charifson, Paul S.; Walters, W. Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9701-9717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The acid/base properties of a mol. are among the most fundamental for drug action.  However, they are often overlooked in a prospective design manner unless it has been established that a certain ionization state (e.g., quaternary base or presence of a carboxylic acid) appears to be required for activity.  In medicinal chem. optimization programs it is relatively common to attenuate basicity to circumvent undesired effects such as lack of biol. selectivity or safety risks such as hERG or phospholipidosis.  However, teams may not prospectively explore a range of carefully chosen compd. pKa values as part of an overall chem. strategy or design hypothesis.  This review summarizes the potential advantages and disadvantages of both acidic and basic drugs and provides some new analyses based on recently available public data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDorb0LfJ8PrVg90H21EOLACvtfcHk0liLGR7dS9SOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOnt7jN&md5=51a3cb91be42ddd1a784afe737c64c60</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm501000a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501000a%26sid%3Dliteratum%253Aachs%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DWalters%26aufirst%3DW.%2BP.%26atitle%3DAcidic%2520and%2520basic%2520drugs%2520in%2520medicinal%2520chemistry%253A%2520A%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9701%26epage%3D9717%26doi%3D10.1021%2Fjm501000a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alves, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braga, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedykh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokshyna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farag, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuz’min, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span> <span> </span><span class="NLM_article-title">Alarms about structural alerts</span>. <i>Green Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4348</span>– <span class="NLM_lpage">4360</span>, <span class="refDoi"> DOI: 10.1039/C6GC01492E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2FC6GC01492E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28503093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOntrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=4348-4360&author=V.+Alvesauthor=E.+Muratovauthor=S.+Capuzziauthor=R.+Politiauthor=Y.+Lowauthor=R.+Bragaauthor=A.+V.+Zakharovauthor=A.+Sedykhauthor=E.+Mokshynaauthor=S.+Faragauthor=C.+Andradeauthor=V.+Kuz%E2%80%99minauthor=D.+Fourchesauthor=A.+Tropsha&title=Alarms+about+structural+alerts&doi=10.1039%2FC6GC01492E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Alarms about structural alerts</span></div><div class="casAuthors">Alves, Vinicius M.; Muratov, Eugene N.; Capuzzi, Stephen J.; Politi, Regina; Low, Yen; Braga, Rodolpho C.; Zakharov, Alexey V.; Sedykh, Alexander; Mokshyna, Elena; Farag, Sherif; Andrade, Carolina H.; Kuz'min, Victor E.; Fourches, Denis; Tropsha, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Green Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4348-4360</span>CODEN:
                <span class="NLM_cas:coden">GRCHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9262</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Structural alerts are widely accepted in chem. toxicol. and regulatory decision support as a simple, transparent means to flag potential chem. hazards or group compds. into categories for read-across.  However, there is a growing concern that alerts disproportionally flag chems. as toxic, which questions their reliability as toxicity markers.  Conversely, rigorously developed, properly validated statistical QSAR models can accurately, reliably predict the toxicity of a chem.; however, their use in regulatory toxicol. has been hampered by a lack of transparency and interpretability.  This work demonstrated that contrary to the common perception of QSAR models as black boxes, they can identify statistically significant chem. substructures (QSAR-based alerts) which influence toxicity.  The authors show using case studies, that the mere presence of structural alerts in a chem., irresp. of the derivation method (expert- or QSAR-based), should be perceived only as hypotheses of possible toxicol. effect.  A new approach is proposed which synergistically integrates structural alerts and rigorously validated QSAR models for a more transparent, accurate safety assessment of new chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXku_XrUJZDbVg90H21EOLACvtfcHk0liLGR7dS9SOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOntrrE&md5=73fac6acfc2a5a5ad5b79bdd554cbca3</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1039%2FC6GC01492E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6GC01492E%26sid%3Dliteratum%253Aachs%26aulast%3DAlves%26aufirst%3DV.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DCapuzzi%26aufirst%3DS.%26aulast%3DPoliti%26aufirst%3DR.%26aulast%3DLow%26aufirst%3DY.%26aulast%3DBraga%26aufirst%3DR.%26aulast%3DZakharov%26aufirst%3DA.%2BV.%26aulast%3DSedykh%26aufirst%3DA.%26aulast%3DMokshyna%26aufirst%3DE.%26aulast%3DFarag%26aufirst%3DS.%26aulast%3DAndrade%26aufirst%3DC.%26aulast%3DKuz%25E2%2580%2599min%26aufirst%3DV.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DTropsha%26aufirst%3DA.%26atitle%3DAlarms%2520about%2520structural%2520alerts%26jtitle%3DGreen%2520Chem.%26date%3D2016%26volume%3D18%26spage%3D4348%26epage%3D4360%26doi%3D10.1039%2FC6GC01492E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gampe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, V. A.</span></span> <span> </span><span class="NLM_article-title">Curse or cure? A perspective on the developability of aldehydes as active pharmaceutical ingredients</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">14357</span>– <span class="NLM_lpage">14381</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVWhs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=14357-14381&author=C.+Gampeauthor=V.+A.+Verma&title=Curse+or+cure%3F+A+perspective+on+the+developability+of+aldehydes+as+active+pharmaceutical+ingredients&doi=10.1021%2Facs.jmedchem.0c01177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients</span></div><div class="casAuthors">Gampe, Christian; Verma, Vishal A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14357-14381</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is a dichotomy between the increasing utility of aldehydes as tool mols. that bind to "undruggable" protein sites and the designation of the aldehyde functional group as a structural alert by the medicinal chem. community.  Herein we compile information about pharmacol. active aldehydes that are being used in humans.  We summarize the learnings from these data, discuss advantages and challenges assocd. with aldehydes, and derive strategies for the successful development of aldehydes within drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppz1oqp1WGV7Vg90H21EOLACvtfcHk0liLGR7dS9SOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVWhs7vE&md5=4696123fdaba8f20895bb11f2b78ff84</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01177%26sid%3Dliteratum%253Aachs%26aulast%3DGampe%26aufirst%3DC.%26aulast%3DVerma%26aufirst%3DV.%2BA.%26atitle%3DCurse%2520or%2520cure%253F%2520A%2520perspective%2520on%2520the%2520developability%2520of%2520aldehydes%2520as%2520active%2520pharmaceutical%2520ingredients%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D14357%26epage%3D14381%26doi%3D10.1021%2Facs.jmedchem.0c01177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mäder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kattner, L.</span></span> <span> </span><span class="NLM_article-title">Sulfoximines as rising stars in modern drug discovery? Current status and perspective on an emerging functional group in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">14243</span>– <span class="NLM_lpage">14275</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00960</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00960" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB38bivV2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=14243-14275&author=P.+M%C3%A4derauthor=L.+Kattner&title=Sulfoximines+as+rising+stars+in+modern+drug+discovery%3F+Current+status+and+perspective+on+an+emerging+functional+group+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.0c00960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry</span></div><div class="casAuthors">Mader Patrick; Kattner Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14243-14275</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sulfoximines have been largely disregarded in medicinal chemistry for a long time.  However, recently, they have risen to the apparent level of stardom on the drug discovery scene.  Considering the outstanding properties of sulfoximines, this versatile functional group has advanced to implementation in several drug discovery programs.  Currently, this fashionable functional group can be found in various hit-to-lead and lead optimization studies in early stages and in several compounds currently in clinical trials.  Herein, we review recent developments to demonstrate the scope and limitations of this interesting and versatile functional group in medicinal chemistry and drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4vGCH7PqQvJ6KlWarZTAzfW6udTcc2eap4va5fKPU1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bivV2isQ%253D%253D&md5=8013be4218e0f70c3b1e02601681f3fd</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00960%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4der%26aufirst%3DP.%26aulast%3DKattner%26aufirst%3DL.%26atitle%3DSulfoximines%2520as%2520rising%2520stars%2520in%2520modern%2520drug%2520discovery%253F%2520Current%2520status%2520and%2520perspective%2520on%2520an%2520emerging%2520functional%2520group%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D14243%26epage%3D14275%26doi%3D10.1021%2Facs.jmedchem.0c00960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A. D. G.</span></span> <span> </span><span class="NLM_article-title">Rings in drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5845</span>– <span class="NLM_lpage">5859</span>, <span class="refDoi"> DOI: 10.1021/jm4017625</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017625" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5845-5859&author=R.+D.+Taylorauthor=M.+MacCossauthor=A.+D.+G.+Lawson&title=Rings+in+drugs&doi=10.1021%2Fjm4017625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Rings in Drugs</span></div><div class="casAuthors">Taylor, Richard D.; MacCoss, Malcolm; Lawson, Alastair D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5845-5859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We have analyzed the rings, ring systems, and frameworks in drugs listed in the FDA Orange Book to understand the frequency, time-lines, mol. property space, and the application of these rings in different therapeutic areas and target classes.  This anal. shows that there are only 351 ring systems and 1197 frameworks in drugs that came onto the market before 2013.  Furthermore, on av. six new ring systems enter drug space each year and approx. 28% of new drugs contain a new ring system.  Moreover, it is very unusual for a drug to contain more than one new ring system and the majority of the most frequently used ring systems (83%) were first used in drugs developed prior to 1983.  These observations give insight into the chem. novelty of drugs and potentially efficient ways to assess compd. libraries and develop compds. from hit identification to lead optimization and beyond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_e_L4z4XCrVg90H21EOLACvtfcHk0lhf9nqdTvKCDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbc%253D&md5=c84ce84b8698eb6fad38fa82b0ab4912</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm4017625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017625%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%2BD.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DLawson%26aufirst%3DA.%2BD.%2BG.%26atitle%3DRings%2520in%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5845%26epage%3D5859%26doi%3D10.1021%2Fjm4017625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="note"><p class="first last">Steroid core substructures that were grouped are the following: hexadecahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthrene; 2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthrene; 7,8,9,11,12,13,14,15,16,17-decahydro-6<i>H</i>-cyclopenta[<i>a</i>]phenanthrene; 6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthren-3(2<i>H</i>)-one; 6,7,8,11,12,13,14,15,16,17-decahydro-1<i>H</i>-cyclopenta[<i>a</i>]phenanthren-3(2<i>H</i>)-one; 6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3<i>H</i>-cyclopenta[<i>a</i>]phenanthren-3-one.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span>; <span class="NLM_string-name">Pirali, T.</span>; <span class="NLM_string-name">Tron, G. C.</span></span> <span> </span><span class="NLM_article-title">Click 1,2,3-triazoles in drug discovery and development: from the flask to the clinic?</span> <i>Adv. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, [Online early access].<span class="refDoi"> DOI: 10.1016/bs.aihch.2020.10.001</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fbs.aihch.2020.10.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=M.+Serafini&author=T.+Pirali&author=G.+C.+Tron&title=Click+1%2C2%2C3-triazoles+in+drug+discovery+and+development%3A+from+the+flask+to+the+clinic%3F&doi=10.1016%2Fbs.aihch.2020.10.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fbs.aihch.2020.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.aihch.2020.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26atitle%3DClick%25201%252C2%252C3-triazoles%2520in%2520drug%2520discovery%2520and%2520development%253A%2520from%2520the%2520flask%2520to%2520the%2520clinic%253F%26jtitle%3DAdv.%2520Heterocycl.%2520Chem.%26date%3D2020%26doi%3D10.1016%2Fbs.aihch.2020.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, J.-M.</span>; <span class="NLM_string-name">Sippl, W.</span></span> <span> </span><span class="NLM_article-title">Homo and Heterodimer Ligands the Twin Drug Approach</span>. In  <i>The Practice of Medicinal Chemistry</i><i>,</i> <span class="NLM_edition">3</span>rd ed.; <span class="NLM_contrib-group"><span class="NLM_string-name">Wermuth, C. G.</span></span>, Ed.; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">414</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2FB978-0-12-374194-3.00018-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=380-414&author=J.-M.+Contreras&author=W.+Sipplauthor=C.+G.+Wermuth&title=The+Practice+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-374194-3.00018-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-374194-3.00018-4%26sid%3Dliteratum%253Aachs%26aulast%3DContreras%26aufirst%3DJ.-M.%26atitle%3DHomo%2520and%2520Heterodimer%2520Ligands%2520the%2520Twin%2520Drug%2520Approach%26btitle%3DThe%2520Practice%2520of%2520Medicinal%2520Chemistry%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26pub%3DElsevier%26date%3D2008%26spage%3D380%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreone, P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of daclatasvir in hepatitis C: an overview</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2016.00038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.14218%2FJCTH.2016.00038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28097103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC1c7mslSqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=336-344&author=N.+Gamalauthor=S.+Gittoauthor=P.+Andreone&title=Efficacy+and+safety+of+daclatasvir+in+hepatitis+C%3A+an+overview&doi=10.14218%2FJCTH.2016.00038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview</span></div><div class="casAuthors">Gamal Nesrine; Gitto Stefano; Andreone Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">336-344</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a growing public health concern, with 184 million people infected worldwide.  During the past decade, interferon has been the backbone of HCV treatment, even though it remains far from ideal.  The latest development of the new direct antivirals has drastically changed the treatment approach for chronic hepatitis C (CHC).  Inhibitors of the HCV NS5A region have garnered remarkable interest among treating physicians, due to their high potency and favourable safety profile.  In particular, treatment with daclatasvir (DCV) has yielded high rates of vriologic response in patients infected with genotype (Gt) 1 and Gt 3, when used in combination with other antivirals of a different class, such as sofosbuvir.  Although few data are available for DCV treatment of the other Gts, the results in patients with Gt 2 and Gt 4 infection appear promising, as do those for unique patient populations.  NS5A-resistant viral variants can pre-exist or emerge after treatment failure for the HCV NS5A inhibitors.  Nonetheless, DCV-resistant viral variants continue to be sensitive to interferon and other classes of antivirals such as NS3/4A and NS5B inhibitors.  Herein, we aimed to provide an overview of the current knowledge about DCV in the treatment of CHC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIlu-VdjyoXRWfpMXQLRstfW6udTcc2eYR_jCi70YdHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7mslSqsA%253D%253D&md5=9a82491790340af8fdd774ee06128421</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2016.00038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2016.00038%26sid%3Dliteratum%253Aachs%26aulast%3DGamal%26aufirst%3DN.%26aulast%3DGitto%26aufirst%3DS.%26aulast%3DAndreone%26aufirst%3DP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520daclatasvir%2520in%2520hepatitis%2520C%253A%2520an%2520overview%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2016%26volume%3D4%26spage%3D336%26epage%3D344%26doi%3D10.14218%2FJCTH.2016.00038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flisiak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flisiak-Jackiewicz, M.</span></span> <span> </span><span class="NLM_article-title">Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1080/17474124.2017.1309284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1080%2F17474124.2017.1309284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28317409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1Slsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=559-567&author=R.+Flisiakauthor=M.+Flisiak-Jackiewicz&title=Ombitasvir+and+paritaprevir+boosted+with+ritonavir+and+combined+with+dasabuvir+for+chronic+hepatitis+C&doi=10.1080%2F17474124.2017.1309284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C</span></div><div class="casAuthors">Flisiak, Robert; Flisiak-Jackiewicz, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">559-567</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Hepatitis C is a leading cause of cirrhosis and hepatocellular carcinoma responsible for almost 700,000 deaths worldwide annually.  Until 2014, management of HCV infections was based on interferon alfa contg. regimens, with efficacy of 40-70% and a high adverse event rate.  Interferon-free therapeutic options improved sustained viral response (SVR) rate to >90% and safety profile to placebo-like levels.:.  This article describes all-oral regimen consisting of three direct acting antivirals (DAA) - ombitasvir (OBV), paritaprevir (PTV) and dasabuvir (DSV), which in clin. practice is boosted with ritonavir (r) and sometimes with ribavirin (RBV).  This combination is registered for treatment of patients infected with HCV genotype 1 and 4.  We focused on the regimen characteristics, pharmacokinetics, risk of resistance as well as efficacy and safety in clin. trials and real world studies.:.  Combination of OBV/PTV/r±DSV±RBV provides SVR rate of about 95% and good safety profile even in patients with compensated liver cirrhosis and failure with previous therapy.  Currently it should be of particular value in areas with a predominance of genotype 1b infections.  Due to the complexity and risk of drug to drug interactions, it will probably be replaced in coming few years with pangenotypic combinations of next generation DAAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEip3CV8OzerVg90H21EOLACvtfcHk0lhf9nqdTvKCDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1Slsrw%253D&md5=805164f84b6755b5561b7a7a53f0aabd</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1080%2F17474124.2017.1309284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2017.1309284%26sid%3Dliteratum%253Aachs%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DFlisiak-Jackiewicz%26aufirst%3DM.%26atitle%3DOmbitasvir%2520and%2520paritaprevir%2520boosted%2520with%2520ritonavir%2520and%2520combined%2520with%2520dasabuvir%2520for%2520chronic%2520hepatitis%2520C%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D11%26spage%3D559%26epage%3D567%26doi%3D10.1080%2F17474124.2017.1309284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2020.00078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.14218%2FJCTH.2020.00078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=33604263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB3snmtVektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2021&pages=125-132&author=X.+Liuauthor=P.+Hu&title=Efficacy+and+safety+of+glecaprevir%2Fpibrentasvir+in+patients+with+chronic+HCV+infection&doi=10.14218%2FJCTH.2020.00078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection</span></div><div class="casAuthors">Liu Xiaoqing; Hu Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-132</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease, including decompensated cirrhosis and hepatocellular carcinoma.  Over 95% of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved for patients with HCV infection.  The glecaprevir/pibrentasvir (G/P) regimen has some features that distinguish it from others and is the only 8-week regimen approved for treatment-naive patients and patients experienced in regimens containing (peg)interferon, ribavirin, and/or sofosbuvir, without an HCV NS3/4A protease inhibitor or NS5A inhibitor (except those with genotype 3).  This review aims to summarize the efficacy and safety of G/P in HCV-infected patients from clinic trials and real-world studies, including those who have historically been considered difficult to cure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT11y4N919DkQwxfk_AGB-EfW6udTcc2ebecQjGfvV7u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3snmtVektA%253D%253D&md5=b8caa6359e28bdf2cc5529ee40b1d2d9</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2020.00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2020.00078%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520glecaprevir%252Fpibrentasvir%2520in%2520patients%2520with%2520chronic%2520HCV%2520infection%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2021%26volume%3D9%26spage%3D125%26epage%3D132%26doi%3D10.14218%2FJCTH.2020.00078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Kügelgen, I.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of P2Y receptors</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2019.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.brainresbull.2019.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=30922852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntVSnt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2019&pages=12-24&author=I.+von%0AK%C3%BCgelgen&title=Pharmacology+of+P2Y+receptors&doi=10.1016%2Fj.brainresbull.2019.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of P2Y receptors</span></div><div class="casAuthors">von Kuegelgen, Ivar</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-24</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular nucleotides.  There are eight mammalian P2Y receptor subtypes divided into two subgroups (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) and (P2Y12, P2Y13, and P2Y14).  The P2Y receptors are expressed in various cell types and play important roles in physiol. and pathophysiol. including inflammatory responses and neuropathic pain.  The antagonism of P2Y12 receptors is used in pharmacotherapy for the prevention and therapy of cardiovascular events.  The nucleoside analog ticagrelor and active metabolites of the thienopyridine compds. ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y12 receptors and reduce thereby platelet aggregation.  The P2Y2 receptor agonist diquafosol is used for the treatment of the dry eye syndrome.  The P2Y receptor subtypes differ in their amino acid sequences, their pharmacol. profiles and their signaling transduction pathways.  Recently, selective receptor ligands have been developed for all subtypes.  The published crystal structures of the human P2Y1 and P2Y12 receptors as well as receptor models will facilitate the development of novel drugs for pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWCjAgvzCJbVg90H21EOLACvtfcHk0lgwylF-JDgY2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntVSnt78%253D&md5=d4c1f902c903cb4c500419cf4ec26f18</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2019.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2019.03.010%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BK%25C3%25BCgelgen%26aufirst%3DI.%26atitle%3DPharmacology%2520of%2520P2Y%2520receptors%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2019%26volume%3D151%26spage%3D12%26epage%3D24%26doi%3D10.1016%2Fj.brainresbull.2019.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marc, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boitard, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balavoine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azizi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llorens-Cortes, C.</span></span> <span> </span><span class="NLM_article-title">Targeting brain aminopeptidase A: a new strategy for the treatment of hypertension and heart failure</span>. <i>Can. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/j.cjca.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.cjca.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=32389345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BB38vltVOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2020&pages=721-731&author=Y.+Marcauthor=S.+E.+Boitardauthor=F.+Balavoineauthor=M.+Aziziauthor=C.+Llorens-Cortes&title=Targeting+brain+aminopeptidase+A%3A+a+new+strategy+for+the+treatment+of+hypertension+and+heart+failure&doi=10.1016%2Fj.cjca.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure</span></div><div class="casAuthors">Marc Yannick; Boitard Solene Emmanuelle; Balavoine Fabrice; Azizi Michel; Llorens-Cortes Catherine</div><div class="citationInfo"><span class="NLM_cas:title">The Canadian journal of cardiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">721-731</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pathophysiology of heart failure (HF) and hypertension are thought to involve brain renin-angiotensin system (RAS) hyperactivity.  Angiotensin III, a key effector peptide in the brain RAS, provides tonic stimulatory control over blood pressure (BP) in hypertensive rats.  Aminopeptidase A (APA), the enzyme responsible for generating brain angiotensin III, constitutes a potential therapeutic target for hypertension treatment.  We focus here on studies of RB150/firibastat, the first prodrug of the specific and selective APA inhibitor EC33 able to cross the blood-brain barrier.  We consider its development from therapeutic target discovery to clinical trials of the prodrug.  After oral administration, firibastat crosses the gastrointestinal and blood-brain barriers.  On arrival in the brain, it is cleaved to generate EC33, which inhibits brain APA activity, lowering BP in various experimental models of hypertension.  Firibastat was clinically and biologically well tolerated, even at high doses, in phase I trials conducted in healthy human subjects.  It was then shown to decrease BP effectively in patients of various ethnic origins with hypertension in phase II trials.  Brain RAS hyperactivity leads to excessive sympathetic activity, which can contribute to HF after myocardial infarction (MI).  Chronic treatment with oral firibastat (4 or 8 weeks after MI) has been shown to normalize brain APA activity in mice.  This effect is accompanied by a normalization of brain RAS and sympathetic activities, reducing cardiac fibrosis and hypertrophy and preventing cardiac dysfunction.  Firibastat may therefore represent a novel therapeutic advance in the clinical management of patients with hypertension and potentially with HF after MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpbZaRLxgQnftos8R3JUhXfW6udTcc2ebecQjGfvV7u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vltVOlsw%253D%253D&md5=8e4b47550cf40efe1b16eceb466203e0</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.cjca.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cjca.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DMarc%26aufirst%3DY.%26aulast%3DBoitard%26aufirst%3DS.%2BE.%26aulast%3DBalavoine%26aufirst%3DF.%26aulast%3DAzizi%26aufirst%3DM.%26aulast%3DLlorens-Cortes%26aufirst%3DC.%26atitle%3DTargeting%2520brain%2520aminopeptidase%2520A%253A%2520a%2520new%2520strategy%2520for%2520the%2520treatment%2520of%2520hypertension%2520and%2520heart%2520failure%26jtitle%3DCan.%2520J.%2520Cardiol.%26date%3D2020%26volume%3D36%26spage%3D721%26epage%3D731%26doi%3D10.1016%2Fj.cjca.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rainusso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coarfa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenbekova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yustein, J. T.</span></span> <span> </span><span class="NLM_article-title">Tegavivint and the β-catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1093/jnci/djz026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1093%2Fjnci%2Fdjz026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=30793158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCgtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2019&pages=1216-1227&author=M.+Nomuraauthor=N.+Rainussoauthor=Y.+C.+Leeauthor=B.+Dawsonauthor=C.+Coarfaauthor=R.+Hanauthor=J.+L.+Larsonauthor=R.+Shuckauthor=L.+Kurenbekovaauthor=J.+T.+Yustein&title=Tegavivint+and+the+%CE%B2-catenin%2FALDH+axis+in+chemotherapy-resistant+and+metastatic+osteosarcoma&doi=10.1093%2Fjnci%2Fdjz026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Tegavivint and the β-catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma</span></div><div class="casAuthors">Nomura, Motonari; Rainusso, Nino; Lee, Yi-Chien; Dawson, Brian; Coarfa, Cristian; Han, Ruolan; Larson, Jeffrey L.; Shuck, Ryan; Kurenbekova, Lyazat; Yustein, Jason T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1216-1227</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">1460-2105</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background : The Wnt/β-catenin pathway is closely assocd. with osteosarcoma (OS) development and metastatic progression.  We investigated the antitumor activity of Tegavivint, a novel β-catenin/transducin β-like protein 1 (TBL1) inhibitor, against OS employing in vitro, ex vivo, and in vivo cell line and patient-derived xenograft (PDX) models that recapitulate high risk disease.  Methods : The antitumor efficacy of Tegavivint was evaluated in vitro using established OS and PDX-derived cell lines.  Use of an ex vivo three-dimensional pulmonary metastasis assay assessed targeting of β-catenin activity during micro- and macrometastatic development.  The in vivo activity of Tegavivint was evaluated using chemoresistant and metastatic OS PDX models.  Gene and protein expression were quantified by quant. Reverse transcription polymerase chain reaction or immunoblot anal.  Bone integrity was detd. via microCT.  All statistical tests were two-sided.  Results : Tegavivint exhibited antiproliferative activity against OS cells in vitro and actively reduced micro- and macrometastatic development ex vivo.  Multiple OS PDX tumors (n = 3), including paired patient primary and lung metastatic tumors with inherent chemoresistance, were suppressed by Tegavivint in vivo.  We identified that metastatic lung OS cell lines (n = 2) exhibited increased stem cell signatures, including enhanced concomitant aldehyde dehydrogenase (ALDH1) and β-catenin expression and downstream activity, which were suppressed by Tegavivint (ALDH1: control group, mean relative mRNA expression = 1.00, 95% confidence interval [CI] = 0.68 to 1.22 vs Tegavivint group, mean = 0.011, 95% CI = 0.0012 to 0.056, P <.001; β-catenin: control group, mean relative mRNA expression = 1.00, 95% CI = 0.71 to 1.36 vs Tegavivint group, mean = 0.45, 95% CI = 0.36 to 0.52, P <.001).  ALDH1high PDX-derived lung OS cells, which demonstrated enhanced metastatic potential compared with ALDHlow cells in vivo, were sensitive to Tegavivint.  Toxicity studies revealed decreased bone d. in male Tegavivint-treated mice (n = 4 mice per group).  Conclusions: Tegavivint is a promising therapeutic agent for advanced stages of OS via its targeting of the β-catenin/ALDH1 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBg4QrTFdBQrVg90H21EOLACvtfcHk0ljESCCsTmg1zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCgtL7E&md5=49bca45ea03e3de9b56051ba0cc3b238</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjz026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjz026%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DM.%26aulast%3DRainusso%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DDawson%26aufirst%3DB.%26aulast%3DCoarfa%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DLarson%26aufirst%3DJ.%2BL.%26aulast%3DShuck%26aufirst%3DR.%26aulast%3DKurenbekova%26aufirst%3DL.%26aulast%3DYustein%26aufirst%3DJ.%2BT.%26atitle%3DTegavivint%2520and%2520the%2520%25CE%25B2-catenin%252FALDH%2520axis%2520in%2520chemotherapy-resistant%2520and%2520metastatic%2520osteosarcoma%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2019%26volume%3D111%26spage%3D1216%26epage%3D1227%26doi%3D10.1093%2Fjnci%2Fdjz026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynadier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheshwari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bette-Bobillo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran Van Ba, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penarete-Vargas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraisse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerdan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vial, H.</span></span> <span> </span><span class="NLM_article-title">Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">2263</span>– <span class="NLM_lpage">2276</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01966.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1111%2Fj.1476-5381.2012.01966.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=22471905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1artL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=2263-2276&author=S.+Weinauthor=M.+Maynadierauthor=Y.+Bordatauthor=J.+Perezauthor=S.+Maheshwariauthor=P.+Bette-Bobilloauthor=C.+Tran+Van+Baauthor=D.+Penarete-Vargasauthor=L.+Fraisseauthor=R.+Cerdanauthor=H.+Vial&title=Transport+and+pharmacodynamics+of+albitiazolium%2C+an+antimalarial+drug+candidate&doi=10.1111%2Fj.1476-5381.2012.01966.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate</span></div><div class="casAuthors">Wein, S.; Maynadier, M.; Bordat, Y.; Perez, J.; Maheshwari, S.; Bette-Bobillo, P.; Ba, C. Tran Van; Penarete-Vargas, D.; Fraisse, L.; Cerdan, R.; Vial, H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2263-2276</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Choline analogs, a new type of antimalarials, exert potent in vitro and in vivo antimalarial activity.  This has given rise to albitiazolium, which is currently in phase II clin. trials to cure severe malaria.  Here we dissected its mechanism of action step by step from choline entry into the infected erythrocyte to its effect on phosphatidylcholine (PC) biosynthesis.  Exptl. Approach We biochem. unravelled the transport and enzymic steps that mediate de novo synthesis of PC and elucidated how albitiazolium enters the intracellular parasites and affects the PC biosynthesis.  Key results Choline entry into Plasmodium falciparum-infected erythrocytes is achieved both by the remnant erythrocyte choline carrier and by parasite-induced new permeability pathways (NPP), while parasite entry involves a poly-specific cation transporter.  Albitiazolium specifically prevented choline incorporation into its end-product PC, and its antimalarial activity was strongly antagonized by choline.  Albitiazolium entered the infected erythrocyte mainly via a furosemide-sensitive NPP and was transported into the parasite by a poly-specific cation carrier.  Albitiazolium competitively inhibited choline entry via the parasite-derived cation transporter and also, at a much higher concn., affected each of the three enzymes conducting de novo synthesis of PC.  Conclusions and Implications Inhibition of choline entry into the parasite appears to be the primary mechanism by which albitiazolium exerts its potent antimalarial effect.  However, the pharmacol. response to albitiazolium involves mol. interactions with different steps of the de novo PC biosynthesis pathway, which would help to delay the development of resistance to this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8v0mm2kzEirVg90H21EOLACvtfcHk0ljESCCsTmg1zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1artL3J&md5=33f6d2d296ba6d7e2179db90f97666eb</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01966.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01966.x%26sid%3Dliteratum%253Aachs%26aulast%3DWein%26aufirst%3DS.%26aulast%3DMaynadier%26aufirst%3DM.%26aulast%3DBordat%26aufirst%3DY.%26aulast%3DPerez%26aufirst%3DJ.%26aulast%3DMaheshwari%26aufirst%3DS.%26aulast%3DBette-Bobillo%26aufirst%3DP.%26aulast%3DTran%2BVan%2BBa%26aufirst%3DC.%26aulast%3DPenarete-Vargas%26aufirst%3DD.%26aulast%3DFraisse%26aufirst%3DL.%26aulast%3DCerdan%26aufirst%3DR.%26aulast%3DVial%26aufirst%3DH.%26atitle%3DTransport%2520and%2520pharmacodynamics%2520of%2520albitiazolium%252C%2520an%2520antimalarial%2520drug%2520candidate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D2263%26epage%3D2276%26doi%3D10.1111%2Fj.1476-5381.2012.01966.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pepys, M. B.</span></span> <span> </span><span class="NLM_article-title">The pentraxins 1975–2018: serendipity, diagnostics and drugs</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2382</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.02382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.3389%2Ffimmu.2018.02382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=30459761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCksro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2382&author=M.+B.+Pepys&title=The+pentraxins+1975%E2%80%932018%3A+serendipity%2C+diagnostics+and+drugs&doi=10.3389%2Ffimmu.2018.02382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The Pentraxins 1975-2018: serendipity, diagnostics and drugs</span></div><div class="casAuthors">Pepys, Mark. B.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2382/1-2382/18</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The phylogenetically ancient, pentraxin family of plasma proteins, comprises C-reactive protein (CRP) and serum amyloid P component (SAP) in humans and the homologous proteins in other species.  They are composed of five, identical, non-covalently assocd. protomers arranged with cyclic pentameric symmetry in a disk-like configuration.  Each protomer has a calcium dependent site that mediates the particular specific ligand binding responsible for all the rigorously established functional properties of these proteins.  No genetic deficiency of either human CRP or SAP has been reported, nor even any sequence polymorphism in the proteins themselves.  Although their actual functions in humans are therefore unknown, gene deletion studies in mice demonstrate that both proteins can contribute to innate immunity.  CRP is the classical human acute phase protein, routinely measured in clin. practice worldwide to monitor disease activity.  Human SAP, which is not an acute phase protein, is a universal constituent of all human amyloid deposits as a result of its avid specific binding to amyloid fibrils of all types.  SAP thereby contributes to amyloid formation and persistence in vivo.  Whole body radiolabeled SAP scintigraphy safely and non-invasively localizes and quantifies systemic amyloid deposits, and has transformed understanding of the natural history of amyloidosis and its response to treatment.  Human SAP is also a therapeutic target, both in amyloidosis and Alzheimer's disease.  Our drug, miridesap, depletes SAP from the blood and the brain and is currently being tested in the DESPIAD clin. trial in Alzheimer's disease.  Meanwhile, the obligate therapeutic partnership of miridesap, to deplete circulating SAP, and dezamizumab, a humanized monoclonal anti-SAP antibody that targets residual SAP in amyloid deposits, produces unprecedented removal of amyloid from the tissues and improves organ function.  Human CRP binds to dead and damaged cells in vivo and activates complement and this can exacerbate pre-existing tissue damage.  The adverse effects of CRP are completely abrogated by compds. that block its binding to autologous ligands and we are developing CRP inhibitor drugs.  The present personal and crit. perspective on the pentraxins reports, for the first time, the key role of serendipity in our work since 1975.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjsPRQBKCnfLVg90H21EOLACvtfcHk0ljESCCsTmg1zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCksro%253D&md5=62b716c18714e7dd224107dfcbb50c8d</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.02382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.02382%26sid%3Dliteratum%253Aachs%26aulast%3DPepys%26aufirst%3DM.%2BB.%26atitle%3DThe%2520pentraxins%25201975%25E2%2580%25932018%253A%2520serendipity%252C%2520diagnostics%2520and%2520drugs%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D2382%26doi%3D10.3389%2Ffimmu.2018.02382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voß, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klewer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-W.</span></span> <span> </span><span class="NLM_article-title">Chemically induced dimerization: reversible and spatiotemporal control of protein function in cells</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2015.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.cbpa.2015.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=26431673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2gsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=194-201&author=S.+Vo%C3%9Fauthor=L.+Klewerauthor=Y.-W.+Wu&title=Chemically+induced+dimerization%3A+reversible+and+spatiotemporal+control+of+protein+function+in+cells&doi=10.1016%2Fj.cbpa.2015.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically induced dimerization: reversible and spatiotemporal control of protein function in cells</span></div><div class="casAuthors">Voss, Stephanie; Klewer, Laura; Wu, Yao-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">194-201</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Small-mol. perturbation of biol. systems is able to tackle biol. problems that are not accessible by classical genetic interference methods.  Chem. induced dimerization (CID) has been used as a valuable tool to study various biol. processes.  Recent years have seen tremendous progress in the development of orthogonal and reversible CID systems.  These new systems allow control over protein function with unprecedented precision and spatiotemporal resoln.  While the primary application of CID has been on dissecting signal transductions, new emerging approaches have extended the scope of this technique to elucidating membrane and protein trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGX6DErfWByLVg90H21EOLACvtfcHk0ljvfxfqP_uPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2gsb%252FI&md5=40daffc34a882fd4bbc1aad5a6496b1c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2015.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2015.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DVo%25C3%259F%26aufirst%3DS.%26aulast%3DKlewer%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.-W.%26atitle%3DChemically%2520induced%2520dimerization%253A%2520reversible%2520and%2520spatiotemporal%2520control%2520of%2520protein%2520function%2520in%2520cells%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D28%26spage%3D194%26epage%3D201%26doi%3D10.1016%2Fj.cbpa.2015.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonpavde, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMannis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seethammagari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bull, J. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancsak, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapteva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slawin, K. M.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1357</span>, <span class="refDoi"> DOI: 10.1007/s00262-017-2027-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2Fs00262-017-2027-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=28608115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGlu77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1345-1357&author=G.+Sonpavdeauthor=J.+D.+McMannisauthor=Y.+Baiauthor=M.+R.+Seethammagariauthor=J.+M.+C.+Bullauthor=V.+Hawkinsauthor=T.+K.+Dancsakauthor=N.+Laptevaauthor=J.+M.+Levittauthor=A.+Moseleyauthor=D.+M.+Spencerauthor=K.+M.+Slawin&title=Phase+I+trial+of+antigen-targeted+autologous+dendritic+cell-based+vaccine+with+in+vivo+activation+of+inducible+CD40+for+advanced+prostate+cancer&doi=10.1007%2Fs00262-017-2027-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer</span></div><div class="casAuthors">Sonpavde, Guru; McMannis, John D.; Bai, Yu; Seethammagari, Mamatha R.; Bull, Joan M. C.; Hawkins, Victoria; Dancsak, Theresa K.; Lapteva, Natasha; Levitt, Jonathan M.; Moseley, Annemarie; Spencer, David M.; Slawin, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1345-1357</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting cell (APC) vaccine in men with metastatic castration-resistant prostate cancer (mCRPC).  To manuf. BPX101, APCs collected in a single leukapheresis were transduced with adenoviral vector Ad5f35 encoding inducible human (ih)-CD40, followed by incubation with protein PA001, which contains the extracellular domain of human prostate-specific membrane antigen.  The ih-CD40 represents a modified chimeric version of the dendritic cell (DC) co-stimulatory mol., CD40, which responds to a bioinert membrane-permeable activating dimerizer drug, rimiducid (AP1903), permitting temporally controlled, lymphoid-localized, DC-specific activation.  Eighteen men with progressive mCRPC following ≤1 prior chemotherapy regimen were enrolled to evaluate three doses of BPX101 (4 × 106, 12.5 × 106 and 25 × 106 cells) administered intradermally every 2-4 wk followed by rimiducid (0.4 mg/kg) i.v. (IV) infusion 24 h after each BPX101 dose.  There were no dose-limiting toxicities.  Immune upregulation as well as anti-tumor activity was obsd. with PSA declines, objective tumor regressions and robust efficacy of post-trial therapy.  This novel antigen-targeted and in vivo activated immunotherapy platform may warrant further development as monotherapy and as a component of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPqUDTm2BizLVg90H21EOLACvtfcHk0ljvfxfqP_uPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGlu77P&md5=cd625f66250e778611a43b50db4c68dd</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1007%2Fs00262-017-2027-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-017-2027-6%26sid%3Dliteratum%253Aachs%26aulast%3DSonpavde%26aufirst%3DG.%26aulast%3DMcMannis%26aufirst%3DJ.%2BD.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DSeethammagari%26aufirst%3DM.%2BR.%26aulast%3DBull%26aufirst%3DJ.%2BM.%2BC.%26aulast%3DHawkins%26aufirst%3DV.%26aulast%3DDancsak%26aufirst%3DT.%2BK.%26aulast%3DLapteva%26aufirst%3DN.%26aulast%3DLevitt%26aufirst%3DJ.%2BM.%26aulast%3DMoseley%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DD.%2BM.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26atitle%3DPhase%2520I%2520trial%2520of%2520antigen-targeted%2520autologous%2520dendritic%2520cell-based%2520vaccine%2520with%2520in%2520vivo%2520activation%2520of%2520inducible%2520CD40%2520for%2520advanced%2520prostate%2520cancer%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2017%26volume%3D66%26spage%3D1345%26epage%3D1357%26doi%3D10.1007%2Fs00262-017-2027-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakobsen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkilde, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryde, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span> <span> </span><span class="NLM_article-title">Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">710</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1021/bi0264770</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0264770" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=710-717&author=L.+O.+Gerlachauthor=J.+S.+Jakobsenauthor=K.+P.+Jensenauthor=M.+R.+Rosenkildeauthor=R.+T.+Skerljauthor=U.+Rydeauthor=G.+J.+Bridgerauthor=T.+W.+Schwartz&title=Metal+ion+enhanced+binding+of+AMD3100+to+Asp262+in+the+CXCR4+receptor&doi=10.1021%2Fbi0264770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Metal Ion Enhanced Binding of AMD3100 to Asp262 in the CXCR4 Receptor</span></div><div class="casAuthors">Gerlach, Lars Ole; Jakobsen, Janus S.; Jensen, Kasper P.; Rosenkilde, Mette R.; Skerlj, Renato T.; Ryde, Ulf; Bridger, Gary J.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">710-717</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The affinity of AMD3100, a sym. nonpeptide antagonist composed of two 1,4,8,11-tetraazacyclotetradecane (cyclam) rings connected through a 1,4-dimethylene(phenylene) linker to the CXCR4 chemokine receptor was increased 7, 36, and 50-fold, resp., by incorporation of the following: Cu2+, Zn2+, or Ni2+ into the cyclam rings of the compd.  The rank order of the transition metal ions correlated with the calcd. binding energy between free acetate and the metal ions coordinated in a cyclam ring.  Construction of AMD3100 substituted with only a single Cu2+ or Ni2+ ion demonstrated that the increase in binding affinity of the metal ion substituted bicyclam is achieved through an enhanced interaction of just one of the ring systems.  Mutational anal. of potential metal ion binding residues in the main ligand binding crevice of the CXCR4 receptor showed that although binding of the bicyclam is dependent on both Asp171 and Asp262, the enhancing effect of the metal ion was selectively eliminated by substitution of Asp262 located at the extracellular end of TM-VI.  It is concluded that the increased binding affinity of the metal ion substituted AMD3100 is obtained through enhanced interaction of one of the cyclam ring systems with the carboxylate group of Asp262.  It is suggested that this occurs through a strong concomitant interaction of one of the oxygen's directly with the metal ion and the other oxygen to one of the nitrogens of the cyclam ring through a hydrogen bond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomGEp4uVdAELVg90H21EOLACvtfcHk0ljvfxfqP_uPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktw%253D%253D&md5=a555971cbc1f0c31dfa72f4325090ed7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fbi0264770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0264770%26sid%3Dliteratum%253Aachs%26aulast%3DGerlach%26aufirst%3DL.%2BO.%26aulast%3DJakobsen%26aufirst%3DJ.%2BS.%26aulast%3DJensen%26aufirst%3DK.%2BP.%26aulast%3DRosenkilde%26aufirst%3DM.%2BR.%26aulast%3DSkerlj%26aufirst%3DR.%2BT.%26aulast%3DRyde%26aufirst%3DU.%26aulast%3DBridger%26aufirst%3DG.%2BJ.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DMetal%2520ion%2520enhanced%2520binding%2520of%2520AMD3100%2520to%2520Asp262%2520in%2520the%2520CXCR4%2520receptor%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D710%26epage%3D717%26doi%3D10.1021%2Fbi0264770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vo, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2013.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.jinorgbio.2013.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=24176921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWjt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2014&pages=69-73&author=N.+H.+Voauthor=Z.+Xiaauthor=J.+Hankoauthor=T.+Yunauthor=S.+Bloomauthor=J.+Shenauthor=K.+Koyaauthor=L.+Sunauthor=S.+Chen&title=Synthesis%2C+crystallographic+characterization+and+electrochemical+property+of+a+copper%28II%29+complex+of+the+anticancer+agent+elesclomol&doi=10.1016%2Fj.jinorgbio.2013.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol</span></div><div class="casAuthors">Vo, Nha Huu; Xia, Zhiqiang; Hanko, Jason; Yun, Tong; Bloom, Steve; Shen, Jianhua; Koya, Keizo; Sun, Lijun; Chen, Shoujun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-73</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Elesclomol is a novel anticancer agent that was evaluated in a no. of late stage clin. trials.  A new and convenient synthesis of elesclomol and its Cu complex is described.  X-ray crystallog. characterization and the electrochem. properties of the elesclomol Cu(II) complex are discussed.  The Cu(II) cation is coordinated in a highly distorted square-planar geometry to each of the S and amide N atoms of elesclomol.  Electrochem. measurements demonstrate that the complex undergoes a reversible 1-electron redn. at biol. accessible potentials.  In contrast the free elesclomol is found electrochem. inactive.  This evidence is in strong support of the mechanism of action the authors proposed for the anticancer activity of elesclomol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXVMYuAXC35bVg90H21EOLACvtfcHk0lgctqO7qc-a2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWjt7fM&md5=a653d8f8ff02d67ad6e8030b4106266f</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2013.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2013.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DVo%26aufirst%3DN.%2BH.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DHanko%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DT.%26aulast%3DBloom%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DSynthesis%252C%2520crystallographic%2520characterization%2520and%2520electrochemical%2520property%2520of%2520a%2520copper%2528II%2529%2520complex%2520of%2520the%2520anticancer%2520agent%2520elesclomol%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D130%26spage%3D69%26epage%3D73%26doi%3D10.1016%2Fj.jinorgbio.2013.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-Lucio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">The many roles of molecular complexity in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.drudis.2016.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=27575998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=120-126&author=O.+M%C3%A9ndez-Lucioauthor=J.+L.+Medina-Franco&title=The+many+roles+of+molecular+complexity+in+drug+discovery&doi=10.1016%2Fj.drudis.2016.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of molecular complexity in drug discovery</span></div><div class="casAuthors">Mendez-Lucio, Oscar; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-126</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mol. complexity is becoming a crucial concept in drug discovery.  It has been assocd. with target selectivity, success in progressing into clin. development and compd. safety, among other factors.  Multiple metrics have been developed to quantify mol. complexity and explore complexity-property relationships.  However, there is no general agreement regarding how to measure this mol. feature.  Herein, we have surveyed the many roles of mol. complexity in drug discovery discussing in a crit. manner different quantification methods.  Through the anal. of various ref. compd. databases, common pitfalls and workarounds of the quantification of mol. complexity are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyZIwgtqVak7Vg90H21EOLACvtfcHk0lgctqO7qc-a2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P&md5=f731baf9298ee3b0f0c341970a990841</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Lucio%26aufirst%3DO.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520many%2520roles%2520of%2520molecular%2520complexity%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D120%26epage%3D126%26doi%3D10.1016%2Fj.drudis.2016.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, T.</span></span> <span> </span><span class="NLM_article-title">An additive definition of molecular complexity</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00723</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00723" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A280%3ADC%252BC28nosl2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=462-470&author=T.+B%C3%B6ttcher&title=An+additive+definition+of+molecular+complexity&doi=10.1021%2Facs.jcim.5b00723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">An Additive Definition of Molecular Complexity</span></div><div class="casAuthors">Bottcher Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical information and modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">462-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A framework for molecular complexity is established that is based on information theory and consistent with chemical knowledge.  The resulting complexity index Cm is derived from abstracting the information content of a molecule by the degrees of freedom in the microenvironments on a per-atom basis, allowing the molecular complexity to be calculated in a simple and additive way.  This index allows the complexity of any molecule to be universally assessed and is sensitive to stereochemistry, heteroatoms, and symmetry.  The performance of this complexity index is evaluated and compared against the current state of the art.  Its additive character gives consistent values also for very large molecules and supports direct comparisons of chemical reactions.  Finally, this approach may provide a useful tool for medicinal chemistry in drug design and lead selection, as demonstrated by correlating molecular complexities of antibiotics with compound-specific parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWHp0vsfcWMRLDWw4HIq2sfW6udTcc2ebrT7KzoQEJrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nosl2quw%253D%253D&md5=c549b38908b24a36e6f6c6ac1419a8fc</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00723%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DT.%26atitle%3DAn%2520additive%2520definition%2520of%2520molecular%2520complexity%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D462%26epage%3D470%26doi%3D10.1021%2Facs.jcim.5b00723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivanenkov, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagribelnyy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aladinskiy, V. A.</span></span> <span> </span><span class="NLM_article-title">Are we opening the door to a new era of medicinal chemistry or being collapsed to a chemical singularity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10026</span>– <span class="NLM_lpage">10043</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKksbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10026-10043&author=Y.+A.+Ivanenkovauthor=B.+A.+Zagribelnyyauthor=V.+A.+Aladinskiy&title=Are+we+opening+the+door+to+a+new+era+of+medicinal+chemistry+or+being+collapsed+to+a+chemical+singularity%3F&doi=10.1021%2Facs.jmedchem.9b00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?</span></div><div class="casAuthors">Ivanenkov, Yan A.; Zagribelnyy, Bogdan A.; Aladinskiy, Vladimir A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10026-10043</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The paradigm of "drug-like-ness" dramatically altered the behavior of the medicinal chem. community for a long time.  In recent years, scientists have empirically found a significant increase in key properties of drugs that have moved structures closer to the periphery or the outside of the rule-of-five "cage".  Herein, we show that for the past decade, the no. of mols. claimed in patent records by major pharmaceutical companies has dramatically decreased, which may lead to a "chem. singularity".  New compds. contg. fragments with increased 3D complexity are generally larger, slightly more lipophilic, and more polar.  A core difference between this study and recently published papers is that we consider the nature and quality of sp3-rich frameworks rather than sp3 count.  We introduce the original descriptor MCE-18, which stands for medicinal chem. evolution, 2018, and this measure can effectively score mols. by novelty in terms of their cumulative sp3 complexity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvBxU8FqJprLVg90H21EOLACvtfcHk0lgctqO7qc-a2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKksbjJ&md5=369fdff9d9018714e982d7bfe6125109</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00004%26sid%3Dliteratum%253Aachs%26aulast%3DIvanenkov%26aufirst%3DY.%2BA.%26aulast%3DZagribelnyy%26aufirst%3DB.%2BA.%26aulast%3DAladinskiy%26aufirst%3DV.%2BA.%26atitle%3DAre%2520we%2520opening%2520the%2520door%2520to%2520a%2520new%2520era%2520of%2520medicinal%2520chemistry%2520or%2520being%2520collapsed%2520to%2520a%2520chemical%2520singularity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10026%26epage%3D10043%26doi%3D10.1021%2Facs.jmedchem.9b00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can we rationally design promiscuous drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can+we+rationally+design+promiscuous+drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0lhAq4MWTsmWRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan%2520we%2520rationally%2520design%2520promiscuous%2520drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span> <span> </span><span class="NLM_article-title">What do medicinal chemists actually make? A 50-year retrospective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6405</span>– <span class="NLM_lpage">6416</span>, <span class="refDoi"> DOI: 10.1021/jm200504p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200504p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6405-6416&author=W.+P.+Waltersauthor=J.+Greenauthor=J.+R.+Weissauthor=M.+A.+Murcko&title=What+do+medicinal+chemists+actually+make%3F+A+50-year+retrospective&doi=10.1021%2Fjm200504p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">What Do Medicinal Chemists Actually Make? A 50-Year Retrospective</span></div><div class="casAuthors">Walters, W. Patrick; Green, Jeremy; Weiss, Jonathan R.; Murcko, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6405-6416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the dramatically increasing costs of pharmaceutical R&D productivity, as measured by the no. of new drugs approved each year, has languished during the past decade.  Many different explanations have been proposed to account for this decline, such as increasing regulatory scrutiny, the inherent inefficiency of very large organizations, the pursuit of highly speculative targets identified from genomics, and more objective decision-making about advancing marginal compds. into latest age clin. trials.  Another factor often cited to help explain low pharmaceutical productivity is that, paradoxically, many compds. synthesized by medicinal chemists are not "druglike", at least as measured by various criteria.  The authors discuss the past, present and perspectives in the development of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg5xuF4wHqKrVg90H21EOLACvtfcHk0lhAq4MWTsmWRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O&md5=33109f9d55967be0d34f377f433621e4</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm200504p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200504p%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DW.%2BP.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DJ.%2BR.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DWhat%2520do%2520medicinal%2520chemists%2520actually%2520make%253F%2520A%252050-year%2520retrospective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6405%26epage%3D6416%26doi%3D10.1021%2Fjm200504p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raymer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span> <span> </span><span class="NLM_article-title">Lead-like drugs: a perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10375</span>– <span class="NLM_lpage">10384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2is73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10375-10384&author=B.+Raymerauthor=S.+K.+Bhattacharya&title=Lead-like+drugs%3A+a+perspective&doi=10.1021%2Facs.jmedchem.8b00407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Lead-like Drugs: A Perspective</span></div><div class="casAuthors">Raymer, Brian; Bhattacharya, Samit K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10375-10384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lead-like drugs, or drugs below mol. wt. 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chem. practice.  To examine the recent state-of-the-art in lead-like drug discovery, we surveyed recent drug approvals from 2011 to 2017 and top 200 prescribed medications, as well as provide case studies on recently approved lead-like drugs.  Many of these recent drugs are close analogs of previously known drugs or natural substrates, with a key focus of their medicinal chem. optimization being the choice of a low mol. wt. starting point and maintaining low mol. wt. during the optimization.  However, the identification of low mol. wt. starting points may be limited by the availability of suitable low mol. wt. screening sets.  To increase the discovery rate of lead-like drugs, we suggest an increased focus on inclusion and prosecution of lead-like starting points in screening libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqDUrWKytt_7Vg90H21EOLACvtfcHk0lhAq4MWTsmWRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2is73O&md5=e9fc17d69c7d671459fdaf77d6721829</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00407%26sid%3Dliteratum%253Aachs%26aulast%3DRaymer%26aufirst%3DB.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DLead-like%2520drugs%253A%2520a%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10375%26epage%3D10384%26doi%3D10.1021%2Facs.jmedchem.8b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgI8iR12gd6Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lgI8iR12gd6Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kombo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallapragada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speake, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S.</span></span> <span> </span><span class="NLM_article-title">3D molecular descriptors important for clinical success</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1021/ci300445e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300445e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=327-342&author=D.+C.+Komboauthor=K.+Tallapragadaauthor=R.+Jainauthor=J.+Chewningauthor=A.+A.+Mazurovauthor=J.+D.+Speakeauthor=T.+A.+Hauserauthor=S.+Toler&title=3D+molecular+descriptors+important+for+clinical+success&doi=10.1021%2Fci300445e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">3D Molecular Descriptors Important for Clinical Success</span></div><div class="casAuthors">Kombo, David C.; Tallapragada, Kartik; Jain, Rachit; Chewning, Joseph; Mazurov, Anatoly A.; Speake, Jason D.; Hauser, Terry A.; Toler, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-342</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacokinetic and safety profiles of clin. drug candidates are greatly influenced by their requisite physicochem. properties.  In particular, it has been shown that 2D mol. descriptors such as fraction of Sp3 carbon atoms (Fsp3) and no. of stereo centers correlate with clin. success.  Using the proteomic off-target hit rate of nicotinic ligands, we found that shape-based 3D descriptors such as the radius of gyration and shadow indexes discriminate off-target promiscuity better than do Fsp3 and the no. of stereo centers.  We have deduced the relevant descriptor values required for a ligand to be nonpromiscuous.  Investigating the MDL Drug Data Report (MDDR) database as compds. move from the preclin. stage toward the market, we have found that these shape-based 3D descriptors predict clin. success of compds. at preclin. and phase1 stages vs compds. withdrawn from the market better than do Fsp3 and LogD.  Further, these computed 3D mol. descriptors correlate well with exptl. obsd. soly., which is among well-known physicochem. properties that drive clin. success.  We also found that about 84% of launched drugs satisfy either Shadow index or Fsp3 criteria, whereas withdrawn and discontinued compds. fail to meet the same criteria.  Our studies suggest that spherical compds. (rather than their elongated counterparts) with a minimal no. of arom. rings may exhibit a high propensity to advance from clin. trials to market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRhBgMppmbbVg90H21EOLACvtfcHk0lgI8iR12gd6Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE&md5=c750cdc150c2ba3626d98e2eea8c3144</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fci300445e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300445e%26sid%3Dliteratum%253Aachs%26aulast%3DKombo%26aufirst%3DD.%2BC.%26aulast%3DTallapragada%26aufirst%3DK.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DChewning%26aufirst%3DJ.%26aulast%3DMazurov%26aufirst%3DA.%2BA.%26aulast%3DSpeake%26aufirst%3DJ.%2BD.%26aulast%3DHauser%26aufirst%3DT.%2BA.%26aulast%3DToler%26aufirst%3DS.%26atitle%3D3D%2520molecular%2520descriptors%2520important%2520for%2520clinical%2520success%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D327%26epage%3D342%26doi%3D10.1021%2Fci300445e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span> </span><span class="NLM_article-title">FDA’s policy
statement for the development of new stereoisomeric
drugs</span>.  <i>Chirality</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume">4</span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1002/chir.530040513</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1002%2Fchir.530040513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1354468" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA%E2%80%99s+policy%0Astatement+for+the+development+of+new+stereoisomeric%0Adrugs.+Chirality+1992%2C+4%2C+338%E2%80%93340+10.1002%2Fchir.530040513."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fchir.530040513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchir.530040513%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%25E2%2580%2599s%2520policy%250Astatement%2520for%2520the%2520development%2520of%2520new%2520stereoisomeric%250Adrugs%26jtitle%3DChirality%26date%3D1992%26volume%3D4%26spage%3D338%26epage%3D340%26doi%3D10.1002%2Fchir.530040513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">U.S. Food & Drug Administration</span>. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs</a> (accessed 2021-01-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Food+%26+Drug+Administration.+https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fdevelopment-new-stereoisomeric-drugs+%28accessed+2021-01-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span> <span> </span><span class="NLM_article-title">From racemates to single enantiomers - Chiral synthetic drugs over the last 20 years</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1007/128_2006_072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1007%2F128_2006_072" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2006&pages=273-299&author=H.+Murakami&title=From+racemates+to+single+enantiomers+-+Chiral+synthetic+drugs+over+the+last+20+years&doi=10.1007%2F128_2006_072"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2F128_2006_072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F128_2006_072%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DH.%26atitle%3DFrom%2520racemates%2520to%2520single%2520enantiomers%2520-%2520Chiral%2520synthetic%2520drugs%2520over%2520the%2520last%252020%2520years%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D2006%26volume%3D269%26spage%3D273%26epage%3D299%26doi%3D10.1007%2F128_2006_072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Opportunities for tapping into three-dimensional chemical space through a quaternary carbon</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">13291</span>– <span class="NLM_lpage">13315</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13291-13315&author=T.+T.+Talele&title=Opportunities+for+tapping+into+three-dimensional+chemical+space+through+a+quaternary+carbon&doi=10.1021%2Facs.jmedchem.0c00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13291-13315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron.  The spirocyclic quaternary carbon positioned at the center of a bioactive mol. offers conformational rigidity, which in turn reduces the penalty for conformational entropy.  The quaternary carbon is a predominant feature of natural product structures and has been assocd. with more effective and selective binding to target proteins compared to planar compds. with a high sp2 count.  The presence of a quaternary carbon stereocenter allows the exploration of novel chem. space to obtain new mols. with enhanced three-dimensionality.  These characteristics, coupled to an increasing awareness to develop sp3-rich mols., boosted utility of quaternary carbon stereocenters in bioactive compds.  It is hoped that this Perspective will inspire the chemist to utilize quaternary carbon stereocenters to enhance potency, selectivity, and other drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMfj5wUL80Z7Vg90H21EOLACvtfcHk0livjWlQml6SAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1WktLbL&md5=4aebceb05cdc84702ea15908488a4e58</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DOpportunities%2520for%2520tapping%2520into%2520three-dimensional%2520chemical%2520space%2520through%2520a%2520quaternary%2520carbon%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D13291%26epage%3D13315%26doi%3D10.1021%2Facs.jmedchem.0c00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiesinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar’in, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasavin, M.</span></span> <span> </span><span class="NLM_article-title">Spirocyclic scaffolds in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01473</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01473" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=150-183&author=K.+Hiesingerauthor=D.+Dar%E2%80%99inauthor=E.+Proschakauthor=M.+Krasavin&title=Spirocyclic+scaffolds+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.0c01473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Spirocyclic Scaffolds in Medicinal Chemistry</span></div><div class="casAuthors">Hiesinger, Kerstin; Dar'in, Dmitry; Proschak, Ewgenij; Krasavin, Mikhail</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150-183</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates.  The increasing interest in less planar bioactive compds. has given rise to the development of synthetic methodologies for the prepn. of spirocyclic scaffolds.  In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems.  The impact of spirocycles on potency and selectivity, including the aspect of stereochem., is discussed.  Furthermore, we examine the changes in physicochem. properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compds. to their nonspirocyclic counterparts.  In conclusion, the value of spirocyclic scaffolds in medicinal chem. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxeu8qelbAWbVg90H21EOLACvtfcHk0livjWlQml6SAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislWlsL3K&md5=b584a88a9ee65ed93277c946262de216</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26aulast%3DHiesinger%26aufirst%3DK.%26aulast%3DDar%25E2%2580%2599in%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DKrasavin%26aufirst%3DM.%26atitle%3DSpirocyclic%2520scaffolds%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D150%26epage%3D183%26doi%3D10.1021%2Facs.jmedchem.0c01473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. R.</span>; <span class="NLM_string-name">Di Fruscia, P.</span>; <span class="NLM_string-name">Lucas, S. C. C.</span>; <span class="NLM_string-name">Michaelides, I. N.</span>; <span class="NLM_string-name">Nelson, J. E.</span>; <span class="NLM_string-name">Storer, R. I.</span>; <span class="NLM_string-name">Whitehurst, B. C.</span></span> <span> </span><span class="NLM_article-title">Put a ring on it: application of small aliphatic rings in medicinal chemistry</span>.  <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, [Online early access].<span class="refDoi"> DOI: 10.1039/D0MD00370K</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1039%2FD0MD00370K" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=M.+R.+Bauer&author=P.+Di+Fruscia&author=S.+C.+C.+Lucas&author=I.+N.+Michaelides&author=J.+E.+Nelson&author=R.+I.+Storer&author=B.+C.+Whitehurst&title=Put+a+ring+on+it%3A+application+of+small+aliphatic+rings+in+medicinal+chemistry&doi=10.1039%2FD0MD00370K"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1039%2FD0MD00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0MD00370K%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DM.%2BR.%26atitle%3DPut%2520a%2520ring%2520on%2520it%253A%2520application%2520of%2520small%2520aliphatic%2520rings%2520in%2520medicinal%2520chemistry%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2021%26doi%3D10.1039%2FD0MD00370K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4443</span>– <span class="NLM_lpage">4458</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4443-4458&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Analysis+of+past+and+present+synthetic+methodologies+on+medicinal+chemistry%3A+where+have+all+the+new+reactions+gone%3F&doi=10.1021%2Facs.jmedchem.5b01409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4443-4458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  An anal. of chem. reactions used in current medicinal chem. (2014), three decades ago (1984), and in natural product total synthesis has been conducted.  The anal. revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and 1990s (Suzuki-Miyaura and Buchwald-Hartwig).  This suggests an inherent high bar of impact for new synthetic reactions in drug discovery.  The most frequently used reactions were amide bond formation, Suzuki-Miyaura coupling, and SNAr reactions, most likely due to com. availability of reagents, high chemoselectivity, and a pressure on delivery.  The authors show that these practices result in overpopulation of certain types of mol. shapes to the exclusion of others using simple PMI plots.  The authors hope that these results will help catalyze improvements in integration of new synthetic methodologies as well as new library design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLWvt5DxktAbVg90H21EOLACvtfcHk0lisqYejK12j9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM&md5=fd56ba8418f6d4e8c271f4e977ee2a93</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01409%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DAnalysis%2520of%2520past%2520and%2520present%2520synthetic%2520methodologies%2520on%2520medicinal%2520chemistry%253A%2520where%2520have%2520all%2520the%2520new%2520reactions%2520gone%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4443%26epage%3D4458%26doi%3D10.1021%2Facs.jmedchem.5b01409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lisqYejK12j9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajiness, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J.</span></span> <span> </span><span class="NLM_article-title">Molecular properties that influence oral drug-like behavior</span>. <i>Curr. Opin. Drug Discovery Devel.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=15338956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpvFOms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=470-477&author=M.+S.+Lajinessauthor=M.+Viethauthor=J.+Erickson&title=Molecular+properties+that+influence+oral+drug-like+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties that influence oral drug-like behavior</span></div><div class="casAuthors">Lajiness, Michael S.; Vieth, Michal; Erickson, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-477</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Pharmaceutical companies are constantly racing to discover the next therapeutic blockbuster.  The consensus in the industry is to focus on compds. that are by some measure drug-like, but to do this effectively a no. of questions must be answered.  For example, how should drug-like be defined and how might this definition be used to enhance drug discovery.  Has the field moved beyond Lipinski's seminal 'rule-of-five' observations.  This review offers a working definition of oral drug-likeness, describes various approaches used in its characterization and discusses its appropriate use.  The authors will focus primarily on the use of computed mol. properties that attempt to predict the oral drug-like behavior of compds. and propose guidelines for the use of observations and trends established in existing datasets to support drug discovery efforts.  In particular, this review will demonstrate how trends in simple properties of the data can be used prospectively to compare and prioritize groups of compds., chem. libraries and different chem. series with greater reliability than for predicting drug-likeness of single compds.  It is the authors' belief, however, that properties or descriptors that will completely sep. drug-like space from non-drug-like space are unlikely to be found; the focus should instead lie on overall distributions of drug-like and non-drug-like compds. in the property space that tend to overlap significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTz2SN5eShpLVg90H21EOLACvtfcHk0lisqYejK12j9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpvFOms70%253D&md5=7c2d8d16a3d7338da189f26ccade6219</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLajiness%26aufirst%3DM.%2BS.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DErickson%26aufirst%3DJ.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520oral%2520drug-like%2520behavior%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Devel.%26date%3D2004%26volume%3D7%26spage%3D470%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i14"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00181">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32140"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00181?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00181</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Data set of the INN molecules and list of SMARTS used for searching functional groups (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00181/suppl_file/jm1c00181_si_001.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00181/suppl_file/jm1c00181_si_001.xlsx">jm1c00181_si_001.xlsx (1.92 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00181&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-8%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00181%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00181" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797b951f19d93a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
